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ABSTRACT	
 
An anti-metabolite drug, 5-FU (5-fluorouracil), is widely used in the treatment of 
colorectal cancer. However, acquisition of resistance by cancer cells is the main cause 
of the limited clinical use of 5-FU, which needs to be overcome to widen and lengthen 
its utility. Therefore, it is necessary to investigate the factors and pathways involved in 
5-FU-induced apoptosis. Chemotherapeutic agents, such as 5-FU, are believed to exert 
their anti-cancer effect by initiation of apoptosis via the intrinsic cell death pathway, which 
requires activation of caspase-9. However, our group has recently discovered that 5-FU-
induced cell death is initiated by activation of caspase-8, whereas caspase-9 was found 
to be dispensable for this process. Moreover, our group has found that upon treatment 
with 5-FU, caspase-10 is upregulated, which leads to the formation of a newly discovered 
apoptosis-inducing protein complex, FADDosome. This study is composed of two parts. 
In part I, the functional and interactional analysis of the main FADDosome constituents 
revealed that caspase-10 has the ability to activate caspase-8 in vitro. Moreover, it was 
found that FADD and caspase-8 possibly interact via a novel, DED-independent 
mechanism in vitro. In part II, our group discovered that the ATR, Chk1 and Chk2 kinases 
are activated in 5-FU-treated HCT116 cells and play a key role in the 5-FU-induced DNA 
damage signal transduction towards caspase-10 upregulation and FADDosome 
formation. It was found that activation of Chk1 and Chk2 as well as induction of p53 are 
regulated in an ATR-dependent manner in response to 5-FU. It was discovered that 
when Chk1 and Chk2 are inhibited, the 5-FU-treated HCT116 cells appear to shift to an 
alternative cell death mechanism, mediated by another newly discovered apoptosis-
inducing complex, the FLIPosome. The obtained results provide new insights into the 
roles of the proteins and mechanism involved in the FADDosome formation and 
apoptosis regulation in colorectal cancer cells treated with 5-FU. 
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 2 
1.1. Colorectal	Cancer	and	Its	Resistance	to	5-Fluorouracil		
 
Colorectal cancer has been reported to be the fourth leading cause of cancer-related 
deaths throughout the world (Brody, 2015). Currently, 5-FU (5-fluorouracil), a pyrimidine 
anti-metabolite drug, is the most widely used therapeutic in the treatment of colorectal 
cancer (Longley, 2003; De Angelis et al., 2006; Thant et al., 2008). However, despite the 
significant advancement of cancer-related research and improvement of anti-tumour 
therapies, colorectal cancer still remains a major public health problem worldwide.  
 
The anti-cancer effect of 5-FU is associated with its ability to induce apoptosis, which is 
a major goal of the anti-tumour intervention (Hong et al., 2014; Lopez and Tait, 2015). 
Nevertheless, it has been reported that colorectal cancer can acquire resistance to 5-FU 
during the treatment (Thant et al., 2008). Moreover, the reduced response to 5-FU is a 
major cause of the limited clinical use of this cytotoxic drug (Longley et al., 2003; Zhang 
et al., 2008). Unfortunately, the molecular mechanisms leading to development of the 
resistance to 5-FU still remain unclear. Therefore, our aim is to examine the molecular 
pathways and factors involved in induction of cell death in response to 5-FU and thereby 
to investigate the potential mechanisms responsible for acquisition of the resistance to 
5-FU in human colorectal cancer cells.  
 
1.2. What	Is	Apoptosis?		
 
Apoptosis (a-po-toe-sis) is a term that was first introduced by Kerr et al. (1972). The term 
describes a form of the programmed cell death, which is a conserved process (Zhang 
and Yu, 2013; Fuchs and Steller, 2015), involved in maintaining of tissue homeostasis 
by removal of damaged cells, organelles and molecules, such as proteins. Apoptosis 
plays a key role in aging and development of multi-cellular organisms and is necessary 
for maintaining of the cell population in tissues. This process also functions as a defence 
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mechanism in inflammation and immunity, and in response to anti-tumour treatments, 
such as chemotherapy or irradiation. Any dysregulation of the programmed cell death, 
leading to insufficient or excessive apoptosis, contribute to development of a wide range 
of human diseases, including cancer, infection, inflammation, neurodegeneration 
(Alzheimer’s, disease and Parkinson’s disease), developmental and immunological 
disorders (Elmore, 2007; Fuchs and Steller, 2011; Galluzzi et al., 2018). It was reported 
that abnormalities in the regulation of apoptosis contribute to development of therapeutic 
resistance in cancer cells (Bauer and Hefand, 2006; Zhang and Yu, 2013; Koff et al., 
2015). 
 
When cell death occurs, a variety of morphological features and changes can be 
observed. Depending on the mechanisms, which are used in order to dispose of the 
dead cells and their fragments, programmed cell death can be classified into three 
different forms. Type I cell death, known as apoptosis, is characterised by cytoplasmic 
shrinkage, chromatin condensation, DNA fragmentation, plasma membrane blebbing, 
cytoskeleton protein degradation and formation of apoptotic bodies, which are degraded 
within lysosomes of the neighbouring cells that use phagocytosis. During type II cell 
death, called autophagy, the cells undergo extensive cytoplasmic vacuolization followed 
by lysosomal degradation by surrounding cells. Type III cell death, named necrosis, 
which does not manifest any of the characteristics of the type I or II cell death, terminates 
by removal of dead cells without the involvement of phagocytosis and lysosomes (Fuchs 
and Steller, 2011; Galluzzi et al., 2018). It was believed that necrosis functions as a 
passive form of programmed cell death, however recently some studies reported the 
involvement of proteins responsible for regulation of this process. The regulated form of 
necrosis is referred to as “necroptosis”. It can be blocked by using a small molecule 
inhibitor Nec-1 (Necrostatin-1) (Fuchs and Steller, 2011).  
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1.3. Apoptotic	Pathways		
 
Next to morphological features, apoptosis is characterised by an energy-dependent 
cascade of molecular and biochemical events. According to the conventional model of 
apoptosis, two main and distinct molecular networks are involved in initiation of the 
programmed cell death, namely the extrinsic/death receptor pathway and 
intrinsic/mitochondrial pathway.  
 
The extrinsic apoptotic pathway is known to be induced by extracellular stimuli, such as 
death ligands, which can interact with their cognate death receptors (Figure 1). The death 
receptor family belongs to the TNF (tumour necrosis factor) receptor superfamily. Death 
receptors are composed of two domains: a cysteine-rich extracellular domain and an 
intracellular (cytoplasmic) domain, termed death domain. The latter consists of 80 amino 
acids (Ashkenazi and Dixit, 1998) and is necessary for transmitting the death signals 
from the cell surface to the cytoplasmic signalling networks. To date, the best described 
death receptors are: TNF-R1 (tumour necrosis factor receptor 1), CD95 (Fas/Apo1), 
Apo3 (DR3), TRAIL-R1 and TRAIL-R2 (TNF-related apoptosis-inducing ligand receptor 
1 and 2) also known as DR4 and DR5 (death receptor 4 and 5), respectively (Elmore, 
2007; Li et al., 2013; Bertsch et al., 2014; Brenner et al., 2015; Peter et al., 2015) (Figure 
1).  
 
Moreover, the extrinsic apoptotic network requires involvement of specific death ligands, 
that bind to their corresponding death receptors, which form trimers and are localised on 
the surface of the cell membrane (Elmore, 2007; Fuchs and Steller, 2015). Binding of 
the ligands contributes to recruitment of the cytoplasmic adapter proteins, such as FADD 
(Fas-associated via death domain) in the CD95- and TRAIL-R1/2-mediated extrinsic 
pathways or TRADD (TNF-R1-associated via death domain) in the TNF-R1-regulated 
network. Adapter proteins utilise their corresponding death domains to interact with the 
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death receptors. Next, in the TNF-R1 apoptotic pathway, FADD binds to TRADD 
(Wajant, 2002). The role of FADD in the extrinsic apoptotic pathways is to recruit pro-
caspase-8, leading to formation of the DISC (death-inducing signalling complex), at 
which caspase-8 undergoes auto-processing and activation. Subsequently, activated 
caspase-8 can cleave the effector caspases, such as caspase-3, which in turn triggers 
the execution phase of the cell death mechanism (Gonzalvez and Ashkenazi, 2010; He 
et al., 2015; Mohr et al., 2015) (Figure 1).  
 
On the other hand, the intrinsic apoptotic pathway is typically triggered in response to 
intracellular signals, such as DNA damage caused by chemotherapy, UV or irradiation 
(Figure 1). Moreover, it is known that DNA lesions contribute to activation of the tumour 
suppressor p53, which is believed to mediate the transcriptional activation of numerous 
factors involved in initiation of the cell death program (Kamer et al., 2005; Liu et al., 2010; 
Fuchs and Steller, 2015). The intrinsic apoptotic network is regulated by the Bcl-2 family 
of proteins, including Bcl-2, Bcl-X2, Mcl-1, Bid (BH3 interacting-domain death agonist), 
Bak (Bcl-2 homologous antagonist) and Bax. Initiation of this pathway occurs via 
induction of MOMP (mitochondrial outer membrane permeabilisation), which leads to the 
release of cytochrome c and Smac/DIABLO into the cytosol. Together with Apaf-1 
(apoptotic protease activating factor-1), cytochrome c forms a complex termed 
Apoptosome, at which caspase-9 is activated, leading to execution of cell death. It has 
been reported that depending on the cell type, the extrinsic and intrinsic apoptotic 
pathways can converge at the mitochondrial level and influence one another (Ashkenazi 
and Dixit, 1998; Shen et al., 2008; Cullen and Martin, 2009; Li et al., 2015) (Figure 1).  
 
Next to the extrinsic and intrinsic apoptotic networks, an additional apoptotic pathway 
has been described, which requires involvement of T-cells and contributes to perforin-
granzyme-dependent apoptosis. In this pathway, cell death is induced via either 
granzyme A or granzyme B (Elmore, 2007). 
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A common feature of the apoptotic pathways is the involvement of the pro-apoptotic 
cysteine proteases called caspases, which function as the key mediators of programmed 
cell death and are involved in initiation of the execution pathway. Caspases are 
expressed as inactive proenzymes and activated in the extrinsic, intrinsic and granzyme 
B-dependent apoptotic pathways by proteolytic processing events, known as the 
cascade of caspases (Cullen ad Martin, 2009). The granzyme A-mediated network is 
induced in parallel in response to the single stranded DNA damage, without involvement 
of the caspases. The cascade of caspases contributes to amplification of the apoptotic 
signal and subsequent cell death (Figure 1). Activation of caspases is an irreversible 
process. These enzymes possess a proteolytic activity and although they can recognize 
different amino acid sequences within their substrates, the common feature of all 
caspases is to cleave other proteins at aspartic acid residues. Currently, caspases can 
be categorised into the following groups: (I) initiator caspases: caspase-2, -8, -9 and -
10; (II) effector (executioner) caspases: caspase-3, -6 and -7; as well as (III) 
inflammatory caspases: caspase-1, -4 and -5 (Elmore, 2007).  
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Figure 1. The conventional model of apoptosis.  
The extrinsic pathway is triggered by binding of the death ligand to its cognate death receptor. 
Such interaction leads to induction of the death receptor, which recruits the adaptor molecules, 
such as FADD or TRADD and pro-caspase-8. These events contribute to formation of the DISC 
(death-inducing signalling complex), at which caspase-8 is activated and in turn, activates 
caspase-3, leading to initiation of apoptosis. On the other hand, the intrinsic apoptotic pathway is 
induced in response to the cytotoxic stimuli (such as DNA damage) and regulated by p53 and the 
Bcl-2 family of proteins. Activated p53 positively regulates expression of Bak and Bax, which 
together with tBid (truncated Bid) initiate MOMP (mitochondrial outer membrane 
permeabilisation) and subsequently contribute to the release of cytochrome c. The cytosolic 
cytochrome c interacts with Apaf-1 and as a result, forms a complex called Apoptosome, which 
contributes to caspase-9 activation and subsequent initiation of the cascade of caspases followed 
by the cell death induction. Another molecule, named Smac/DIABLO is also released from 
mitochondria into the cytosol, where it inhibits the anti-apoptotic protein XIAP (X-linked inhibitor 
of apoptosis protein). Such inhibition releases the molecular brake that XIAP exerts on caspase-
3 and caspase-9.1 
 
 
 
 
 
1 Image created with BioRender.com  
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1.4. Extrinsic/Death	Receptor	Apoptotic	Pathway		
 
In the CD95- and TRAIL-R1/TRAIL-R2-mediated apoptotic pathway, the adapter protein 
FADD is recruited to the death receptor and associates with pro-caspase-8 or pro-
caspase-10. An interaction between these molecules is believed to occur via their 
cognate death effector domains. This leads to formation of the DISC, at which pro-
caspase-8 is cleaved and activated. An active enzyme is released to the cytosol, which 
contributes to initiation of apoptosis either by caspase-8-mediated cleavage of Bid or by 
activation of caspase-3, -6, -7 during the execution phase (Ohtsuka et al., 2003; Lavrik 
et al., 2005; He et al., 2015; Mohr et al., 2015). The extrinsic apoptotic pathway can be 
inhibited by cFLIP (cellular FLICE-inhibitory protein), which associates with FADD and 
pro-caspase-8 or -10 and as a result, prevents the DISC formation and blocks activation 
of caspase-8 or -10 (Lavrik et al., 2005; Elmore, 2007).  
 
The TNF-R1-regulated signalling network requires formation of the DISC, which consist 
of TNF-R1, TRADD, FADD and TRAF-1/2 (TNFR-associated factor). Similar to the 
CD95- and TRAIL-R1/TRAIL-R2-mediated apoptotic pathway, pro-caspase-8 is 
recruited to the TNF-R1-DISC and cleaved at the complex. Activated caspase-8 
proteolytically processes the executioner caspases (caspase-3, -6 and -7), leading to 
initiation of the cell death. TNF-R1 can also form other signalling platforms, such as a 
membrane-bound complex I and cytoplasmic complex II.  Complex I requires association 
of TNF-R1 with TRADD, RIP1 (receptor-interacting protein 1) and TRAF 1/2, which 
triggers the non-canonical pathways, including NF-κB-signalling network and JNK (c-
Jun-terminal kinase) vie the TRAF-2-dependent mechanism (Lavrik et al., 2005; Elmore, 
2007). Complex II requires association of TRADD and RIP1 with their binding partners, 
FADD and caspase-8. This complex can be inhibited by cFLIP (Micheau and Tschopp, 
2003).  
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1.4.1. The	Roles	of	Caspase-8	and	Caspase-10	
 
The role of caspase-8 in the initiation of the extrinsic apoptotic network has been 
thoroughly investigated and is currently relatively well understood (Fuchs and Steller, 
2015). In addition, there is evidence that caspase-8 can be involved in initiation of non-
conventional apoptotic pathways triggered by anti-cancer drugs, such as etoposide  
(Feoktistova et al., 2011; Imre et al., 2011; Biton and Ashkenazi, 2011; Tenev et al., 
2011) as well as participate in TRAIL-mediated inflammation responses (Henry and 
Martin, 2017).  
 
Similar to caspase-8, caspase-10 is believed to play a role in induction of the death 
receptor-dependent apoptotic pathway. It was demonstrated that this cysteine protease 
shares a significant sequence similarity with caspase-8. Additionally, it was reported that 
the catalytic domains of both caspases are identical in 46% of their protein sequence. 
Moreover, the Casp10 and Casp8 genes are located on the same chromosomal 2q33-
34 region in humans. To date, no homologue of human caspase-10 has been found in 
mice, which is considered as one of the possible reasons for the little focus on caspase-
10-related research (Wachmann et al., 2010; McIlwain et al., 2013). Therefore, our 
understanding of the physiological functions of caspase-10 in the apoptotic network is 
still fairly poor (Filomenko et al., 2006; McIlwain et al., 2013).  
 
It has been suggested that, due to the shared structural homology, caspase-10 can 
functionally substitute caspase-8 in death receptor-induced signalling pathways, 
depending on the cell type (Kischkell et al., 2001). On the contrary, according to Sprick 
et al., (2002), it is very unlikely that caspase-10 can replace caspase-8 in mediating the 
TRAIL- and CD95-dependent apoptosis. Therefore, further and more detailed 
investigation is required to clarify this issue. It was reported that both uncleaved and 
cleaved variants of caspase-10 can proteolytically process Bid, leading to formation of 
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tBid, which in turn can contribute to initiation of apoptosis (Wachmann et al., 2010). Such 
observations led to the conclusion that caspase-8 and -10 share substrate specificity and 
their functions may partially overlap (Parrish et al., 2013; Riley et al., 2015). 
 
Furthermore, there are only few studies, which investigated and described the role of 
caspase-10 and its activity in the initiation of the programmed cell death in response to 
chemotherapy. It was shown by some studies in vitro, that treatment with anti-tumour 
drugs (such as doxorubicin and etoposide) and arsenic dioxide can promote transcription 
of the Casp10 gene via activation of p53 and phosphoacetylation of histone H3, 
respectively, in cancer cells (Filomenko et al., 2006). Interestingly, some of the findings 
suggest that caspase-10 plays an active role in initiation of cell death in a FADD-
dependent and death receptor-independent manner in response to cytotoxic 
chemotherapeutics (Park et al., 2004; Filomenko et al., 2006; Lee et al., 2007). Such 
apoptosis-inducing mechanisms were observed in human lymphoblastic leukaemia cells 
treated with paclitaxel (taxol) (Park et al., 2004) as well as in human U937, HeLa and 
293T cell lines exposed to etoposide (Filomenko et al., 2006).  
 
Nevertheless, there are no reports describing the role of caspase-10 and its upregulation 
or activity in triggering apoptosis in colorectal cancer cells treated with 5-FU. Additionally, 
the exact details of how the caspase-10-mediated initiation of cell death is driven in 
response to doxorubicin, etoposide and arsenic dioxide, mentioned above, still remain 
enigmatic. In summary, our poor understanding of how caspase-10 together with its 
chemotherapy-induced upregulation and/or activation might contribute to initiation of 
apoptosis in cancer cells requires further investigation.  
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1.5. Intrinsic/Mitochondrial	Apoptotic	Pathway		
 
During intrinsic apoptotic pathway, which can be triggered without the involvement of the 
death receptors, activated p53 positively regulates the overexpression of the key pro-
apoptotic proteins, namely Bak and Bax. Moreover, upon induction of the intrinsic 
apoptotic network, the pro-apoptotic protein Bid undergoes the caspase-8-mediated 
cleavage, which in turn leads to formation of truncated Bid (tBid). Bak, Bax and tBid 
contribute to induction of MOMP (Tait and Green, 2010; David, 2012). As a result, the 
pro-apoptotic cytochrome c (Liu et al., 1996) and the IAPs (inhibitors of apoptosis) 
antagonist named Smac/DIABLO (Verhagen et al., 2000) are released. The cytosolic 
cytochrome c can interact with Apaf-1 and consequently, forms a complex called 
Apoptosome (Cullen and Martin, 2009; Li et al., 2015). Formation of the Apoptosome 
stimulates initiation of a cascade of caspases, which consists of subsequent proteolytic 
processing events leading to activation of downstream caspases and consequently, 
induction of cell death. 
 
1.5.1. Regulation	by	Bcl-2	Family	Members	
 
The mitochondrial pathway functions as an initial stage of the intrinsic apoptotic network 
and is mostly regulated by the Bcl-2 family of proteins, which are responsible for 
controlling of the release of pro-apoptotic proteins, such as cytochrome c, 
Smac/DIABLO, and the serine protease HtrA2/Omi (van Loo et al., 2002; Garrido et al., 
2005; Wang and Youle, 2009) from the mitochondrial intermembrane space into the 
cytosol. Upon intracellular stimuli, such as DNA damage, toxins, chemotherapeutic 
agents, UV radiation, viral infection or stress signals, the inner mitochondrial membrane 
undergoes changes, which contribute to opening of the pores, loss of the 
transmembrane potential and finally, induction of MOMP, which is one of the main 
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characteristics of the intrinsic network (Elmore, 2007; Wang and Youle, 2009; Márquez-
Jurado et al., 2018). 
 
The regulators of these events, Bcl-2 family of proteins, consist of at least 25 members 
and can be divided into two classes: pro-apoptotic proteins, which include Bcl-10, Bak, 
Bax, Blk and Bok, as well as anti-apoptotic proteins, including Bcl-2, Bcl-G, Bcl-L10, Bcl-
Rambo, Bcl-w, Bcl-X, Bcl-XS, Bcl-XL, Mcl-1, A1 and Bag. The anti-apoptotic members 
of the Bcl-2 family can be inhibited by the BH3-only family of proteins, which share a 
BH3 motif and due to their function act as pro-apoptotic factors. The BH3-only family 
includes: Bad, Bid, Bim, Bik, Puma, Noxa, Bmf and Hrk (Elmore, 2007; Wang and Youle, 
2009). It was demonstrated that the key regulators of the mitochondrial apoptotic 
pathway are Bak and Bax, at which the intracellular signals converge (Zong et al., 2001). 
These factors play a critical role in determining, whether cells undergo apoptosis or 
inhibit the process. Bak and Bax can be negatively or positively regulated by the 
members of the anti-apoptotic Bcl-2 and BH3-only protein families, respectively (Elmore, 
2007; Wang and Youle, 2009) (Figure 2).  
 
In healthy cells, Bak is normally located inside the mitochondria, whereas Bax residues 
in cytosol and translocates to mitochondria upon initiation of apoptosis (Figure 2). During 
cell death, both proteins undergo conformational changes and subsequent 
oligomerisation, which is necessary for mitochondrial membrane permeabilisation and 
subsequent release of cytochrome c (Leber et al., 2007) (Figure 2). Until recently, it was 
unclear, how changed conformation and oligomerisation of Bak and Bax contributes to 
permeabilisation of the mitochondrial membrane. It was reported by Uren et al. (2017), 
that Bak and Bax form symmetric homodimers, that act as a basic unit for pore formation, 
which was confirmed by biophysical, biochemical and structural studies. Each dimer 
contains a transmembrane domain, which allows anchoring inside the mitochondria and 
an extended hydrophobic surface, localised on the mitochondrial outer membrane. It was 
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proposed that Bak and Bax have a preference for forming of the lipid pores over 
proteinaceous ones, however the exact mechanism still remains unclear (Uren et al. 
2017).  
 
Figure 2. Activation and oligomerisation of Bak and Bax followed by release of cytochrome 
c and apoptosis. 
Upon initiation of the mitochondrial pathway, the pro-apoptotic factors Bak and Bax translocate 
to the mitochondria outer membrane and oligomerise in order to trigger MOMP. The anti-apoptotic 
Bcl-2 family proteins inhibit Bak and Bax, whereas pro-apoptotic BH3-only family proteins 
positively regulate these factors. Additionally, BH3-only family proteins negatively regulate the 
Bcl-2 proteins. During MOMP, cytochrome c is released to the cytosol, leading to caspase-3 
activation and apoptosis (Uren et al., 2017).2 
 
 
The existence of the “cross-talk” between the extrinsic and intrinsic/mitochondrial 
apoptotic pathways has been widely reported. One of the examples is the caspase-8-
mediated cleavage of Bid (BH3 interacting-domain death agonist), which occurs in type 
II cells, when the cascade of caspases cannot be induced due to existence of XIAP. Until 
being cleaved, Bid remains inactive and is located in the cytosol. After the caspase-8-
mediated cleavage and activation, a truncated fragment of Bid (tBid) localises to 
mitochondria, and then, together with activated Bax initiates the release of cytochrome 
 
2 Image created with BioRender.com 
 14 
c leading to induction of intrinsic apoptotic pathway (Li et al., 1998; Luo et al., 1998; 
Wang, 2001; Kamer et al., 2005).  
 
1.5.2. Roles	of	Cytochrome	c	and	Smac/DIABLO		
 
Cytochrome c is a pro-apoptotic protein, which is released during MOMP into the cytosol. 
Other proteins, that are also released during the process include Smac/DIABLO and 
HtrA2/Omi (Loo et al., 2002; Garrido et al., 2006; Wang and Youle, 2009). These 
molecules are involved in activation of the caspase-dependent mitochondrial network. In 
particular, cytochrome c is known to interact with Apaf-1 and consequently, forms a 
complex called Apoptosome (Cullen and Martin, 2009; Li et al., 2015). At the complex, 
Apaf-1 binds to pro-caspase-9, which in turn forms clusters, leading to its activation and 
execution of the cell death. The apoptotic function of cytochrome c has been 
demonstrated by numerous genetic and biochemical studies in vitro and in vivo (Liu et 
al., 1996; Hakem et al., 1998; Kuida et al., 1998; Hao et al., 2005). Furthermore, 
Smac/DIABLO and HtrA2-Omi bind to the IAP (Inhibitors of apoptosis) and play a key 
role in neutralizing the inhibitory effects of IAP on effector caspases activity, which 
consequently promotes execution of apoptosis (Wang and Youle, 2009). In particular, 
Smac/DIABLO binds to XIAP, however association with cIAP1 and cIAP2 has also been 
reported (Srinivasula et al., 2000). Nevertheless, various studies suggest that 
Smac/DIABLO can play more complex roles in apoptosis. One of the splicing variants, 
Smac beta can sensitise cells to apoptosis, despite lacking its ability to associate with 
IAPs. Such observation suggests, that acting as an IAP antagonist is not the only function 
of Smac (Roberts et al., 2001). It was also reported that Smac3, another splicing variant 
of Smac, is involved in XIAP autoubiquitination and degradation (Fu et al., 2003). Other 
studies have demonstrated that knocking-out Smac in HCT116 cells lead to the delayed 
release of cytochrome c and resistance to NSAIDs (nonsteroidal anti-inflammatory 
drugs) (Kohli et al., 2004). 
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1.5.3. Regulation	by	p53	
 
The tumour suppressor protein p53, encoded by TP53 gene, functions as a sensor of 
the cellular stress and mediates transient and permanent cell cycle arrest as well as 
plays a critical role in tumorigenesis prevention by being involved in regulation of 
numerous processes, including apoptosis, DNA repair and oncogenes activation (Russo 
et al., 2005; Collavin et al., 2010; Li et al., 2015). p53 is known to induce and regulate 
the intrinsic apoptotic pathway, however, it has been described that this tumour 
suppressor can be also involved in mediating and promoting the extrinsic apoptotic 
network (Ryan et al., 2001; Li et al., 2015). p53 is a transcription factor, which consists 
of characteristic domains, including: N-terminal transactivation domain (1 – 92 residues), 
a central core sequence-specific DNA-binding domain (100 – 300 residues) and 
C-terminal tetramerization and regulatory domain (323 – 393 residues) (Stavridi et al., 
2005) (Figure 3). 
 
 
 
Figure 3. Domains of the tumour suppressor p53 and their functions.  
The p53 protein structure consists of several domains. To date, the following domains have been 
identified: N-terminal domain (responsible for transcriptional transactivation), the central core 
domain (a sequence specific DNA binding domain), and the C-terminal domain (it encompasses 
the tetramerization and negative regulation domain) (Stavridi et al., 2005).3 
 
3 Image created with BioRender.com 
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Mutations in the TP53 gene and deactivation of p53 are described as one of the most 
frequently occurring events associated with the subsequent development of a wide range 
of human cancers (Kandoth et al., 2013). Inactivation of p53 happens as a result of a 
single monoallelic missense mutations, which mainly occur in the DNA-binding domain. 
Typically, p53 is expressed as a stable, full-length protein, which lacks its sequence-
specific DNA-binding activity due to the mutations (Brosh and Rotter, 2009).   
 
Depending on the mechanism, p53-mediated apoptosis can be regulated 
transcriptionally or non-transcriptionally. To date, numerous p53 targets have been found 
and include: the pro-survival Bcl-2 and Bcl-XL as well as pro-apoptotic Bcl-2 proteins 
(Bax, Puma, Noxa and Bid), which can be regulated negatively and positively by p53, 
respectively (Oda et al., 2000; Sax et al., 2002; Shen et al., 2008). It was demonstrated 
by in vitro studies that, when Puma is overexpressed, Bax expression is also elevated, 
which leads to the change of Bax conformation and induction of the mitochondrial 
apoptotic pathway (Liu et al., 2003).  
 
Moreover, it was reported, that Noxa can be translocated to the mitochondria and 
associate with pro-survival members of the Bcl-2 family, which in turn contributes to 
activation of caspase-9 (Oda et al., 2000). Other examples of p53 targets include the 
death receptors (such as Fas, DR4, DR5, CD95), PIDD (p53-induced protein with death 
domain) and Wip1 (wild-type p53-induced phosphatase-1), which have been shown to 
be positively regulated by p53 (Wu et al., 1997; Sheikh et al., 1998; Lu et al., 2008; 
Amaral et al., 2010; Li et al., 2015).  
 
Wip1, also known as serine/threonine protein phosphatase 1D (PPM1D), is involved in 
regulation of cell cycle checkpoints in response to stress associated with DNA damage 
(Yamaguchi et al., 2007; Lu et al., 2008; Song et al., 2010; Lowe et al., 2013; Song et 
al., 2013). Wip1 belongs to the PP2C (protein phosphatase 2C) family of proteins 
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(Yamaguchi et al., 2007). Moreover, this Mg2+/Mn2+-dependent monomeric enzyme 
consists of two domains, including the N-terminal and C-terminal domain. It has been 
reported that he N-terminal domain performs a catalytic function and is more conserved 
than the non-catalytic C-terminal domain (Kleiblova et al., 2013).  
 
1.6. Execution	Cell	Death	Network	
 
Execution pathway, at which the extrinsic, intrinsic and granzyme B-mediated networks 
converge, begins with processing and activation of the effector (executioner) caspase-
3, -6 and -7. The execution phase of apoptosis is considered as the final pathway of the 
programmed cell death. The effector caspases promote activation of cytoplasmic 
endonuclease and proteases. The endonuclease degrades the genetic material within 
the nucleus, whereas the proteases digest the cytoskeletal and nuclear proteins. 
Moreover, caspase-3, -6 and -7 proteolytically process a variety of substrates, such as 
PARP (poly (ADP-ribose) polymerase), cytokeratins, NuMA (nuclear protein) and the 
alpha fodrin (plasma membrane cytoskeletal protein). Cleavage of these substrates 
gives rise to the biochemical and morphological changes observed in the cells 
undergoing apoptosis (Elmore, 2007).  
 
The most important of the executioner caspases is caspase-3, which is cleaved and 
activated by the initiator caspases, including caspase-8, -9 and -10. Upon initiation of the 
execution pathway, caspase-3 activates the endonuclease CAD (caspase-activated 
DNase) by cleavage of ICAD (inhibitor of caspase-activated DNase), which typically 
functions as an inhibitor of CAD. In dividing and growing cells, ICAD forms a complex 
with CAD, which supresses the activity of CAD. After CAD is released and activated, it 
metabolises chromosomal DNA localised in nuclei, which leads to condensation of the 
chromatin. Moreover, caspase-3 is involved in formation of the apoptotic bodies by 
mediating the cytoskeletal reorganization and fragmentation of the cell (Elmore, 2007).  
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1.7. Targeting	Apoptosis	in	Cancer		
 
It is known that tumours and their therapy-resistance can frequently develop as a result 
of dysregulation of the apoptotic pathways (Owens et al., 2013; Koff et al., 2015). Such 
dysregulation is typically associated with the enhanced or impaired expression of the 
critical proteins involved in both positive and negative regulation of the cell death. In 
particular, overexpression of IAPs as well as an unbalanced expression of the proteins 
that belong to the Bcl-2 family (mainly Bax, Bcl-2 and Bcl-XL) are known to contribute to 
tumorigenesis. Moreover, IAPs and Bcl-2 family of proteins have been implicated in the 
development of resistance to chemotherapy and radiation, what was demonstrated by 
many studies in vitro (Violette et al., 2002; LaCasse et al., 2008; Owens et al., 2013; 
Ehrenschwender et al., 2014).  
 
Occurrence of mutation or damage in the TP53 gene leads to disruption of the p53-
mediated DNA damage recognition and repair or apoptosis. Another protein, which is 
involved in DNA damage repair and mediates regulation of the cell cycle progression is 
ATM (ataxia telangiectasia-mutated). This kinase is activated in response to DNA double 
strand breaks, which in turn leads to ATM-mediated phosphorylation of p53. Thus, 
disruption of activation and functions of ATM and p53 promotes tumorigenesis (Kurz and 
Lees-Miller, 2004; Kitagawa and Kastan, 2005; Elmore, 2007). 
 
Members of the IAP family have been widely studied as therapeutic targets for the 
treatment of cancer, spinal cord injuries, stroke and multiple sclerosis (Elmore, 2007). 
Targeting and inhibition of these proteins in cancer cells holds a significant promise in 
the treatment of various malignancies. Among eight currently known members of IAPs 
family, survivin, cIAP1, cIAP2 and XIAP are described as the most commonly 
overexpressed apoptotic regulatory proteins, which in turn can lead to enhanced 
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inhibition of cell death and development of a wide range of human cancers (LaCasse et 
al., 2008; Owens et al., 2013; Koff et al., 2015).  
 
To date, many promising IAP-targeted therapies have been developed and include 
application of single-stranded antisense oligodeoxynucleotides, adenoviruses 
expressing dominant-negative mutants of a target gene and most importantly small 
molecules inhibitors (Smac mimetics), which function as IAP antagonists (Owens et al., 
2013; Bai and Wang, 2014; Koff et al., 2015) (Figure 4). Upon binding to the Smac 
mimetics, IAPs undergo ubiquitination and degradation by proteasomes. Loss of IAPs 
triggers two events: (I) formation of a protein complex, consisting of RIP1, FADD and 
caspase-8, which induces apoptosis and (II) activation of non-canonical NF-κB pathway, 
production of TNF-a and autocrine/paracrine cell death (Varfolomeev et al., 2007) 
(Figure 4). The effect of the Smac mimetics in cancer cells has been investigated in 
combination with other treatments, including chemotherapy, radiotherapy, small 
molecular inhibitors of kinases, death receptor agonists, proteasome and Bcl-2. 
Responses to such treatments were examined on xenograft mouse models and by using 
in vitro studies (Fulda and Vucic, 2012). Interestingly, it has been demonstrated by the 
pre-clinical studies that targeting IAPs with Smac mimetics can contribute to the 
enhancement of sensitivity to the clinically used anti-cancer drugs, including 5-FU, in 
various tumours (Owens et al., 2013; Koff et al., 2015).  
 
Small molecule inhibitors were also developed for anti-apoptotic Bcl-2 family of proteins 
(Figure 4). These inhibitors are non-peptide molecules, which can mimic the pro-
apoptotic BH3-only proteins (BH3 mimetics). The BH3 mimetics compete with the pro-
apoptotic Bcl-2 family members and bind to anti-apoptotic Bcl-2 family proteins, which 
leads to the release of the pro-apoptotic proteins (Figure 4). The advantage of some BH3 
mimetics is to exhibit their antitumor activity by specific binding to their targets. Some of 
the compounds have been already advanced into clinical trials and were conducted in 
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patients with lymphoma, leukaemia and small-cell lung cancer (Wilson et al., 2010; 
Gandhi et al., 2011; Roberts et al., 2012). Leukaemia showed a substantial susceptibility 
to the treatment with BH3 mimetics (Robert et al., 2012), whereas the response of solid 
tumours was limited. This was mostly caused by overexpression of Mcl-1, the anti-
apoptotic protein, which belongs to the Bcl-2 family (Konopleva et al., 2006). Further 
approaches and strategies are focused on developing pan Bcl-2 inhibitors or Mcl-1 
selective inhibitors to treat solid tumours (Bai and Wang, 2014).  
 
Another group of small inhibitors includes Mdm2/p53 interaction antagonists, which 
mimic the p53 binding residues and target Mdm2 (Bai and Wang, 2014) (Figure 4). 
Several of these inhibitors have advanced to the clinical trials, including RO-5503781, 
MI-77301 and CGM097 (http://clinicaltrials.gov). The mode of action of Mdm2 
antagonists is associated with their ability to bind with Mdm2, which in turn contributes 
to stabilisation and activation of p53, followed by cell cycle arrest and apoptosis in cancer 
cells with wild type p53 (Tovar et al., 2006). The response to treatment with Mdm2 
inhibitors is currently examined in various cancers, including solid tumours, leukaemia 
and acute myeloid leukaemia (Bai and Wang, 2014).  
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Figure 4. Proteins involved in regulation of apoptotic pathways and small-molecule 
inhibitors targeting these proteins. 
Inhibitors of apoptosis (IAPs), such as cIAP1/2 prevent cell death by ubiquitination of RIP1. This 
event blocks DISC formation in the extrinsic apoptotic pathway and subsequent activation of 
caspase-8 at the complex. cIAP1/2 are also involved in regulation of the canonical and non-
canonical NF-κB-mediated pathway. Another inhibitor of apoptosis, XIAP, blocks cell death by 
inhibition of caspase-3 and -9, which are involved in the intrinsic apoptotic network. However, 
Smac can prevent the XIAP-mediated inhibition of caspases. The small molecule inhibitors, 
named Smac mimetics, can bind to IAPs, including cIAP1/2 and XIAP, and thereby antagonise 
their inhibitory effects. Upon initiation of the intrinsic apoptotic pathway, pro-apoptotic Bak and 
Bax function as the effectors of MOMP, which leads to the release of cytochrome c. The BH3 
mimetics compete with the pro-apoptotic Bcl-2 family members for binding to anti-apoptotic Bcl-
2 family proteins, which leads to their inhibition and subsequent release of Bak and Bax. The 
tumour suppressor, p53 promotes apoptosis by transcriptional regulation of genes that express 
proteins involved in apoptosis. This transcription factor can also activate Bak and Bax. The Mdm2 
protein functions as a regulator of the stability and transcriptional activity of p53 by negative-
feedback loop. The small molecule inhibitors, Mdm2 antagonists, outcompete p53 for binding to 
Mdm2 (Bai and Wang, 2014).4 
 
4 Image created with BioRender.com 
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1.8. Non-Conventional	 Pathways	 and	 Signalling	 Protein	
Platforms	Involved	in	Cell	Death	Induction	
 
The programmed cell death is a tightly controlled process, that is regulated by various 
molecular factors and mechanisms. Conventionally, it is believed that cell death is 
triggered by the extrinsic/death receptor pathway and the intrinsic/mitochondrial 
pathway. Moreover, to date, numerous signalling protein complexes involved in the 
regulation of apoptotic networks have been described. These include the well-known 
protein platforms, such as DISC (Lavrik et al., 2005; Elmore, 2007; Fuchs and Steller, 
2015) TNF complex II, (Micheau and Tschopp, 2003), Apoptosome (Cullen and Martin, 
2009; Li et al., 2015), PIDDosome (Tinel and Tschopp, 2004), TLR (toll-like receptor) 
complexes (Vercammen et al., 2008) and RIP1-platform accompanied by TNF-α 
secretion (Biton and Ashkenazi, 2011). 
 
Recently, it has become more evident that cancer cells subjected to the chemotherapy-
based treatments can undergo apoptosis that is induced by molecular mechanisms, 
which are not covered by the classical models of programmed cell death. The strict 
division into the intrinsic and extrinsic apoptotic networks has been recently challenged 
by findings from our laboratory (Mohr et al., 2018) as well as other studies, which 
remodelled the molecular mechanisms responsible for initiation of programmed cell 
death in response to various cytotoxic agents. Moreover, there is more evidence that 
cytotoxic stress-induced cell death can be regulated and initiated by newly discovered 
protein complexes, such as RIPoptosome (Feoktistova et al., 2011; Tenev et al., 2011), 
FADDosome and FLIPosome (Mohr et al., 2018). 
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1.8.1. Apoptosis	Can	Be	Caspase-9-Independent		
 
It has been shown in our research that caspase-9 (classified as an initiator caspase), 
which is believed to play a key role in initiation of the conventional intrinsic/mitochondrial 
apoptotic pathway, is not essential for induction of apoptosis in cancer cells treated with 
5-FU (Mohr et al., 2018). Importantly, some of the first findings regarding initiation of 
casapse-9-independent apoptosis go back to late 1990s, when Hakem et al., (1998) 
demonstrated, that Casp9-/- mouse splenocytes are sensitive to UV and can undergo 
apoptosis. Additionally, this study suggests that induction of the programmed cell death 
in the absence of caspase-9 depends on both stimulus and cell type, what implies the 
existence of multiple cellular death networks.  
 
Furthermore, Marsden et al., (2002) showed that activation of the cascade of caspases 
could be regulated by the Bcl-2 protein and did not require involvement of the 
Apoptosome (a protein complex consisting of cytochrome c, Apaf-1 and caspase-9) in 
mouse lymphocytes and fibroblastoid cells subjected to cytokine withdrawal or treatment 
with dexamethasone, etoposide and g-irradiation. The study suggests that caspase-9 is 
not required for induction of apoptosis in haematopoiesis and that the main function of 
the Apoptosome is rather to accelerate, but not to initiate the cascade of caspases 
(Marsden et al., 2002). Later studies confirmed that the loss of caspase-9 did not lead to 
evasion of apoptosis in response to diverse insults, however, it contributed to the partial 
and transient resistance to etoposide and dexamethasone in MEFs (Marsden et al., 
2004; Delft et al., 2009) and thymocytes (Delft et al., 2009).  
 
Numerous in vitro studies reported that the acquired resistance to chemotherapy is 
associated with the p53 status, in addition to the level of major regulatory proteins 
involved in initiation of intrinsic apoptotic network. In fact, mutations in TP53 gene and 
loss of p53 function occur commonly in the majority of human cancers (Violette et al., 
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2002; Longley et al., 2003; Boyer et al., 2004; Muller and Vousden, 2013). Similar to 
others, we showed that the deficiency of p53 provides protection against 5-FU in isogenic 
knockout HCT.p53-/- cells treated with 5-FU for 48 h, when compared with wild-type 
HCT116 cells subjected to the same treatment (Longley et al., 2003; Boyer et al., 2004).   
 
Conventionally, it is believed that p53 is activated in response to DNA damage, which in 
turn contributes to positive regulation of pro-apoptotic Bax and Bak proteins followed by 
cytochrome c release and caspase-9 activation. Nevertheless, the finding that caspase-
9 is not essential for 5-FU-induced apoptosis refutes the classical model of programmed 
cell death. Taken together, our results showing that HCT.p53-/- cells are protected 
against the treatment with 5-FU and the caspase-9 findings, summarised above, lead to 
a conundrum that requires different models and answers with respect to apoptosis 
induction in response to chemotherapeutic drugs. 
 
1.8.2. PIDDosome	
 
The PIDDosome complex was initially studied and first reported by Tinel and Tschopp 
(2004). Their research provided answers for the role of caspase-2, which is known as 
the initiator caspase involved in the DNA-damage response and stress-induced 
apoptosis. Tinel and Tschopp (2004) demonstrated that caspase-2 is activated at the 
PIDDosome, a protein platform that encompasses PIDD and an adapter protein RAIDD 
(CASP2- and RIPK1-domain-containing adaptor with death domain; also known as 
CRADD) (Tinel and Tschopp, 2004). However, there is also evidence that caspase-2 
can be activated without involvement of PIDD, e.g. in dying neurons or in cell extracts in 
vitro (Manzl et al., 2009; Ribe et al., 2012). 
 
PIDD is a ~100 kDa protein, which was first characterised by Lin et al., (2000) and 
contains a C-terminal death domain (DD). The protein sequence also comprises N-
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terminal LRRs (leucine-rich repeats), ZU5 (ZO-1 and Unc5-like) domains and UPA 
(uncharacterised protein domain conserved in UNC5, PIDD and ankyrins). It has been 
reported that PIDD possess autoproteolytic activity and can cleave itself into three 
fragments: PIDD-N, PIDD-C and PIDD-CC, which sizes are 48 kDa, 51 kDa and 37 kDa, 
respectively. Different transcription and splice variants of PIDD were also identified. The 
adapter protein RAIDD contains the C-terminal DD and N-terminal caspase-recruitment 
domain (CARD), which associate with PIDD DD and caspase-2 CARD, respectively. 
Apart from the CARD domain, caspase-2 also contains two subunits, p19 and p12 
(Sladky et al., 2017) (Figure 5).  
 
 
Figure 5. Domain organisation of the PIDDosome complex constituents. 
The domains of PIDD include: N-terminal LRRs (leucine-rich repeats), ZU5 (ZO-1 and Unc5-like) 
domains, UPA (uncharacterised protein domain conserved in UNC5, PIDD and ankyrins) and C-
terminal death domain (DD). The structure of RAIDD comprises N-terminal CARD and C-terminal 
DD domains. Caspase-2 contains three domains, including N-terminal CARD, p19 and p12. The 
DD and CARD of the adapter protein RAIDD interact with PIDD DD and caspase-2 CARD, 
respectively, to form the PIDDosome complex. the cleavage fragments, PIDD-N, PIDD-C and 
PIDD-CC, resulting from PIDD auto-processing are also indicated (Sladky et al., 2017).5 
 
 
In order to elucidate the molecular mechanisms responsible for caspase-2 activation at 
the PIDDosome, Tinel and Tschopp (2004) overexpressed various DD- and CARD-
containing proteins in 293T cells. By using immunoprecipitation, the authors examined, 
 
5 Image created with BioRender.com 
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which molecules could bind to caspase-2. Tinel and Tschopp (2004) found, that the only 
interaction partners of caspase-2 were RAIDD and PIDD, and subsequently, 
reconstituted the caspase-2-activating complex, which they termed PIDDosome. 
Examination of the cell lysates extracted from non-stimulated HeLa, 293T and Jurkat T 
cells as well as Ramos B lymphocytes showed that the PIDDosome complex could be 
also formed spontaneously under more physiological conditions. The gel filtration 
analysis of the 293T and Jurkat T cell revealed that caspase-2, RAIDD and PIDD eluted 
in fractions corresponding to the size of ~670 kDa, confirming that these molecules can 
form a stable, high molecular weight protein platform (Tinel and Tschopp 2004).  
 
The authors also wondered about the physiological function of the capsase-2 activation 
at the PIDDosome complex. In order to examine that, Tinel and Tschopp (2004) 
investigated the effect of PIDD overexpression in HeLa and Ramos B lymphocytes 
exposed to genotoxic drugs and compared the results with the control wild-type and 
PIDDDDD-expressing cells. They observed that upon treatment with doxorubicin or 
etoposide, the PIDD-overexpressing cells can undergo apoptosis, whereas most of the 
control cells remained viable. Moreover, it was reported, that in the presence of 
overexpressed PIDD, almost all caspase-2 molecules were processed and the activity 
of the effector caspase-3 was strongly increased. These findings showed that PIDD-
mediated caspase-2 activation can sensitise cells to apoptosis in response to genotoxic 
drugs (Tinel and Tschopp, 2004). 
 
Studying of erythroleukaemia cell line by Lin et al. (2000) allowed to find that PIDD 
functions as a direct transcriptional target of p53. Moreover, p53-dependent transcription 
of the Pidd gene was observed in mouse embryonic fibroblast exposed to g-irradiation 
as well as in AML-4 (leukaemia) and MCF7 (breast cancer) cells. Additionally, the 
authors found that apoptosis could be induced in cells lacking p53 and supressed in cells 
with knocked down PIDD (Lin et al., 2000). Moreover, it was reported that application of 
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antisense nucleotides targeting PIDD mRNA delayed apoptosis induction in p53-
overexpressing K562 (myelogenous leukaemia) cells (Lin et al., 2000). The same 
phenomenon was observed in H1299 cells with increased p53 expression accompanied 
by application of RNA interference against PIDD mRNA (Baptiste-Okoh et al., 2008). In 
parallel, other proteins involved in the cell death regulation and controlled in the p53-
dependent manner were described, namely Puma and Noxa. It has been confirmed by 
various studies in vivo that Puma and Noxa, but not PIDD, were required for the p53-
mediated DNA damage response and cell death induction (Villunger et al., 2003; Kim et 
al., 2009; Manzl et al., 2009). Additionally, it was suggested that PIDD can play a role 
outside of the p53-mediated pathways, as it was still expressed at low levels in p53-
lacking HCT116 and HEK-239 cells (Tinel e al., 2007). Induction of the basal PIDD 
expression, independent of p53, was also reported by Cuenin et al. (2008), which 
suggests different mechanisms involved in regulation of PIDD levels in cells.  
 
It was described that the PIDD-originating segments, in particular PIDD-C and PIDD-CC, 
can perform different functions within cells and form complexes with various proteins 
(Sladky et al., 2017). For example, PIDD-CC is a key component of the RAIDD- and 
caspase-2-containing PIDDosome complex, involved in mediation of cell death. On the 
contrary, PIDD-C forms a protein platform with RIP1 and Nemo (Sladky et al., 2017)/ It 
was proposed that Nemo is ubiquitinated and degraded at the complex, which 
contributes to a subsequent activation of NF-κB signalling pathway and cell survival. It 
was shown by numerous in vitro and in vivo studies that PIDD is indeed involved in NF-
κB activation (Bock et al., 2012; Bock et al., 2013), but it does not play a role in the cell 
survival or DNA repair. Further experiments have demonstrated that the PIDD-
C/RIP1/Nemo complex is most likely involved in inflammation (Bock et al., 2013). 
Furthermore, the MS-analysis of the overexpressed PIDD revealed that its full-length 
form or PIDD-C can form a complex, which comprises PCNA (proliferating cell nuclear 
antigen), RFC5 (replication factor C subunit 5) and RFC4 (replication factor C subunit 4). 
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The complex is localised in the nucleus and involved in translesion DNA synthesis 
(Logette et al. 2011). The exact role of the PIDD-N fragment still remains to be defined 
(Sladky et al., 2017).  
 
Various reports, inspired by the findings obtained by Tinel and Tschopp (2004), 
investigated the role of PIDD in triggering of the caspase-2-mediated cell death (Bock et 
al., 2012; Janssens and Tinel, 2012). Studying p53-deficient zebrafish embryos, which 
were resistant to radiotherapy, revealed that upon inhibition of the Chk1 (checkpoint 
kinase 1), the cell death could be restored. Interestingly, it was found that the cell death 
in zebrafish embryos was independent of caspase-3, -8 and -9, Bcl-2, Noxa, Puma, 
cytochrome c, p63 or p73, could not be blocked by Bcl-2 overexpression, but required 
involvement of caspase-2 and was regulated by the ATM/ATR (ataxia telangiectasia and 
Rad3-related protein)/caspase-2 signalling network (Sidi et al., 2008). Importantly, it was 
reported that this mode of cell death was conserved in various human tumours, however 
it was only partially confirmed by in vivo studies (Manzl et al., 2013). Other reports 
examined the ATM/ATR/caspase-2 signalling axis induced upon Chk1 inhibition and 
found that activated ATM, but not ATR, was associated with PIDD (Ando et al., 2012), 
which contributed to formation of the PIDDosome formation and subsequent initiation of 
caspase-2-mediated apoptosis in HeLa cells. On the other hand, ATM-mediated 
assembly of the PIDDosome suppressed an interaction between PIDD and RIP1, which 
indicated that ATM can regulate the mode of PIDD action (pro-survival vs. pro-apoptotic) 
in the cells (Ando et al., 2012). Interestingly, binding of ATM to PIDD was also observed 
in response to irradiation or etoposide alone, without inhibition of Chk1, however the 
combined treatment was more efficacious in promoting of the PIDDosome formation 
(Ando et al., 2012). Nevertheless, it still remains enigmatic, how caspase-2 drives this 
type of cells death.  
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Interestingly, at the same time, it was demonstrated that using siRNA to target PIDD or 
RAIDD expression did not affect the processing of caspase-2 in HCT116 cells treated 
with 5-FU (Vakifahmetoglu et al., 2006). Moreover, it was reported that PIDD-
overexpressing mouse fibroblasts could trigger apoptosis dependent on RAIDD, but not 
caspase-2. These findings indicated that PIDD could be involved in initiation of the cell 
death, which did not require engagement of caspase-2 (Berube et al., 2005). Manzl et 
al., (2009) examined the role of PIDD in ell death induction by using PIDD-deficient mice. 
The authors observed that caspase-2 was activated in the etoposide-treated primary 
lymphocytes, which were unable to form the PIDDosome complex. Similar, the loss of 
RAIDD did not affect the levels of caspase-2 activation in the cells. Moreover, mouse 
lymphocytes and SV40-transformed MEFs (mouse embryonic fibroblasts) were 
susceptible to apoptosis independent of PIDD and caspase-2 in response to DNA 
damage, endoplasmic reticulum stress and growth factor deprivation as well as TNF and 
FAS-mediated cell death initiation.  
 
Taken together, these findings suggest the existence of alternative functions of capsase-
2 and its activation mechanisms, other than PIDDosome, in response to DNA damage 
(Manzl et al., 2009). Importantly, the authors suggested that, upon DNA damage, 
processing of caspase-2 occurs downstream of MOMP and Apoptosome, and requires 
involvement of Apaf-1 and caspase-9, which is in contrast to other reports describing  
that caspase-2 activation takes place upstream of mitochondria in HeLa and Jurkat cells 
(Guo et al., 2002; Robertson et al., 2002; Robertson et al., 2004). Interestingly, similar 
to Manzl et al. (2009), the most recent study by Fava et al. (2017) demonstrated that 
PIDD-mediated caspase-2 activation is not involved in cell death initiation and DNA 
damage-induced p53 activation. Instead, it was found that the PIDDosome-regulated 
caspase-2 activation contributes to activation of p53 in the process of centrosome 
amplification and can function as a sensor of aberrant centrosome numbers (Fava et al., 
2017). These findings indicate that PIDD plays an important role in cell differentiation 
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and organogenesis (Sladky et al., 2017). Interestingly, it was recently discovered that 
NPM1 (nucleophosmin), an oncogenesis regulator, which is often found to be mutated 
or dysregulated in acute myeloid leukaemia and other tumours, is directly involved in the 
PIDDosome formation in response to DNA damage (Sidi and Bouchier-Hayes, 2017).   
 
To conclude, many contradictions arise from the initial findings indicating that the 
PIDDosome promotes apoptosis in response to DNA damage and other stimuli, and 
subsequent results showing that the PIDDosome constituents demonstrate inconsistent 
phenotypes and that the complex formation is regulated in a differential fashion under 
various experimental conditions. These contradictions require different models and 
answers with respect to identification of the upstream and downstream regulators of the 
PIDDosome, functions of PIDD and caspase-2, and other molecular pathways that these 
proteins are potentially involved in.   
 
1.8.3. RIPoptosome	
 
The study by Geserick et al. (2009) was first to describe the RIPoptosome, a novel 
cytosolic protein platform encompassing caspase-8, RIP1, FADD and cFLIP isoforms 
(Figure 6). The complex was identified upon induction of the cell death by CD95 and in 
response to IAP antagonist-mediated depletion of cIAPs (Geserick et al., 2009). The 
RIPoptosome contributes to induction of the cell death machinery in various cancer cell 
lines exposed to cytotoxic and genotoxic stresses. To date, there have been many 
reports describing that the RIPoptosome formation occurs in response to a wide range 
of stimuli, including DNA damage, IAPs depletion, accumulation of RIP1, exposure to 
chemotherapeutics and application of Smac mimetics. It was demonstrated that the 
RIPoptosome can be assembled in response to application of IAP antagonists (Smac 
mimetics) alone or in combination with TLR3 stimulation (Feoktistova et al., 2011) and 
DNA-damaging anti-tumour drugs, such as etoposide (Tenev et al., 2011; Riley et al., 
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2015). The most recent studies reported that RIPoptosome-mediated cell death can be 
also induced in response to: (I) treatment with BV6 plus glucocorticoids in acute 
lymphoblastic leukaemia (Belz et al., 2014), (II) overexpression of ZFP36 in glioblastoma 
(Selmi et al., 2015), (III) application of dimethyl fumarate (DMF; FDA approved as 
Tecfidera®) and targeting Thioredoxin-1 (Trx-1) in T-cell lymphomas and leukaemias 
(Schroeder et al., 2017).  
 
Caspase-8, RIP1, FADD and cFLIP are also components of the TNF-induced complex 
II. However, the RIPoptosome is formed without involvement of the TNF-R1 and TNF 
signalling, which indicates that this protein platform functions as an independent 
signalling complex (Schilling et al., 2014) (Figure 6). In the RIPoptosome, caspase-8 is 
cleaved and activated, which leads to initiation of the cell death. Importantly, Feoktistova 
et al., (2011) and Tenev et al., (2011) have identified RIP1 to be the core driver of the 
complex assembly, hence the term RIPoptosome. Apart from caspase-8, RIP1, FADD 
and cFLIP isoforms, the complex may also contain caspase-10, however this depends 
on the cell type and stimulation. Moreover, depending on the expression levels and 
activity of these molecular components, the cells can either undergo caspase-dependent 
apoptosis or RIP1-RIP3-dependent necroptosis (Feoktistova et al., 2011).  
 
Conventionally, the above mentioned RIPoptosome constituents are believed to be 
involved in triggering the extrinsic/death receptor apoptotic pathway (Micheau and 
Tschopp, 2003; Lavrik et al., 2005; Elmore, 2007). In the classical model of apoptosis, 
capase-8 (and also caspase-10) can be recruited to CD95 or TRAIL receptors in a 
FADD-dependent manner in response to interaction of the death receptors with their 
complementary death ligands. Such events lead to formation of the DISC, at which 
caspase-8 and -10 undergo multimerization followed by proteolytic cleavage and 
activation. Finally, active caspase-8 and -10 can proteolytically process and activate their 
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downstream targets, such as caspase-3, -6 and -7 (classified as effector caspases) 
(Ohtsuka et al., 2003; Yu et al., 2009; He et al., 2015; Koff et al., 2015).  
 
The molecular mechanisms responsible for the RIPoptosome formation, its regulation 
and RIPoptosome-mediated cell death induction in cancer cells exposed to various 
stimuli have been widely studied and are currently well understood. Feoktistova et al., 
(2011) reported, that the loss of IAPs caused by Smac mimetics contributed to 
enhancement of the cell death induced by poly(I:C) in HaCaT and MET-1 but not A5RT3 
cells. Importantly, it was described that knocking down of cIAP1 in HaCaT cells 
contributed to sensitisation of the cells to TLR3-mediated cell death. The cells were 
further sensitised in response to IAP inhibitors. Such results indicate, that cIAP1 plays 
the decisive role in TLR3-induced apoptosis and necroptosis, whereas cIAP2 is involved 
in the cell death resistance (Feoktistova et al., 2011). These findings also argue that 
TLR3-mediated cell death is controlled in a cell type-specific manner.  
 
At the same time, Tenev et al. (2011) found that the treatment with etoposide contributes 
to a strong reduction of cIAPs and XIAP in different tumour cell lines, which leads to 
formation of the RIPoptosome. Moreover, it was demonstrated by Tenev et al. (2001) 
camptothecin and tenoposide also caused degradation of cIAP1, cIAP2 and XIAP, but 
only the latter triggered formation of the caspase-8/RIP1/FADD complex. Similar results 
were obtained by Belz et al., (2014), which demonstrated that a combination of the IAP 
inhibitor BV6 and glucocorticoids (dexamethasone) lead to a strong reduction of the 
cIAP1, cIAP2 and XIAP. Additionally, Belz et al., (2014) observed that upon the 
treatment, the activity of caspase-8 and production of ROS were significantly increased. 
As a result, these events led to the RIPoptosome formation and cell death induction in 
tumour cells (Belz et al., 2014). Furthermore, Tenev et al. (2011) found that cIAPs 
regulate the RIPoptosome formation by targeting RIP1, caspase-8, caspase-8/cFLIP 
heterodimers, but not FADD, for ubiquitination and degradation. These results were 
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supported by the observation that application of the proteasome inhibitor, lactacysting, 
promoted the RIPoptosome formation.  
 
Taken together, the results obtained by Feoktistova et al. (2011), Tenev et al. (2011) and 
Belz et al. (2014) showed that degradation of IAPs drives the RIPoptosome assembly 
and the RIPoptosome-mediated cell death induction, which was observed in various 
cancer cells lines exposed to a wide range of stimuli. These findings indicate that the 
RIPoptosome is not cell type- nor stimulus specific, but rather a fairly common cell death 
induction mechanism. In addition to that, another function of cIAPs was discovered, as 
it was found that these proteins regulate the complex assembly by targeting of the 
RIPoptosome components for ubiquitination and subsequent degradation. This suggest 
that cIAPs play different roles in the context of RIPoptosome.  
 
A very recent study by Schroeder et al. (2017) discovered another mechanism 
responsible for the RIPoptosome formation and subsequent cell death induction. The 
authors examined the effect of DMF-mediated suppression of Trx-1, which functions as 
a main regulator of NF-κB transcriptional activity. It was reported that active NF-κB can 
promote survival of various tumours, including T-cell lymphomas and leukaemias via 
positive regulation of the IAPs and cFLIP expression in the cells. Thus, Schroeder et al. 
(2017) wondered, whether targeting of Trx-1 could antagonise NF-κB, downregulate 
IAPs and cFLIP, and in turn contribute to formation of the RIPoptosome and subsequent 
cell death. First, the authors confirmed that DMF-mediated inhibition of NF-κB leads to 
depletion of cIAP2 and cFLIP, but not XIAP and Bcl-2 family members and caused cell 
death in HH (human lymphoma), SeAx (cutaneous T-cell lymphoma cell line) and CEM 
(T-cell leukaemia cell line) cells. Moreover, the study has demonstrated that application 
of DMF caused an increase of caspase-8 activity in the cells. The RIPoptosome was also 
formed in response to the treatment, which was confirmed by investigation of the 
caspase-8/RIP1/FADD interactions by using the proximity ligation assay and co-
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immunoprecipitation of caspase-8. Thus, in addition to the previous findings, it appears 
that the RIPoptosome can be formed indirectly by inhibition of NF-κB, leading to the loss 
of cIAP2 and cFLIP, which provides more insights into the mechanisms responsible for 
the complex assembly.  
 
It was discovered that RIPoptosome mediates different modes of cell death, namely 
apoptosis and necroptosis (Figure 6). Feoktistova et al., (2011) demonstrated that, 
regardless of the IAPs status, application of zVAD or Nec-1 alone barely affected the 
poly(I:C)-induced apoptosis and TLR-3-mediated HMGB-1 release. Interestingly, when 
zVAD and Nec-1 were used in combination, the HMGB-1 release was supressed, and 
the cells were rescued from apoptosis. Additionally, the analysis of the cell morphology 
revealed that the depletion of IAPs and blocking of caspases with zVAD lead to TLR3 
stimulation followed by induction of RIP1-mediated necroptosis. Thus, these findings 
indicate that the RIPoptosome can trigger both apoptosis and necroptosis (Figure 6). 
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Figure 6. Activation and signalling of the novel cell death-inducing protein platform, 
RIPoptosome and its regulation by cFLIP isoforms.  
Upon intracellular stimuli, the RIPoptosome complex, which consists of RIP1, FADD and 
caspase-8, is formed in tumour cells. At the complex, caspase-8 is activated and initiates 
apoptosis (right panel). The RIPoptosome also regulates the RIP3-dependent necroptosis (left 
panel). Different cFLIP isoforms control the RIPoptosome assembly and the mode of the cell 
death (apoptosis vs. necroptosis). In the presence of cFLIP-L, the caspase-8/cFLIP-L 
heterodimers are formed, which cause that the process of caspase-8 activation is limited. This in 
turn leads to the RIP1 cleavage and RIPoptosome disassembly (middle panel). Moreover, cFLIP-
S positively regulates the RIPoptosome formation and promotes a shift towards the RIP1-RIP3-
dependent necroptosis in tumour cells (left panel) (Imre et al., 2011).6 
 
 
6 Image created with BioRender.com 
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Similar to the results obtained by Feoktistova et al. (2011), observations by Tenev et al. 
(2011) also demonstrated that the RIPoptosome mediates different cell death modes 
(caspase-dependent apoptosis vs. caspase-independent necroptosis). The authors 
reported that the application of Nec-1 completely and partially blocked caspase 
activation in etoposide-treated HT1080 cells and MDA-MB-231 cells, respectively, in 
response to etoposide. However, in both cases formation of the RIPoptosome was 
strongly reduced. Exposure to a combination of Nec-1 and zVAD inhibited the etoposide-
induced cell death machinery, however it promoted the RIP3-mediated activation of 
caspases in MDA-MB-231 cells (Tenev et al., 2011). Such findings indicated, that 
etoposide induces apoptotic cell death in HT1080 cells, whereas in MDA-MB-231 cells 
both apoptosis and necroptosis are triggered in response to the treatment. Moreover, 
these results further confirmed the involvement of the RIPoptosome in mediation of 
different cell death modes. However, it is noteworthy, that the mode of the cell death 
triggered in response to etoposide depends on the cell type.  
 
Similar to Feoktistova et al. (2011) and Tenev et al. (2011), Schroeder et al. (2017) also 
demonstrated that RIPoptosome can be involved in induction of both apoptosis and 
necroptosis. As mentioned, administration of DMF induced the RIPoptosome formation 
and caspase-8 dependent apoptosis in HH, SeAx and CEM cells. In order to assess, 
whether RIPoptosome can mediate necroptosis, the authors used CD4+ T-cells, isolated 
from patients with the Sézary Syndrome. Such T-cells are characterised by strongly 
increased activity of NF-kB and elevated levels of cIAP2 and cFLIP. DMF-mediated 
inhibition of NF-kB led to the RIPoptosome formation and induction of the cell death in 
CD4+ T-cells, which could be inhibited by treatment with combination of zVAD and Nec-
1, but not by zVAD alone. Similar effects were observed in CEM cells. These results 
indicate, that inhibition of capase-8 activity leads to a switch to the necroptotic mode of 
the cell death in tumour cells and confirms the involvement of the RIPoptosome in both 
apoptosis and necroptosis.  
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Identification and analysis of the RIPoptosome components was performed by using co-
immunoprecipitation of caspase-8 in response to: (I) treatment with Smac mimetics plus 
poly(I:C) (Feoktistova et al., 2011) or etoposide (Tenev et al., 2011), (II) stimulation with 
BV6 plus dexamethasone, (III) exposure to etoposide alone (Selmi et al., 2015), (IV) 
overexpression of ZFP36 (Selmi et al., 2015) and administration of DMF (Schroeder et 
al., 2017). The caspase-8 complex, induced upon TLR3-stimulation, contained RIP1, 
FADD, cFLIP (p43 cleavage fragment) and caspase-10 (p47/p43 segment) (Feoktistova 
et al., 2011). Similarly, stimulation of HT1080 and MDA-MB-231 cells with Smac 
mimetics and etoposide allowed co-purification of caspase-8 bound to RIP1, FADD and 
cFLIP-L (Tenev et al., 2011). The caspase-8/RIP1/FADD complex was also found in 
response to the BV6 plus dexamethasone treatment in Jurkat and Reh cells (Belz et al., 
2014), upon overexpression of ZFP36 (Selmi et al., 2015) and after application of DMF 
in CEM and SeAX cells (Schroeder et al., 2017).  
 
However, Tenev et al. (2011), Belz et al. (2014), Selmi et al. (2015) and Schroeder et al. 
(2017) did not detect caspase-10 within the RIPoptosome, which was in contrast the 
results obtained by Feoktistova et al. (2011). It is noteworthy, that each group used 
different cell lines and treatments to induce the RIPoptosome assembly and cell death. 
Therefore, the levels of caspase-10 could be different, depending on the cell type and/or 
stimulus or it might be inducible in some cell types but not others. Nevertheless, the 
biological significance and the activity of caspase-10 in terms of the RIPoptosome 
formation and its role in the complex activation still remain enigmatic and requires further 
examination and clarification (Feoktistova et al., 2011).  
 
In order to examine the composition of the RIPoptosome in more detail, Feoktistova et 
al. (2011) and Tenev et al. (2011) performed chromatographic gel filtration analysis 
followed by caspase-8 immunoprecipitation of the selected elution fractions. The 
complex was extracted from: (I) cFLIP-S-overexpressing HaCaT cells treated with z-VAD 
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alone (control) or with the IAP antagonist plus z-VAD combination (Feoktistova et al., 
2011), and (II) HT1080 cells exposed to z-VAD alone (control) or to the etoposide/Smac 
mimetics/z-VAD combination. The RIPoptosome components were detected in elution 
fractions corresponding to the size of ~2MDa by both groups. Interestingly, it was 
observed that caspase-8 and RIP1 were mostly detectable in their monomeric forms 
(Feoktistova et al., 2011) and overall, only small proportions of the total caspase-8, RIP1 
and FADD were associated with the RIPoptosome (Feoktistova et al., 2011; Tenev et 
al., 2011). These findings suggest that other molecules might be present within the 
complex, however further studies are required to identify the yet unknown RIPoptosome 
components. Feoktistova et al. (2011) detected caspase-8, RIP1 and cFLIP-S in the 
fractions corresponding to ~2MDa in response to zVAD alone and combined with IAP 
antagonist. Similarly, Tenev et al. (2011) also detected caspase-8 and RIP1 in the 
fractions corresponding to ~2MDa after exposure to z-VAD alone and the etoposide, 
Smac mimetics and z-VAD combination. Interestingly, the subsequent 
immunoprecipitation of the selected gel filtration fractions at ~2MDa led to the co-
purification of RIP1 by both groups, and additionally cFLIP-S and FADD by Tenev et al. 
(2011). None of these proteins were co-purified in the controls. Therefore, the role of the 
uncomplexed RIPoptosome components detected in the ~2MDa range in response to z-
VAD alone and the exact mechanisms whereby IAPs influence the complex assembly 
requires further investigation and clarification. 
 
Interestingly, a recent study by Jang et al. (2014) proposed a mechanism and a 
molecular model for the formation and an overall structure of the RIPoptosome core by 
investigation of the interactions between RIP1 and FADD death domains. The authors 
expressed and purified the proteins of interest (RIP1 DD, residues 583−664 and FADD 
DD, residues 93−184), reconstituted the RIP1 DD/FADD DD complex in vitro, which was 
in turn examined by using electron microscopy and gel filtration. Electron microscopy 
showed a population of the monodispersed and homogeneous particles, which were 
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structurally similar to the Fas DD/FADD DD complex (Wang et al., 2010). Gel filtration 
analysis resulted in elution of the RIP1 DD/FADD DD complex in the range 
corresponding to ~120 kDa. Using MALS (multiangle light scattering) allowed to 
determine the molecular weight of the protein platform at 118.7 kDa and therefore 
confirmed the gel filtration result. MALS was also used to assess the stoichiometry of the 
RIP1 DD/FADD DD complex. It was revealed that the protein platform consists of five 
RIP1 DDs and five FADD DDs. Furthermore, Jang et al. (2014) performed a mutational 
analysis of the complex formation in vitro by using pull-down assays and gel filtration. 
The mutations were generated in both RIP1 DD and FADD DD, and were based on the 
previously resolved Fas DD and FADD DD structure (Wang et al., 2010). Additionally, 
FADD DD was fused with the (His)6 tag. The pull-down and gel filtration results confirmed 
that RIP1 DD and FADD DD can form a stable protein platform, which resembles the 
Fas DD/FADD DD complex. These findings suggest that the molecular mechanisms 
responsible for the RIPoptosome and Fas-DISC assembly are similar. Therefore, the 
authors proposed a schematic model of the RIPoptosome (Jang et al., 2014).  
 
The study by Jang et al. (2014) provides interesting and important insights into the 
general formation mechanism used by death domains in terms of the RIPoptosome 
assembly. The authors assume that the other members of the DD superfamily, which 
apart from the DD, encompasses CARD, DED (death effector domain) and PYD (pyrin 
domain), form protein platforms and interact by using molecular mechanisms similar to 
those used by DDs. Nevertheless, to date there have been no reports, that tested and 
confirmed such hypothesis. Moreover, the study by Jang et al. (2014) contains a few 
limitations. Provided that the authors investigated the RIPoptosome formation 
mechanisms by using truncated fragments of RIP1 and FADD, without including the 
other components, namely caspase-8 and cFLIP-S, the proposed model provides only a 
part of the answer on how the complex is assembled. Moreover, the presence of 
caspase-8 and/or cFLIP-S might affect the stoichiometry and the structural conformation 
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of the complex as well as its components, which might differ from the described model. 
Therefore, further biochemical studies, which would aim to reconstitute the RIPoptosome 
complex in vitro by using caspase-8, RIP1, FADD and cFLIP-S, preferably at their full-
length forms, are necessary to provide more details regarding the RIPoptosome 
structure and assembly mechanism.  
 
cFLIP was identified by Feoktistova et al. (2011) and Tenev et al. (2011) as a critical 
regulator of the cell death induction and RIPoptosome formation (Figure 6). It was 
observed that knocking down of cFLIP led to a strong sensitisation to TLR3- or Smac 
mimetic- and etoposide-induced cell death (Feoktistova et al., 2011; Tenev et al., 2011). 
Additionally, Smac mimetics and etoposide combination caused an increased 
RIPoptosome formation (Tenev et al., 2011). Interestingly, in the absence of IAPs, 
various cFLIP isoforms were shown to regulate the RIPoptosome assembly and play a 
role in the switch between cell death modes (apoptosis vs. necroptosis) in a differential 
manner (Feoktistova et al., 2011). Upon treatment with IAP antagonist, overexpression 
of cFLIP-L completely blocked the cell death and RIPoptosome formation in HaCaT cells. 
In contrast, overexpressed cFLIP-S promoted the cell death and the complex assembly 
as well as contributed to the increase of the RIP1 levels in the absence of IAPs in HaCaT 
cells. Interestingly, the study reported that in the cFLIP-S-expressing cells caspase-8 
activity within the RIPoptosome was blocked. It was also found that increased levels of 
cFLIP-S favoured initiation of the RIP1-RIP3-meadiated necroptosis. In contrast to 
HaCaT findings, analysis of HeLa cells showed an inhibition of the TLR3-mediated cell 
death in the presence of both overexpressed cFLIP isoforms. However, similar to HaCaT 
results, overexpressed cFLIP-S, but not cFLIP-L, promoted formation of the 
RIPoptosome complex. On the contrary, the protein complex assembly was not 
observed in human keratinocytes (PKs) with supressed IAPs functions. These results 
indicate that formation of the RIPoptosome highly depends on the cell type. The findings 
also argue, that the cFLIP isoforms perform opposite functions in terms of the regulation 
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of the complex assembly, and that this process depends on the stoichiometry of the 
proteins (Feoktistova et al., 2011).  
 
Further study by Feoktistova et al., (2012), in which the authors investigated the role of 
stoichiometry of the molecular components in terms of the RIPoptosome formation and 
cell death induction, described that the decision point for the complex assembly lies in 
the balance between RIP1 and cIAPs. This was shown by an increased cell death 
initiation and promotion of the RIPoptosome formation in HaCaT cells in response to the 
induced expression of RIP1. In this case, cIAP1 was also recruited to the complex. In 
other words, elevation of RIP1 levels or, as shown by previous study, depletion of IAPs 
leads to RIPoptosome assembly, followed by initiation of apoptosis or necroptosis. 
Another decision point regards the switch between the apoptotic and necroptotic modes 
of cell death. Feoktistova et al., (2012) proposed that the switch to necroptosis depends 
on the regulation of the RIP1/RIP3 interaction by caspase-8/cFLIP heterodimers. In 
particular, the authors assume that increased interaction between caspase-8 and cFLIP-
L contributes to the RIP1 cleavage and, as a result, leads to the RIPoptosome 
disassembly and blocks cell death induction (Figure 6). On the other hand, it was 
demonstrated that preferable binding of caspase-8 and cFLIP-S prevents the RIP1 
cleavage, which promotes the RIP1/RIP3 interaction and RIP1/RIP3-dependent initiation 
of necroptosis (Feoktistova et al., 2012) (Figure 6). The role of RIP3 in triggering of the 
necroptotic cell death was supported by reconstitution of RIP3 expression in HeLa cells, 
which were in turn susceptible to necroptosis in the absence of IAPs. Moreover, 
overexpression of cFLIP-S in these cells contributed to the increase of the cell death, 
which was dependant on RIP3, but not caspase-8 (Feoktistova et al., 2012). Taken 
together, previous and these findings indicate that the balance between cFLIP-S and 
RIP3 is critical for execution of necroptosis in the cells.  
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Nevertheless, the question still remains, whether RIP3 functions as one of the 
components of the RIPoptosome in the necroptotic cell death, or whether this protein is 
regulated, directly or indirectly, downstream of the complex. Due to some limitations, 
Feoktistova et al. (2011) and Tenev et al., (2011) were unable to detect RIP3 after 
performing caspas-8 co-immunoprecipitation, thus the exact function and activity of RIP3 
in induction of RIPoptosome-mediated necroptosis still remains unclear.  
 
Taken together, the recent findings indicate that caspase-8 is not only activated via the 
classical pathway of the death receptor triggering, but also by a novel, intracellular 
complex, the RIPoptosome. Alternatively, when apoptosis is blocked, the complex can 
switch to the necroptotic mode of the cell death. Thus, targeting the RIPoptosome for 
novel therapeutic approaches holds a significant promise in sensitisation of the 
treatment-resistant tumours to cell death.  
 
1.8.4. FADDosome	and	FLIPosome	
 
Similar to the previous reports, our group has described another example of a protein 
platform, which contains caspase-8 and contributes to initiation of cell death in response 
to chemotherapeutic compounds (Mohr et al., 2018). This recently discovered complex, 
which we refer to as FADDosome (Figure 7), has been shown to initiate the cell death in 
cancer cells subjected to treatment with 5-FU, irinotecan or raltitrexed without 
requirement for induction of the death receptor signalling pathways (Mohr et al., 2018).  
 
As already mentioned, upon treatment with 5-FU apoptosis is induced in caspase-9-
independent manner and, contrary to the Feoktistova et al. (2011) and Tenev et al. 
(2011) findings, it does not require formation of the RIPoptosome complex. However, we 
observed that p53 was necessary for execution of apoptosis in 5-FU-treated cancer cells. 
Moreover, we found that p53 plays an important role in execution of apoptosis via 
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mitochondrial network in HCT116 cells, but is dispensable for the caspase-8-mediated 
cell death. Thus, we have demonstrated that upon exposure to 5-FU, caspase-8 is 
activated in the p53-independent manner (Mohr et al., 2018). 
 
Further experiments have shown that caspase-10 was upregulated in response to 5-FU 
and this process was independent of p53. The immunoprecipitation of caspase-8 led to 
co-purification of caspase-10 and FADD, but not cIAP2 or the death receptors. The 
observation was supported by studying of the 5-FU-treated HCT116 and 293 cells, which 
were overexpressing caspase-10- and FADD, respectively. The results have shown that 
caspase-10 and FADD could be co-immunoprecipitated with caspase-8 in HCT116 cells, 
whereas caspase-8 and -10 could be co-precipitated with pulled-down FADD in 293 
cells. The sucrose gradient analysis unveiled that the size of the caspase-10/caspase-
8/FADD complex was ~2 MDa (Mohr et al., 2018) and the result was similar to the 
observed size of the RIPoptosome (Feoktistova et al., 2011, Tenev et al., 2011). The 
immunoprecipitation of caspase-8 led to co-purification and identification of other 
constituents of the FADDosome, namely RIP1 and TRAF2. We found that caspase-10 
and RIP1 were necessary for the recruitment of TRAF2 to the complex, which could in 
turn promote ubiquitination and degradation of cFLIP-L (Mohr et al., 2018) (Figure 7).  
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Figure 7. The FADDosome-mediated cell death induction and a model of the protein-
protein interactions within the complex. 
A. Upon DNA damage (indicated by the red star) caused by anti-cancer drugs, such as 5-FU, 
caspase-10 is upregulated in the p53-independent manner, which leads to formation of the novel 
apoptosis-inducing protein platform, FADDosome, encompassing caspase-10, caspase-8, 
FADD, RIP1 and TRAF2. At the complex, caspase-8 is cleaved and activated, which leads to 
activation of caspase-3 and subsequent induction of apoptosis (adapted from Mohr et al., 2018). 
B. Within the FADDosome, FADD possibly acts as a scaffold and binds to caspase-10, caspase-
8 and cFLIP-L. Moreover, RIP1, which is also recruited to the complex, interacts with FADD. Next, 
TRAF2 binds to RIP1 and ubiquitinates cFLIP-L, leading to its degradation. Moreover, cleavage 
and activation of caspase-8 at the complex is possibly facilitated and/or mediated by caspase-10. 
7 
 
 
7 Image created with BioRender.com 
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Moreover, we observed that the loss or inhibition of any of these factors in cancer cells 
exposed to 5-FU promotes a switch to an alternative cell death mechanism, which 
required assembly of the FLIPosome platform consisting of cFLIP-L and caspase-8 
(Figure 8). Moreover, our results showed that in the absence of caspase-10 and RIP1, 
cIAP1 undergoes degradation in response to 5-FU. At the FLIPosome, cFLIP-L is 
cleaved by caspase-8, leading to generation of the cFLIP-p43 fragment and subsequent 
NF-κB activation, TNF-α expression and autocrine/paracrine cell death (Figure 8). 
Importantly, our group has demonstrated that FLIPosome-mediated apoptosis is p53-
independet and overall, more efficacious than the FADDosome, which might provide a 
great advantage in the treatment of tumours with impaired p53 functions (Mohr et al., 
2018).  
 
Although we have identified caspase-10 to act as the core driver of the FADDosome 
assembly in 5-FU-induced apoptosis, the exact molecular mechanisms whereby 
upregulated caspase-10 forms the FADDosome and recruits other constituents requires 
clarification. Moreover, it still remains to be defined, what molecular factors and signalling 
pathways regulate the FADDosome and FLIPosome formation in response to 
chemotherapeutic drugs. 
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Figure 8. The FLIPosome-mediated cell death induction and a model of the protein-protein 
interactions within the complex. 
A. The 5-FU-treated cells lacking caspase-10, RIP1, TRAF2 or ATR switch to an alternative mode 
of apoptosis, mediated by another novel cell-death-initiating protein platform, FLIPosome, which 
leads to cleavage of cFLIP-L, followed by NF-kB activation and TNF-a production. Finally, these 
events lead to initiation of the autocrine/paracrine cell death (adapted from Mohr et al., 2018). B. 
In the process of the FLIPosome assembly, caspase-8 binds to cFLIP-L, which contributes to the 
caspase-8-mediated processing of cFLIP-L to cFLIP-p43.8 
 
 
 
8 Image created with BioRender.com 
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In parallel, Henry and Martin (2017) discovered another protein platform, which similarly 
to the complex described by our group, was also termed FADDosome. The authors 
examined the role of TRAIL receptor signalling pathway in mediating NF-kB and MAPK 
activation, cytokine production and inflammation signalling. Henry and Martin (2017) 
discovered that upon TRAIL stimulation, cancer cells can form a pro-inflammatory 
complex, consisting of caspase-8, FADD and RIP1.  
 
Henry and Martin (2017) studied the TRAIL-induced cytokine production in various 
cancer cell lines. They found that the secretion of IL-6 (interleukin 6), IL-8 (interleukin 8), 
CXCL1 (chemokine (C-X-C motif) ligand 1), MIF (macrophage migration inhibitory factor) 
and MCP-1 (monocyte chemoattractant protein-1) was significantly increased in HeLa 
cells. The cytokine production was also observed in PancTu-1, HCT116, HaCaT, 3LL 
and primary human prostate epithelial cells after application of TRAIL. These findings 
indicate that TRAIL-mediated cytokine synthesis is a general property of the TRAIL-R 
signalling pathway. In addition, Henry and Martin (2017) described that stimulation of the 
TRAIL receptor contributed to production of pro-inflammatory molecules, which are 
involved in induction of chemotaxis of neutrophils and monocytes towards in the cells.  
 
Furthermore, zVAD-mediated inhibition of caspase activity led to suppression of 
apoptosis induction, but not the cytokine/chemokine production in HeLa and HT29 
exposed to TRAIL, indicating that inflammatory responses occur independent of caspase 
activity and can be uncoupled from apoptotic pathways (Henry and Martin, 2017). Next, 
the authors wondered, what molecular factors are involved in the TRAIL-mediated 
inflammatory response. The results revealed that knocking down of RIP1, FADD and 
TAK1, but not TRADD, abolished the cytokine/chemokine production in HeLa cells upon 
TRAIL stimulation. Surprisingly and unexpectedly, the authors found that caspase-8 
knockdown inhibited the inflammatory responses in TRAIL-treated HeLa cells, which was 
in contrast to the results obtained after application of zVAD. In addition, knocking down 
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of caspase-8 and FADD in HT-29 and HCT116 cells blocked TRAIL-mediated 
cytokine/chemokine secretion. In order to further confirm the role of caspase-8 in the 
TRAIL-induced inflammatory signalling, Henry and Martin (2017) used CRIPR/Cas9 and 
deleted Casp8 gene in HeLa and HCT116 cells, which similar to the previous results, 
abolished the inflammatory responses in the tested cell lines. These findings were 
supported by the observation that the re-introduction of wild-type caspase-8, caspase-8 
active site (C360A) mutant and caspase-8 linker (D374A/D384A) restored the 
cytokine/chemokine production in HeLa.Casp8-/- and HCT.Casp8-/- cells in response to 
TRAIL. On the contrary, application of the caspase-8 oligomerization (F122G/L123G) 
mutant did not restore the TRAIL-induced cytokine/chemokine production in the cells. 
Taken together, these results indicate that TRAIL-mediated inflammatory response in 
tumour cells require caspase-8 to act as a scaffold, whereas activity or proteolytic 
processing of caspase-8 are dispensable for this process.  
 
Co-immunoprecipitation of caspae-8 allowed to identify other molecules involved in 
TRAIL-mediated inflammatory signalling, namely caspase-10, FADD, RIP1, cFLIP, 
TRAF2, TAK1, Nemo and A20, indicating formation of a protein complex. Henry and 
Martin (2017) suggested that TRAIL receptor can form a transmembrane complex I, 
followed by detachment and subsequent generation of the cytosolic complex II, which 
would resemble the formation of the TNF-signalling complex I and II. The TRAIL-R 
complex II was termed the FADDosome. Importantly, the authors found that caspase-8 
is critical for the recruitment of RIP1 and other components to the complex, which was 
confirmed by failed co-purification of caspase-10, RIP1, cFLIP and A20 after using 
biotinylated-TRAIL, co-immunoprecipitation of FADD and ligand-mediated precipitation 
of the TRAIL receptor protein complex in HeLa.Casp8-/- cells (Henry and Martin, 2017).  
 
It is noteworthy, that in comparison to the FADDosome discovered by our group (Mohr 
et al., 2018), the FADDosome described by Henry and Martin (2017) encompassed 
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additional components (such as TAK1, Nemo and A20) and performed a distinct function 
(TRAIL-mediated inflammatory signalling). Thus, despite the fact, that these two 
complexes share the same name, they are most likely different.   
 
Such contradictions and refinements in our knowledge provide new insights into how 
apoptosis is triggered in tumour cells subjected to treatment with cytotoxic and genotoxic 
drugs. Therefore, it is currently possible to develop novel approaches for examination of 
the molecular mechanisms and targeting of factors involved in development of the drug-
resistance in cancer cells.  
 
1.9. Interactions	 Between	 Caspase-10,	 Caspase-8,	 FADD	
and	cFLIP		
 
It is believed that the protein-protein interactions between caspase-10, -8, cFLIP and 
FADD are possible due to the presence of DEDs in the structures of these molecules 
(Riley et al., 2015). It was described that FADD also contains the death domain, which 
is structurally similar to DED and allows this adaptor protein to interact with the death 
receptors. A few models for the DISC assembly at the levels of DEDs interactions have 
been proposed, which demonstrated an association between the death receptors, 
caspase-8 and FADD. Interestingly, it was proposed that the stoichiometry of the 
caspase-8 and FADD molecules at the DISC equals 9:1, and that one FADD molecule 
has the ability to associate with multiple DED-containing proteins, namely pro-caspase-
10, pro-caspase-8 and cFLIP. In this model, binding of multiple molecules to FADD would 
result in forming so called “chains”. Such chains were observed by studying of 
fluorescently tagged caspase-8 in single cells (Dickens et al., 2012; Schleich et al., 
2012). In contrast, a report by Riley et al. (2015) described that upon a sub-apoptotic 
DISC stimulation, even at high levels, the ratio between FADD and caspase-8 (or cFLIP) 
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was 1:2. Therefore, the exact stoichiometry of the molecules involved in the DISC 
formation remains to be defined.   
 
Furthermore, it had been described that FADD promotes an interaction between 
caspase-8 (and similarly, caspase-10) molecules, which stimulates forming dimers by 
these caspases (Wachmann et al., 2010; Parrish et al., 2013). To date, several studies 
have determined the interaction of FADD with death receptors and its role in the DISC 
formation (Scott et al., 2008; Wang et al., 2010). The biochemical structures of FADD 
DD or DED domains have also been resolved (Eberstadt et al., 1998; Berglund et al., 
2000). There is only one report available, which describes the structure of full-length 
FADD and proposes a model illustrating the mechanisms responsible for the interaction 
between FADD and zymogen caspase-8 (Carrington et al., 2006). The nuclear magnetic 
resonance (NMR) spectroscopy data revealed that the FADD structure is comprised of 
12 a helices (6 per domain) and that both C- and N- protein termini are oriented in a way 
allowing them to face one another. The main aim of the study was to identify the specific 
binding surface for pro-caspases, located on the DED of FADD. In order to do that 
Carrington et al., (2006) used a set of FADD proteins containing different mutations that 
could affect the binding of pro-caspase-8, however, all the FADD mutants could still 
interact with the CD95 death receptor. The results obtained by CD95 co-
immunoprecipitation allowed identifying the potential residues in FADD, which can be 
responsible for binding of procasapse-8 and these include: S12, R38, D44 and E51. 
Importantly, these sites can be found within helices a1 and a4 of FADD.  
 
In order to further elucidate the binding mechanisms between FADD and pro-caspase-
8, Carrington et al., (2006) used the MC159 protein, also known as viral FLICE-inhibitory 
protein (vFLIP) containing two DED domains, DED1 and DED2, which, due to their 
structural similarity, have been suggested to function as the equivalents of the pro-
caspase DED2 and FADD DED, respectively. The analysis of the MC159 biochemical 
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structure unveiled that DED2 helices a1 and a4 can interact with DED1 helices a2 and 
a5. Further investigation showed that the FADD/pro-caspase-8 interaction engages 
F122 and L123 residues within pro-caspase DED2. Such observations were confirmed 
by using pro-caspase-8 proteins containing mutations of both residues, which impaired 
the interaction between inactive pro-caspase-8 mutant and FADD in 293T cells 
(Carrington et al., 2006). To conclude, these results suggest that pro-caspases can bind 
to FADD through their DED2, but not DED1. 
 
A successful dimerization of caspases leads to their cleavage and subsequent activation, 
which is necessary for initiation of apoptosis in the cells. Only one study by Keller et al., 
(2009) has investigated the molecular mechanisms driving the dimerization of caspases 
so far, but it provides great insights into how this process works on structural level. Keller 
et al., (2009) investigated the structure of the zymogen caspase-8 as well as the 
mechanisms responsible for its activation together with associated conformational 
changes. In this study, a set of various recombinant caspase-8 constructs was used, 
including active-, cleavage- and dimerization-site mutants, which were established by 
introducing C360A, D374A/D384A and F468A single amino acid substitutions, 
respectively. Their biochemical structures were determined by using NMR methods. The 
obtained data revealed that an inactive caspase-8 represents the typical caspase fold 
and can only form monomers. It has been reported that the uncleaved form of the 
enzyme constitutes a highly flexible fragment termed linker. The linker consists of 40 
residues and serves as a connection between p18 and p11 subunits of zymogen 
caspase-8. 
 
It was shown that the structures of the inactive and active forms of caspae-8 do not differ 
significantly between each other. The most important differences are associated with the 
topology of the linker and the loop regions. Interestingly, the study revealed that 
conformation of the zymogen caspase-8 does not allow interacting with any substrates, 
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because the necessary binding pocket cannot be formed by the uncleaved enzyme. 
However, due to its flexibility, the linker has the ability to change its conformation, so that 
it becomes convenient for substrates to interact with the enzyme. Such observation 
explains the occurrence of occasional events, when zymogen caspase-8 reveals its 
basal activity. 
 
Most importantly, Keller et al., (2009) demonstrated that the mechanisms of the induced 
proximity model are mainly responsible for triggering the dimerization of caspase-8 but 
are not directly involved in its proteolytic processing. Caspase-8 can only be cleaved 
after successful dimerization, which plays a crucial role in initiation of conformational 
changes of the zymogens followed by the cleavage of the linker (Figure 9). These 
observations were supported by using the dimerization-site mutant (F468A), which, 
despite the presence of the active Cys360 site, was not able to process itself nor interact 
with the used substrate, Ac-DEVD 7-amino-4-methylcoumarin (AMC). In addition, Keller 
et al., (2009) reported that dimerization is also necessary for triggering the catalytic 
activity of caspase-8, as it allows formation of the binding pocket. 
 
It has been described, that caspase-8 can be fully activated, when both Asp374 and 
Asp384 cleavage sites, present in the linker, are proteolytically processed (Figure 9). 
Such conclusion was supported by using the single cleavage-site mutants and the AMC 
substrate. It was demonstrated that the D374A and D384A mutants showed a slight 
reduction in their activity, in comparison with the wild-type caspase-8. Most importantly, 
the dimerization process was decreased in both cases (Keller et al., 2009). Therefore, it 
is crucial for zymogen caspase-8 molecules to form dimers and to be cleaved in order to 
achieve its full activity potential (Figure 9).  
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Figure 9. Model for cleavage and activation of caspase-8.  
Inactive pro-caspase-8 molecules come into close proximity and form dimers. 
Dimerization promotes conformational changes of the pro-caspase-8 molecules, which 
facilitate their cleavage. First, pro-caspase-8 undergoes self-cleavage at the Asp384 site 
(indicated by red arrows), which leads to the release of the p10 subunit. Secondly, pro-
caspase-8 undergoes trans-proteolytic cleavage at the Asp374 and Asp216 sites 
(indicated by green arrows). As a result, these events lead to formation of the active 
caspase-8 heterotetramer composed of the p18 and p10 subunits (Keller et al., 2009).9 
 
 
 
 
 
 
 
9 Image created with BioRender.com 
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1.10. DNA	Damage	Response	
 
Investigation and analysis of the interactions and functional relationships between the 
FADDosome components still leaves the question, what factors drive the formation of 
the complex. In this context, we wondered, what signalling pathways and molecular 
constituents are involved in the regulation of the FADDosome formation in response to 
5-FU. While upregulation of caspase-10 in response to 5-FU might be a part of the 
answer, the exact details of how the signal from the damaged DNA is transduced towards 
the FADDosome still remain unknown.  
 
Therefore, two serine/threonine kinases, ATR and ATM (Kamer et al., 2005; Shiloh and 
Ziv, 2013) as well as their substrates, the serine/threonine kinases Chk1 and Chk2, 
respectively, are the potential candidates, which we believe might play a role in 
promoting the caspase-10 upregulation and subsequent FADDosome formation in 
response to 5-FU. To be more specific, we hypothesise that upon genotoxic stress, the 
ATR/Chk1- and/or ATM/Chk2-mediated pathways are triggered in cancer cells and in 
turn, trigger a signalling cascade, which is responsible for induction of the caspase-10 
upregulation and the FADDosome assembly. Therefore, it is essential to investigate the 
molecular mechanisms and factors involved in the signal transduction from the 5-FU-
induced DNA damage site as well as in the formation of the FADDosome or other 
apoptosis-inducing complexes. 
 
Conventionally, ATM and ATR are known to play a crucial role in recognition of DNA 
lesion (caused by anti-cancer drugs, UV or irradiation) and subsequent initiation of the 
DNA damage response (Kamer et al., 2005; Shiloh and Ziv, 2013; Blackford and 
Jackson, 2017) (Figure 10). These kinases are known to activate a wide range of targets 
by preferential phosphorylation at the pS/pTQ motif (Matsuoka et al., 2007; Shiloh and 
Ziv, 2013; Blackford and Jackson, 2017). It has been described that upon the genotoxic 
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stress, ATR and ATM can phosphorylate and activate the downstream Chk1 and Chk2, 
respectively (Table 1). After being activated, Chk1 and Chk2 phosphorylate a wide range 
of targets involved in the DNA damage response, which as a result can initiate DNA 
repair and cell survival or apoptosis (Zinkel et al., 2005; Matsuoka et al., 2007; Liu et al., 
2010; Liu et al., 2011; Shiloh and Ziv, 2013).  
 
Conventionally, the roles of Chk1 and Chk2 is to delay the cell cycle progression upon 
occurrence of DNA damage, and subsequently to promote DNA repair or cell death 
initiation (Figure 10). Moreover, these kinases are involved in signalling pathways 
mediating the damage-induced transcription and chromatin remodelling (Bartek and 
Lukas, 2003). Induction of these mechanisms is critical to protect cells against DNA 
damage progression and cancer. Furthermore, it has been reported that the core DNA 
damage response signalling pathway is formed by ATM/Chk2, ATR/Chk1, p53 and p21 
(Jaarsveld et al., 2019) (Figure 10).  
 
1.10.1. The	 Roles	 of	 ATM-	 and	 ATR-Mediated	 Signalling	
Pathways	in	the	DNA	Damage	Response	
 
ATM and ATR are known as the members of phosphoinositide 3-kinase (PI3K)-related 
kinases (PIKKs) family of proteins (Abraham, 1998). These kinases were discovered 
over 20 years ago and since then have been widely investigated (Blackford and Jackson, 
2017). The gene encoding for ATM was identified by Savitsky et al. (1995), which 
followed the initial studies on patients suffering from A-T (Gotoff et al., 1967; Taylor et 
al., 1975; Houldsworth and Lavin, 1980; Painter and Young, 1980), a rare inherited 
autosomal-recessive genetic condition (Taylor et a., 2015). The main features of this 
genetic condition are: (I) the progressive neurological decline, which leads to the loss of 
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voluntary movement coordination, including abnormal gait (ataxia) and (II) dilated blood 
vessel (telangiectasia) (Blackford and Jackson, 2017).  
 
Sequencing of the Rad3 gene (Seaton et al. 1992; Bentley et al. 1996), which was first 
found in yeast and involved in regulation of the cell-cycle checkpoints and DNA repair 
(Savitsky et al. 1995), was an initial step towards identification of ATR. It was later 
discovered that Rad3 shared a structural similarity with ATM (Bentley et al., 1996). 
Moreover, the subsequent studies by Bentley et al. (1996) and Cimprich et al. (1996) 
identified and cloned the human counterpart of the yeast Rad3 gene, which was then 
named ATM- and Rad3-related (ATR) (Bentley et al., 1996). With the discovery of ATM 
and ATR, numerous studies have been conducted, which allowed to greatly improve our 
knowledge and understanding of ATM and ATR in the DNA damage response.  
 
It has been described that ATM can sense double strand breaks (DSBs) (Kamer et al., 
2005; Zinkel et al., 2005; Matsuoka et al., 2007; Liu et al., 2011; Shiloh and Ziv, 2013), 
whereas ATR is involved in cellular response to the occurrence of single-stranded DNA 
(ssDNA) (Zinkel et al., 2005; Liu et al., 2010; Liu et al., 2011). Interestingly, it is believed 
that induction of DSBs contributes to relocation of ATM to the DNA lesion site and its 
activation, however the molecular mechanism involved in this process is still not well 
understood. Additionally, the occurrence of DSBs leads to recruitment of MRN (MRE11–
RAD50–NBS1) complex, which similarly to ATM, acts as a sensor of the DNA damage. 
The interaction between activated ATM and MRN complex at the lesion site leads to 
initiation of a DNA damage-mediated signalling cascade (Shiloh and Ziv, 2013). 
Moreover, it has been described that the MRN complex is not required for the activation 
of ATM at the DNA damage site, however it is crucial for the ATM-mediated DNA damage 
response (Hartlerode et al., 2015) (Figure 10).  
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On the other hand, the single-stranded DNA (ssDNA) gaps are first recognised by 
replication protein A (RPA), which is regulated by Bid and believed to function as an 
initial sensor of ssDNA. Following the association of Bid-regulated RPA to the DNA 
damage site, ATR and its regulator, namely ATR-interacting protein (ATRIP), are 
recruited to the RPA-coated ssDNA and as a result, form the DNA damage sensor 
complex. As a consequence, ATR can be activated within the complex and, similarly to 
ATM, can then in turn phosphorylate its downstream substrates (Liu et al., 2010; Liu et 
al., 2011) (Figure 10).  
 
In the non-stressed human cells, ATM remains inactive and typically forms homodimers. 
Following the DNA damage, this kinase can phosphorylate itself at Ser1981, which in 
turn leads to dissociation of the ATM homodimers and formation of phosphorylated 
monomers. The autophosphorylation-driven monomerization of ATM is believed to be 
crucial to activate its function in triggering of the DNA damage response (Bakkenist and 
Kastan, 2003). Moreover, it has been reported, that autophosphorylation at Ser367 and 
Ser1893 are also required for ATM activation, which allows this kinase to reach its full 
activity potential (Kozlov et al., 2006; Kozlov et al., 2011). However, some reports have 
demonstrated that in mice the phosphorylation of ATM at Ser367, Ser1899 and Ser1987, 
which function as the equivalents of the human phosphorylation sites, are not required 
to induce the activity of this kinase (Daniel et al., 2008). Another study has reported that 
in frogs (Xenopus), autophosphorylation of ATM is dispensable to initiate the 
monomerization of this kinase (Lee and Paull, 2005). This indicates that ATM 
monomerization is critical for its activation and allows this molecule to perform its 
functions in the DNA damage response. However, it is very likely that the role of 
autophosphorylation in the ATM activation is not a conserved process among different 
species (Awasthi et al., 2016).  
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It has been shown by various reports that ATR can by phosphorylated at Ser435, Ser428 
and Thr1989 (Daub et al., 2008; Dephoure et al., 2008). A study by Liu et al., (2011) 
demonstrated that phosphorylation of ATR at Thr1989 occurred in response to DNA 
damage caused by UV irradiation, ionizing radiation and hydroxyurea in vivo. A 
subsequent co-immunoprecipitation of ATRIP (ATR-interacting protein) with the 
phosphorylated ATR revealed that this kinase undergoes phosphorylation at the ATR-
ATRIP complex. Moreover, the authors found that phosphorylation at Thr1989 occurred 
only in the chromatin fractions, indicative of ATR phosphorylation on chromatin. Further 
experiments performed by Liu et al., (2011) demonstrated that phosphorylation at 
Thr1989 was crucial for ATR function, as it was found that mutation of this site abrogated 
the ATR-driven phosphorylation of its main substrate, namely Chk1 after exposure to UV 
irradiation. Moreover, the authors showed that phosphorylation of Thr1989 was not 
mediated by any other kinase, but occurs as a result of autophosphorylation, as it was 
observed that caffeine (a pan inhibitor of ATR and ATM), but not inhibitors of CDKs 
(cyclin-dependent kinases), ATM or DNA-PKs (DNA-dependent protein kinases), was 
able to block the ATR phosphorylation at Thr1989 in response to UV irradiation. 
Furthermore, Liu et al., (2011) reported that phosphorylation at this site also depends on 
ATRIP and RPA activity. Taken together, phosphorylation at Thr1989 is regarded as a 
hallmark of DNA-damage mediated ATR activity.  
 
The molecular mechanisms and factors involved in initiation of the ATM- and ATR-
mediated DNA damage response are summarised in Table 1. 
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Table 1. Main characteristics of the ATM- and ATR-controlled mechanisms and factors 
involved in initiation of the DNA damage response.   
Kinase DNA damage 
recognised 
Other proteins 
and complexes 
involveda 
Formation of the DNA 
damage sensor 
complexesb 
Main 
targetsc 
ATM double strand 
breaks (DSBs)1, 3, 4 
MRN (MRE11–
RAD50–NBS1) 
complex4 
ATM is relocated to and 
activated at the DSB site in 
response to DNA damage, 
followed by recruitment of 
MNR complex to the lesion 
site4 
Checkpoint 
kinase 2 
(Chk2)4 
ATR single-stranded 
DNA (ssDNA)2, 3 
Bid-regulated 
Replication Protein 
A (RPA) and ATR-
interacting protein 
(ATRIP)2, 3 
Bid-controlled RPA (initial 
sensor) is recruited to and 
coats ssDNA, followed by 
association of ATR-ATRIP 
complex and subsequent 
activation of ATR2, 3 
Checkpoint 
kinase 1 
(Chk1)2, 3 
1 Matsuoka et al., 2007; 2 Liu et al., 2010; 3 Liu et al., 2011; 4 Shiloh and Ziv, 2013 
a Proteins and complexes that, similarly to ATM and ATR, function as sensors and associate with 
the DNA lesion as well as interact with the respective kinase.  
b Molecular mechanisms responsible for interactions between ATM and ATR, and the respective 
protein complexes at the DNA damage sites 
c Targets of ATM and ATR, which are phosphorylated and activated after formation of the DNA 
damage sensor complexes. These targets can in turn activate their downstream substrates and 
as a result, induce a DNA damage response signalling cascade. 
 
 
1.10.2. The	Roles	of	 Chk1	and	Chk2	 in	 the	DNA	Damage	
Response	
 
Similar to ATM and ATR, the Chk1 and Chk2 kinases also belong to the phosphoinositide 
3-kinase (PI3K)-related kinases (PIKKs) family of proteins (Bartek and Lukas, 2003). The 
first studies on Chk1 and Chk2 knockout and knockdown mouse models, which were 
conducted about two decades ago, provided new insights into the biological requirement 
of these kinases. It was demonstrated that, despite the overlapping functions of Chk1 
and Chk2 in checkpoint signalling, the loss of Chk1, but not Chk2, disrupted the 
mammalian development and viability (Liu et al., 2000; Takai et al., 2000, Hirao et al., 
2002; Takai et al., 2002). It was found that the Chk1-deficient mice were lethal at an early 
embryonic stage (Liu et al., 2000; Takai et al., 2000), which was the main cause of the 
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limited studies on the role of Chk1 in cell-cycle checkpoint regulation in vivo (Bartek and 
Lukas, 2003). On the contrary, it was observed that the loss of Chk1 in DT-40 lymphoma 
cells did not affect the cell division, but instead promoted sensitisation of the cells to cell 
death caused by severe DNA damage, which could not be repaired. Moreover, further 
studies on Chk1 knockdowns revealed, that Chk1 was responsible for regulation of 
Cdc25A and required for the S-phase, intra-S-phase and G2/M checkpoints after 
exposure to irradiation and drugs-induced DNA-damage (Zhao et al., 2002; Gatei et al., 
2003; Sørensen et al., 2003; Xiao et al., 2003).  
 
In contrast to Chk1 knockdowns, the Chk2-deficient mice were viable and fertile. 
Moreover, it was observed that these mice were only prone to tumour development when 
subjected to treatment with carcinogens (Takai et al., 2002; Hirao et al., 2002). It was 
reported that Chk2 plays a role in the intra-S phase checkpoint induced by DSB in HCT-
15 human colon carcinoma cells lacking Chk2 (Falck et al., 2001; Falck et al., 2002). 
Moreover, several studies demonstrated that mice lacking Chk2 exhibited 
radioresistance as well as defective p53-regulated transcription and apoptosis (Jack et 
al., 2002; Takai et al., 2002). Taken together, these results confirmed that the functions 
of Chk1 and Chk2 in regulation of various cell-cycle checkpoints were partly overlapping, 
whereas their biological requirements for development and viability of embryos were 
found to be fairly distinct.  
 
It is believed that Chk1 and Chk2 are dependent on and regulated by ATR and ATM, 
respectively, however there is some evidence that a close “crosstalk” exists between 
these proteins (Gatei et al., 2003; Sørensen et al., 2003; Zabludoff et al., 2008; Matthews 
et al., 2013). Interestingly, Chk1 and Chk2 phosphorylate and regulate numerous 
downstream effectors, of which some are overlapping, and some are unique for each 
kinase. The most common substrates of Chk1 and Chk2 is p53 and its negative 
regulator, Mdm2 (Bartek and Lukas, 2003) (Figure 10). The roles of these kinases and 
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their targets in the DNA damage response are well understood. However, only a few 
molecular links to the cell death induction have been established for Chk1 and Chk2 so 
far (Gonzalez et al., 2003; Urist et al., 2004). In contrast, the most recent studies 
demonstrated that the increase of Chk1 and Chk2 activation in response to 
chemotherapeutic drugs, such as cisplatin or doxorubicin, leads to resistance 
development in tumour cells rather than apoptosis induction (Jaarsveld et al., 2019). 
Taken together, it remains to be unravelled, whether and to what extent Chk1 and Chk2 
are involved in regulation and initiation of cell death in response to a variety of treatments 
including 5-FU. 
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Figure 10. The ATR/Chk1- and ATM/Chk2-signalling pathways in the DNA damage 
response.  
Upon induction of the ssDNA (left panel), Bid-regulated RPA is recruited to the site of the lesion, 
followed by recruitment if the ATR-ATRIP complex. At the complex, ATR is phosphorylated and 
activated. On the other hand, upon occurrence of the DSB (right panel), the MRN complex is 
formed at the site of the lesion. The complex consists of MRE11, RAD50 and NBS1 proteins. 
Next, ATM is relocated to the DNA damage site, at which it undergoes phosphorylation and 
activation. Activated ATR and ATM phosphorylate their downstream substrates, Chk1 and Chk2, 
respectively, as well as p53. Depending on the levels of the DNA damage, the DNA damage 
response either leads to the DNA repair or apoptosis induction (Ryan et al., 2016).10 
 
 
 
 
 
 
 
 
10 Image created with BioRender.com  
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1.10.3. ATM	 and	 ATR	 Signalling	 in	 Caspase-Mediated	
Apoptotic	Pathways		
 
To date, a few molecular links to the apoptosis induction, which requires involvement of 
various caspases, such as caspase-2, -3 and -8, have been established for ATM and 
ATR (Cicca and Elledge, 2010). It has been reported that ATM is involved in caspase 
and cytokine signalling in HeLa cells in response to extensive DNA damage (Biton and 
Ashkenazi, 2011) (Figure 11A). It was demonstrated that upon genotoxic stress, ATM 
promotes formation of a RIP1-reguated protein complex accompanied by secretion of 
TNF-α, which does not require involvement of p53. The adaptor protein FADD and 
initiator caspase-8 are then recruited by RIP1, which leads to cleavage and activation of 
caspase-8. This event contributes to caspase-8-mediated processing of caspase-3 and 
induction of apoptosis (Figure 11A). In parallel, extensive DNA damage also induces 
ATM-mediated signalling towards the RIP1-dependent production of proinflammatory 
cytokines, including interleukin 6 and 8 (IL-6 and IL-8, respectively), which alert 
neighbouring cells of the damage (Biton and Ashkenazi, 2011) (Figure 11A).  
 
Moreover, both ATM and ATR were found to be involved in DNA-damage signalling 
towards another initiator caspase, namely caspase-2, in MEFs, HeLa and HCT.p53-/- 
cells (Sidi et al., 2008; Ho et al., 2009; Ando et al., 2012). It was reported that 
ATM/ATR/caspase-2-mediated pathway is triggered independently of p53, Bcl-2 and 
caspase-3 (Sidi et al., 2008) However, upon some treatments, such as with lidamycin, 
the further downstream pathway of ATR, ATM and caspase-2 requires involvement of 
the executioner caspase-3, which is then cleaved and activated, leading to initiation of 
apoptosis (Pan et al., 2009). Interestingly, a study by Ando et al. (2012) has linked ATM 
and ATR to regulation of the PIDDosome complex formation (Figure 11B). The authors 
found that these kinases are required for PIDD phosphorylation, which is in turn 
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necessary for binding of RAIDD. These events lead to recruitment of caspase-2 and 
assembly of the PIDDosome, at which caspase-2 undergoes activation (Ando et al., 
2012) (Figure 11B).  
 
A      B 
  
Figure 11. Roles of ATM and ATR in apoptotic pathways mediated by caspases.  
A. Upon extensive DNA damage, ATM signals towards Nemo, which in turn promotes formation 
of the RIP1-regulated TNFR-1 complex. The DNA damage-induced signalling from ATM to Nemo 
also leads to production of TNF-α, which is involved in induction of the feedforward signalling loop 
towards the TNFR-1 receptor. The adaptor protein FADD and initiator caspase-8 are then 
recruited by RIP1. As a result, caspase-8 undergoes cleavage and activation, and in turn 
processes caspase-3, which eventually leads to initiation of apoptosis. Moreover, the ATM-
mediated signalling from the DNA damage site also promotes the RIP1-regulated production of 
proinflammatory cytokines, such as interleukin 6 (IL-6) and 8 (IL-8). Secretion of the cytokines 
alerts neighbouring cells of the DNA damage (Biton and Ashkenazi, 2011). B. Occurrence of the 
DNA lesions induces the ATR/ATM-mediated signalling towards PIDD, which in turn undergoes 
phosphorylation and activation. As a result, activated PIDD interacts with RAIDD and recruits 
caspase-2. These events lead to formation of the PIDDosome complex, at which caspase-2 is 
activated, leading to initiation of apoptosis (Ando et al., 2012).11 
 
 
 
11 Image created with BioRender.com 
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It has been reported that upon induction of the DNA damage, ATM and ATR are activated 
in prostate cancer (DU145 and PC3 cells) (Garcia et al., 2015), whereas ATR alone 
undergoes activation in keratinocytes (HaCaT cells) (Kemp and Sancar, 2016). It was 
described that these kinases promote apoptotic signalling towards caspase-3, which 
plays a key role in initiation of cell death in response to DNA lesions in DU145, PC3 and 
HaCaT cells (Garcia et al., 2015; Kemp and Sancar, 2016). Moreover, in prostate cancer, 
activation of ATM and ATR contributes to induction of Chk1, phosphorylation of H2AX 
and downregulation of Cdc25C (Garcia et al., 2015). In keratinocytes and similar to 
findings described by others (Sidi et al., 2008, Pan et al., 2009; Biton and Ashkenazi 
2011), the ATR-regulated caspase-3 activation and apoptosis are induced without 
involvement of p53 (Kemp and Sancar, 2016).  
 
Taken together, in many human cancers, ATM and ATR play a critical role in signalling 
from the DNA damage site towards various caspases, such as the initiator caspase-2 
and -8 as well as the executioner caspase-3, leading to induction of apoptosis. Therefore, 
in this study, inspired by the ATM/ATR-mediated signalling towards the caspase-
dependent apoptotic pathways, it was hypothesised that these kinases are also involved 
in the 5-FU-induced caspase-10 upregulation and FADDosome formation in colorectal 
cancer cells.  
 
1.11. Research	Motivation	
 
Previously, our group demonstrated, that upon treatment with 5-FU, irinotecan or 
raltitrexed, apoptosis can be induced in a caspase-8-dependent manner, without 
involvement of the death receptor signalling network (Mohr et al., 2018). We have shown 
that apoptosis is triggered through involvement of a protein complex termed 
FADDosome, which is formed upon exposure to the chemotherapeutic drugs. We have 
identified the main constituents of the FADDosome, namely caspase-10, caspase-8, 
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FADD, RIP1 and TRAF2. At the FADDosome, caspase-8 is activated in the p53-
independent manner, leading to initiation of apoptosis. We found that when ATR, 
caspase-10, RIP1 or TRAF2 are inhibited or lost, 5-FU-treated cancer cells are able to 
switch to an alternative cell death mechanism, which requires assembly of the 
FLIPosome platform consisting of cFLIP-L and caspase-8 (Mohr et al., 2018).  
 
Nevertheless, the biological importance and the exact roles of the main FADDosome 
components in promoting the 5-FU-induced complex formation and caspase-8 
activation, still remain unclear. Thus, understanding the roles of factors and mechanisms 
involved in the FADDosome is crucial, in order to design better therapeutic approaches 
and help overcome resistance in cancer cells. 
 
Since treatment with cytotoxic drugs leads to DNA damage in many cases, the question 
raised, how the signal from the DNA-damage site is translated into cell death signals in 
cancer cells. The serine/threonine kinases ATR and ATM are known to play a crucial 
role in sensing DNA lesions and triggering of the conventional DNA damage response 
machinery. Upon genotoxic stress, ATR and ATM phosphorylate and activate the 
downstream Chk1 and Chk2, respectively. Another target, which is phosphorylated by 
ATR and ATM is the tumour suppressor p53. After being activated, Chk1, Chk2 and p53 
regulate a wide range of targets involved in the DNA damage response, which as a result 
can initiate DNA repair and cell survival or apoptosis. To date, a few studies reported 
that ATR and ATM play a role in the DNA damage-initiated cell death signalling. In 
particular, these kinases have been linked to signalling towards the caspase-2-, 
caspase-3- and caspase-8-mediated apoptotic pathways. Thus, it is assumed that ATR 
and/or ATM could also be involved in signalling from the DNA damage site towards 
caspase-10 and FADDosome in response to 5-FU. Moreover, our knowledge of the roles 
of Chk1 and Chk2 in genotoxic stress-induced cell death remains incomplete and 
requires investigation. 
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In our previous report we demonstrated that HCT.p53-/- cells were protected from 
apoptosis triggered by the 5-FU treatment (Mohr et al., 2018). Additionally, our group 
found that caspase-9, which has been reported to be crucial for the initiation of the 
classical intrinsic apoptosis cascade, was dispensable for the 5-FU-induced apoptosis 
(Mohr et al., 2018). These findings suggested that the resistance of HCT.p53-/- cells to 
5-FU was not associated with inhibition of the conventional apoptotic pathway. With 
respect to that, our group found that p53 was involved in the transcriptional regulation of 
TRAIL-R2 (DR5) in HCT116 cells exposed to 5-FU (Mehrabadi, 2018). It was also 
discovered, that DR5 was not involved in caspase-8 activation, as described in the 
classical model of apoptosis, but in activation of JNK in responses to 5-FU (Mehrabadi, 
2018). Thus, it is hypothesised that ATR and/or ATM can potentially regulate the TRAIL-
R2/JNK axis via p53 after treatment with 5-FU. Moreover, it was shown that JNK can 
phosphorylate and regulate Bid (Dhanasekaran and Reddy, 2008), which suggests that 
the potential meeting point of the FADDosome and the p53-mediated TRAIL-R2/JNK 
signalling network possibly occurs downstream of Bid. 
 
Taken together, a better understanding of the functions of the ATR/Chk1- and 
ATM/Chk2-signalling pathways in the DNA damage-induced apoptosis is important, as 
it might help with finding ways of pushing cancer cells into the cell death response, which 
is the main goal of the anti-tumour approaches. In this context, it is essential to 
investigate the molecular mechanisms and factors involved in the signal transduction 
from the 5-FU-induced DNA-damage site leading to initiation of apoptosis in cancer cells. 
Better understanding of the roles of these pathways is a key point to be addressed, as it 
might help to bypass resistance in cancer cells and to reduce the toxic side effects of 
anti-tumour treatments. 
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1.12. Aims	and	Objectives	
 
The aims of this study are: 
 
• to investigate the functional relationships and interactions between the main 
FADDosome constituents, namely caspase-10, caspase-8, FADD and cFLIP-L 
in terms of the complex formation and caspase-8 activation (Figure 12A, B, C 
and D); 
 
• to analyse the ATR/Chk1- and ATM/Chk2-signalling pathways and to identify 
factors involved in regulation of the FADDosome formation and apoptosis in 
cancer cells treated with chemotherapeutic drugs (Figure 13). 
 
With respect to the first aim, it is hypothesised that upregulated caspase-10 competes 
with cFLIP-L for binding to caspase-8, which in turn leads to formation of the 
FADDosome and not the FLIPosome (Figure 12B). It is assumed that within the complex, 
FADD functions as the binding partner of caspase-10, caspase-8 and cFLIP-L and that 
these proteins interacts via their cognate DED domains (Figure 12B). It is also postulated 
that the decrease of the caspase-10 levels or its loss promotes an interaction between 
caspase-8 and cFLIP-L, causing a switch to the FLIPosome (Figure 12B). Moreover, it 
is hypothesised that at the FADDosome, activation of caspase-8 is mediated by 
caspase-10, which in addition might be facilitated by FADD (Figure 12C). These 
hypotheses are based on how caspase-10, caspase-8, c-FLIP-L and FADD are 
conventionally believed to interact and function as well as on what is known about the 
assembly mechanisms of the other novel apoptosis-inducing protein platforms, such as 
RIPoptosome.  
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In order to test these hypotheses, the wild type and mutated variants of human 
recombinant DDEDs caspase-10, DDEDs caspase-8, DDEDs cFLIP-L and FADD-FL, 
which are expressed in E. coli and purified using column chromatography, are used. This 
is followed by characterisation of the functional relationships and interactions between 
the proteins of interest using activity and pull-down assays performed in a cell free 
setting. 
 
A       B    
  
 
B       C 
  	
Figure 12. Hypotheses related to the interactions and functional relationships between the 
FADDosome components. 
A. The main FADDosome components include FADD, caspase-10, caspase-8 and cFLIP-L. B. 
Domain organisation of FADD, caspase-10, caspase-8 and cFLIP-L. C. In the present study, it is 
hypothesised that the FADDosome is formed, when upregulated caspase-10 outcompetes cFLIP-
L for binding to caspase-8. On the other hand, it I assumed that when the caspase-10 levels are 
reduced or the protein is lost, caspase-8 binds to cFLIP-L, which promotes formation of the 
FLIPosome. Moreover, the interaction between caspase-10, caspase-8, cFLIP-L and FADD 
within the FADDosome possibly occurs by involvement of their cognate DED domains. C. It is 
assumed that caspase-8 is cleaved and activated at the complex in the caspase-10-dependent 
manner. Additionally, FADD might be also involved in this process and facilitate it by interacting 
with caspase-10 and caspase-8.12 
 
 
12 Image created with BioRender.com 
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To address the second aim of this research, a model of 5-FU-induced apoptosis in 
colorectal cancer cells was proposed (Figure 13). In this model, it is hypothesised that 
ATM and/or ATR functions as the key sensors of the 5-FU-induced DNA damage. It is 
assumed that in response to such damage, ATM and ATR are activated and in turn, are 
involved in phosphorylation and activation of Chk1 and Chk2 as well as induction of p53. 
It is postulated that the sensed 5-FU-induced DNA damage is translated into apoptotic 
signals, which in turn contributes to the p53-independent caspase-10 upregulation and 
subsequent FADDosome formation. Moreover, in the current study, it is hypothesised 
that activated ATM and/or ATR are also involved in regulation of a distinct, p53-mediated 
TRAIL-R2/JNK signalling pathway. Since it was found previously that Bid can be 
phosphorylated by JNK, It is assumed that the FADDosome and the p53-driven TRAIL-
R2/JNK axis converge downstream of Bid (Figure 13). Thus, the proposed model and 
hypotheses are based on our previous findings as well as on the knowledge of the 
pathways and factors involved in the DNA damage response and the 
intrinsic/mitochondrial apoptotic network. 
 
To address these hypotheses, human colon cancer HCT.shctrl cell line, which is a 
derivative of HCT116 cells, is used. HCT.shctrl cells were selected in this study, as they 
function as control for other HCT116 knockdown cell lines. HCT.shctrl and HCT116 cells 
respond to 5-FU in the same manner. In order to assess the effect of 5-FU on proteins 
phosphorylation/activation and regulation of molecular pathways in cancer cells, the 
analytic methods, such as Western blot, Nicoletti assay and flow cytometry, are used.  
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Figure 13. The hypothetical molecular model of the 5-FU-induced apoptosis. 
In the proposed model of apoptosis, it is hypothesised that upon 5-FU-induced DNA damage, 
ATR and/or ATM can act as the critical sensors of such damage and in turn, can be 
phosphorylated and activated. It is also hypothesised, that this event would lead to the 
subsequent phosphorylation and activation of Chk1 and/or Chk2 and accumulation of p53. It is 
assumed that after sensing the 5-FU-induced DNA damage, ATR and/or ATM together with Chk1 
and/or Chk2, could translate the sensed lesion into the apoptotic signals in cancer cells. It is 
believed that this leads to caspase-10 upregulation, followed by FADDosome complex formation 
and initiation of apoptosis. In addition, in this model, it is hypothesised that ATR and/or ATM 
regulate the p53-driven TRAIL-R2/JNK axis and Bid phosphorylation. It is assumed that in the 
further downstream pathway, dephosphorylated Bid is cleaved to tBid by caspase-8, which 
functions as a meeting point of the FADDosome and TRAIL-R2/JNK pathways.13 
 
 
13 Image created with BioRender.com 
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Following research objectives would facilitate the achievement of the first aim: 
 
 
• design of protein expression constructs and cloning into pET-28a vector  
• expression of DDEDs caspase-10 (wild type), DDEDs caspase-8 (wild type), 
DDEDs cFLIP-L (wild type) and FADD-FL  
• purification of wild type proteins 
• expression of DDEDs caspase-10 (C401A), DDEDs caspase-10 (D415A), DDEDs 
caspase-8 (C360A) and DDEDs caspase-8 (D374A/D384A) 
• purification of selected mutated proteins 
• design of protein expression constructs and cloning into pGEX-4T-3 vector 
• expression of DDEDs caspase-10 (C401A), DDEDs caspase-10 (D415A), DDEDs 
caspase-8 (C360A) and DDEDs cFLIP-L (wild type and D376A mutant) 
• purification of selected mutated proteins 
• analysis of the role of caspase-10 and/or FADD in the caspase-8 cleavage in 
vitro in terms of the FADDosome  
• assessing, whether FADD can interact with caspase-8, cFLIP-L and/or caspase-
10 in vitro in terms of the FADDosome  
• investigating the competition between caspase-10 and cFLIP-L for binding to 
caspase-8 in vitro in terms of the switch from FADDosome to FLIPosome and 
vice versa. 
 
Following research objectives would facilitate the achievement of the second aim: 
 
• analysis of ATR, ATM, Chk1 and Chk2 phosphorylation and p53 induction levels 
in 5-FU-induced apoptosis 
• exploring the roles of ATR and ATM in Chk1 and Chk2 phosphorylation and p53 
induction in response to 5-FU 
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• investigating the roles of ATR and ATM in caspase-10 upregulation and 
formation of the FADDosome after treatment with 5-FU 
• assessing the roles of Chk1 and Chk2 in caspase-10 upregulation in response 
to 5-FU and etoposide 
• establishing, whether inhibition of Chk1 and/or Chk2 activation contributes to a 
switch to the FLIPosome mode of apoptosis after exposure to 5-FU 
• exploring the roles of ATR and ATM in regulation of the p53-mediated TRAIL-
R2/JNK axis, JNK activation and Bid phosphorylation. 
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CHAPTER	2	
MATERIALS	AND	METHODS	
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2.1 Materials	
 
Cell	Lines	
 
Table 2. List of cell lines. 
Cell lines Source/Manufacturer Description 
HCT116 ATCC, Manassas, VA, USA Human colorectal carcinoma cells 
HCT.shctrl Cell line stock of the lab Human colorectal carcinoma cells – control knockdown 
HCT.shATR Cell line stock of the lab Human colorectal carcinoma cells – ATR knockdown 
HCT.shCaspase-10 Cell line stock of the lab Human colorectal carcinoma cells – caspase-10 knockdown 
HCT.p53-/- Cell line stock of the lab (gift from Bert Vogelstein) 
Human colorectal carcinoma cells – 
p53 knockout 
 
 
Antibodies	
 
Table 3. List of primary antibodies.  
Primary 
antibodies 
MW of target 
protein (kDa) 
Catalogue 
number Manufacturer 
ATM 250 A6093 Sigma, St. Louis, MO, USA 
ATR 230 A300-138A Bethyl Laboratories, Montgomery, Texas, USA 
Caspase-10 59 M059-3 Medical & Biological Laboratories, Woburn, MA, USA 
Caspase-8/p18 55 SC-5263 Biotechnology, Santa Cruz, CA, USA 
CuZnSOD 17 MAB3418 R&D Systems, Minneapolis, MN, USA 
Chk1 52 2360S Cell Signalling Technology, Beverly, MA, USA 
 76 
Primary 
antibodies 
MW of target 
protein (kDa) 
Catalogue 
number Manufacturer 
Chk2 61 2662S Cell Signalling Technology, Beverly, MA, USA 
cIAP1 72 AF8181 R&D Systems, Minneapolis, MN, USA 
FADD (Clone 1F7) 25 05-486 Clone 1F7, Upstate (Millipore), Billericay, MA, USA 
GST-tag 26 2625S Cell Signalling Technology, Beverly, MA, USA 
(His)6-tag 2 AB18184 Abcam, Cambridge, England, GB 
p21 21 SC-6246 Biotechnology, Santa Cruz, CA, USA 
p53 53 SC-126 Biotechnology, Santa Cruz, CA, USA 
phospho-Chk1 54 8191S Cell Signalling Technology, Beverly, MA, USA 
phospho-Chk2 62 2197S Cell Signalling Technology, Beverly, MA, USA 
phospho-ATM 250 5883S Cell Signalling Technology, Beverly, MA, USA 
phospho-ATR 230 30632S Cell Signalling Technology, Beverly, MA, USA 
 
 
Table 4. List of secondary antibodies.  
Secondary antibodies Species Catalogue number Manufacturer 
Anti-goat IgG-HRP 
(horseradish peroxidase) mouse SC-2354 
Biotechnology, Santa Cruz, 
CA, USA 
Anti-mouse IgG-HRP 
(horseradish peroxidase) goat SC-2005 
Biotechnology, Santa Cruz, 
CA, USA 
Anti-rabbit IgG-HRP 
(horseradish peroxidase) mouse SC-2357 
Biotechnology, Santa Cruz, 
CA, USA 
Anti-sheep IgG-HRP 
(horseradish peroxidase) rabbit SC-2770 
Biotechnology, Santa Cruz, 
CA, USA 
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Bacteria	Strains	
 
Table 5. List of bacteria strains. 
Strain Manufacturer Genotype 
E. coli TOP10 
competent cells 
ThermoScientific, 
Waltham, MA, USA 
F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 
araD139 Δ(ara-leu) 7697 galE15 galK16 
rpsL (Strr) endA1 λ- 
E. coli BL21(DE3) 
competent cells 
ThermoScientific, 
Waltham, MA, USA F
– dcm ompT hsdS (rB– mB–) gal λ(DE3) 
E. coli BL21-RIL 
competent cells 
Agilent Technologies, 
Santa Clara, CA, USA 
F– ompT hsdS (rB– mB–) dcm+ Tetr gal 
endA Hte [argU ileY leuW Camr] 
 
 
Cloning		
 
Table 6. List of plasmids used for cloning and protein expression. 
Plasmids Manufacturer 
pET-28a vector Merck, Kenilworth, NJ, USA 
pGEMâ-T Easy Vector Promega, Madison, WI, USA 
pGEX-4T-3 vector GE Healthcare, Chicago, IL, USA 
 
 
 
Table 7. List of enzymes used for cloning.  
Enzymes Manufacturer 
Restriction enzymes ThermoScientific, Waltham, MA, USA 
T4 ligase enzyme ThermoScientific, Waltham, MA, USA 
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Table 8. List of commercial kits. 
Commercial Kits Manufacturer 
GenElute™ Gel Extraction Kit Sigma, St. Louis, MO, USA 
GenElute™ Plasmid Miniprep Kit Sigma, St. Louis, MO, USA 
QuickChange® II Site-Directed Mutagenesis kit Stratagene, San Diego, CA, USA 
Pierce® BCA Protein Assay Kit ThermoScientific, Waltham, MA, USA 
SuperSignal™ West Pico Trial Kit ThermoScientific, Waltham, MA, USA 
 
 
Protein	purification	
 
Table 9. List of columns used for protein purification. 
Protein Purification Columns Manufacturer 
IMAC 5 ml His-trap FF nickel-nitrilotriacetic (Ni-NTA) 
acid-sepharose column GE Healthcare, Chicago, IL, USA 
SEC 120 ml HiLoad Superdex 75 16/60 column GE Healthcare, Chicago, IL, USA 
 
 
 
Solutions		
 
Table 10. List of buffers and solutions.  
Solution Recipe 
Anode I buffer 300 mM Trizma base, 20% (v/v) methanol 
Anode II buffer 25 mM Trizma base, 20% (v/v) methanol 
Antibody dilution buffer 3% (w/v) bovine serum albumin (BSA) in TBS-Tween 20 
Blocking buffer 5% (w/v) non-fat dry milk in TBS-Tween 20 
Buffer A 50 mM Trizma base [pH 7.5], 500 mM NaCl, 20 mM imidazole 
Buffer A* 50 mM Trizma base [pH 7.5], 1 M NaCl, 20 mM imidazole 
Buffer A** 50 mM Trizma base [pH 7.5], 500 mM NaCl, 80 mM imidazole 
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Solution Recipe 
Buffer B 50 mM Trizma base [pH 7.5], 500 mM NaCl, 500 mM imidazole 
Buffer C 50 mM Trizma base [pH 7.5], 100 mM NaCl 
Buffer D 8 M urea, 50 mM Trizma base [pH 7.5], 500 mM NaCl, 20 mM imidazole 
Calcium chloride 100 mM, sterilised 
Cathode buffer 25 mM Trizma base, 40 mM hexanoic acid, 20% (v/v) methanol 
Cellular lysis buffer (bacteria 
cells) 
50 mM Trizma base, 100 mM NaCl, 1 mM EDTA, 50 mM 
MgCl2 
Coomassie stain buffer 40% (v/v) methanol, 10% (v/v) acetic acid, 0.1% Coomassie Brilliant Blue R-250 
Coomassie destain buffer 40% (v/v) methanol, 10% (v/v) acetic acid 
Nicoletti buffer 50 µg/ml propidium iodide, 0.1% (w/v) sodium citrate, 0.1% (w/v) Triton X-100 
NP-40 lysis buffer (cancer 
cells) 
50 mM Trizma base [pH 7.4], 10% (v/v) glycerol, 0.5% (v/v) 
NP-40, 150 mM NaCl, 1 mM MgCl2 ,1 mM CaCl2, 1 mM KCl, 
protease inhibitor cocktail tablet 
Protein loading buffer 
65 mM Trizma base [pH 6.8], 10% (v/v) glycerol, 4% (w/v) 
SDS, 4% (v/v) β-mercaptoethanol, 0.2% (w/v) bromophenol 
blue 
SDS-PAGE running buffer 
(10x) 192 mM glycine, 25 mM Trizma base, 1% (w/v) SDS 
Solubilisation buffer for 
inclusion bodies 
6 M guanidine hydrochloride or 8 M urea, 500 mM NaCl, 20 
mM Trizma base [pH 8.0] 
TAE buffer (50x) 50 mM EDTA [pH 8.0], 2 M Trizma base, 1 M acetic acid 
TBS-Tween 20 buffer 10 mM Trizma base [pH 8.0], 150 mM NaCl, 0.1% Tween 20 
Triton X-100 lysis buffer 
(cancer cells) 
2.5 mM EDTA, 1% (v/v) Triton X-100, 30 mM Trizma base 
[pH 7.5], 150 mM NaCl, 10% (v/v) glycerol, protease 
inhibitors cocktail tablet 
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Reagents		
 
Table 11. List of reagents 
Chemical reagents Manufacturer 
1,2-bis-(dimethylamino)-ethane (TEMED) Sigma, St. Louis, MO, USA 
5-Fluorouracil (5-FU) Sigma, St. Louis, MO, USA 
Acrylamide-bis-acrylamide Sigma, St. Louis, MO, USA 
Agarose Sigma, St. Louis, MO, USA 
Aminohexanoic acid Sigma, St. Louis, MO, USA 
Ammoniumpersulfate (APS) Sigma, St. Louis, MO, USA 
Ataxia telangiectasia mutated protein (ATM) 
inhibitor (KU55933) Stratech, Newmarket, England, GB 
Ataxia telangiectasia and Rad3-related protein 
(ATR) inhibitor (AZD6738) Stratech, Newmarket, England, GB 
BCA protein assay reagent (bicinchoninic acid) Pierce/ThermoScientific, Waltham, MA, USA 
Bovine serum albumin (BSA) Sigma, St. Louis, MO, USA 
Calcium chloride Sigma, St. Louis, MO, USA 
Checkpoint kinase (Chk) inhibitor (CHIR-124) Stratech, Newmarket, England, GB 
DNA ladders ThermoScientific, Waltham, MA, USA 
Enhanced chemiluminescent (ECL) Western 
blotting substrate 
Pierce/Thermoscientific, Waltham, MA, 
USA 
Ethylene-dinitrilo-tetraacetic acid (EDTA) Sigma, St. Louis, MO, USA 
Ethanol Sigma, St. Louis, MO, USA 
Etoposide Sigma, St. Louis, MO, USA 
Glycerol Sigma, St. Louis, MO, USA 
Glycine Sigma, St. Louis, MO, USA 
Guanidine hydrochloride (GuHCl) Melford, Ipswich, England, GB 
Imidazole ThermoScientific, Waltham, MA, USA 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
Sigma, St. Louis, MO, USA 
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Chemical reagents Manufacturer 
Laemmli buffer Sigma, St. Louis, MO, USA 
Luria-Bertani (LB) medium Sigma, St. Louis, MO, USA 
Luria-Bertani (LB) agar Sigma, St. Louis, MO, USA 
Magnesium chloride Sigma, St. Louis, MO, USA 
Methanol Sigma, St. Louis, MO, USA 
Nickel sulphate ThermoScientific, Waltham, MA, USA 
Phosphate-buffered saline (PBS) Sigma, St. Louis, MO, USA 
PhosStop phosphatase inhibitor cocktail tablets Roche, Basel, Switzerland 
Ponceau S stain solution Sigma, St. Louis, MO, USA 
Pre-stained protein marker, broad range (7-
175KDa) 
New England Biolabs, Ipswich, MA, 
USA 
Propidium iodide solution Sigma, St. Louis, MO, USA 
PVDF (polyvinylidene difluoride) membrane GE Healthcare, Chicago, IL, USA 
Non-fat dry milk powder Tesco PLC, Welwyn Garden City, England, GB 
Sodium chloride Sigma, St. Louis, MO, USA 
Sodium citrate Sigma, St. Louis, MO, USA 
Sodium-dodecyl-sulphate (SDS) Sigma, St. Louis, MO, USA 
SYBR Safe Roche, Basel, Switzerland 
Thrombin Melford, Ipswich, England, GB 
Triton X-100 Sigma, St. Louis, MO, USA 
Trizma base Sigma, St. Louis, MO, USA 
Trypsin/EDTA solution Lonza, Basel, Switzerland 
Tween 20 Sigma, St. Louis, MO, USA 
Urea Melford, Ipswich, England, GB 
Western blot chemiluminescence reagent SuperSignal West Pico, Thermo Scientific 
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Table 12. List of SDS-PAGE gels and reagents. 
Reagent 
6% 
separating 
gel (9 ml) 
10% 
separating 
gel (9 ml) 
12% 
separating 
gel (9 ml) 
15% 
separating 
gel (9ml) 
4% 
stacking 
gel (1.5 ml) 
H2O 5.22 ml 4.32 ml 3.87 ml 3.2 ml 1.1 ml 
30% 
acrylamide 1.35 ml 2.25 ml 2.7 ml 3.375 ml 187.5 µl 
1.5 M Tris 
[pH 8.8] 2.25 ml 2.25 ml 2.25 ml 2.25 ml - 
0.5 M Tris 
[pH 6.8] - - - - 200 µl 
10% APS 90 µl 90 µl 90 µl 90 µl 15 µl 
10% SDS 90 µl 90 µl 90 µl 90 µl 15 µl 
TEMED 3.6 µl 3.6 µl 3.6 µl 3.6 µl 1.5 µl 
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2.2 Methods	
 
Cell	Culture		
 
The cells used in this study include: HCT.shctrl (stable HCT116 human colorectal 
carcinoma cells knockdown control), HCT.shATR and HCT.shCaspase-10 (stable 
HCT116 human colorectal carcinoma cells knockdowns), and HCT.p53-/- (HCT116 
knockout). All cell lines are derivatives of the HCT116 cells (human colorectal carcinoma 
cells) (ATCC®). The details of the HCT116 cell line characteristics are summarised in 
Table 13. 
 
 
Table 13. Characteristics of the HCT116 cell line (ATCC®).1 
Characteristic Description 
Organism Homo sapiens 
Tissue Colon  
Morphology Epithelial 
Culture properties Adherent 
Disease Colorectal carcinoma  
Age Adult  
Gender Male 
p53 tumor suppressor status Wild type 
Ras proto-oncogene status Mutated in codon 13 
1 Retrieved from the American Type Culture Collection (ATCC) webpage 
(https://www.lgcstandards-atcc.org/en.aspx).  
 
 
The HCT.shctrl, HCT.shATR and HCT.shCaspase-10 and HCT.p53-/- were grown in 
McCoy’s 5A medium. Upon reaching 70-80% confluence, the cells were washed with 5 
ml 1 x PBS (phosphate buffer saline). The cells were then trypsinised by addition of 2 ml 
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of trypsin/EDTA solution followed by incubation for 2-5 minutes at room temperature until 
the cells detached from the culture flask. Next, 12 ml of fresh medium was added to 
neutralise the trypsin/EDTA solution. 2 ml of suspended cells were transferred into a new 
flask containing 12 ml of fresh medium (sub-culturing ratio = 1:6). The cells were 
incubated at 37ºC and 5% CO2. The sub-culturing of the cells was performed every 3 
days. 
 
Generation	of	Stable	Knockdown	Cell	Lines	
 
The HCT116 derived stable knockdown cell lines were generated in the Mohr/Zwacka 
laboratory using RNA interference (RNAi). In order to knock down the target genes, the 
small hairpin (sh) motifs, which are listed in Table 14, were used. 
 
Table 14. Small hairpin motifs used for generation of stable HCT116 knockdowns. 
Target gene Small hairpin motif Reference 
ATR (shATR) 
5’-
GATCCCCGGCGTCGTCTCAGCTCGTCT
TCAAGAGAGACGAGCTGAGACGACGCC
TTTTTGGAAA-3’ 
Ariumi et al. 
(2005) 
Caspase-10 (shCaspase-10) 5’-GCATTGACTCAGAGAACTTAA-3’ Mohr et al. (2018) 
 
 
Sense and antisense oligos containing the short-hairpin sequences and 5’ and 3’ 
overhangs with the BbsI and EcoRI sites, respectively, were hybridised to generate 
double stranded DNA (dsDNA) fragments. The generated dsDNA fragments were then 
cloned into a modified pU6.ENTR plasmid (Life Technologies). The resulting pU6.ENTR 
plasmids were utilised to generate the pAd.sh vectors using the LR Clonase II system 
(Life Technologies) and the pBlockiT.sh plasmids (Life Technologies), which were then 
used to generate stable knockdown cell lines. For stable knockdowns generation, 
transection of the respective pBlockiT.sh plasmids into cells was performed using the 
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FuGene HD system (Promega). The transfected cells were then grown for three days 
and split into selection medium supplemented with blasticidin. Arising clones were 
picked, transferred to 24-well tissue culture plates and assessed for gene silencing using 
Western blot. A cell line generated with empty vectors, namely HCT.shctrl, was utilised 
as RNAi control.  
 
Drug	Treatments	
 
In order to induce apoptosis, cells at 50-60% confluence were subjected to treatment 
with (I) 5-Fluorouracil (PBS) at 200 μM concentration and (II) etoposide (DMSO) at 100 
μM concentration. The cells were then incubated at 37ºC and 5% CO2 for 24 h. In order 
to induce inhibition of selected proteins, cells were exposed to (I) ATM inhibitor KU55933 
(DMSO) at 2 μM concentration, (II) ATR inhibitor AZD6738 (DMSO) at 2 μM 
concentration or (III) Chk1/Chk2 inhibitor CHIR124 (DMSO) at 250 nM concentration. 
The cells were pre-treated with respective inhibitors 30 minutes prior to the addition of 
5-FU or etoposide at the concentrations described above. The cells were then incubated 
at 37ºC and 5% CO2 for 24 h. 
 
Western	Blot	
 
In order to prepare cell extracts, cells were treated with 5-FU alone (24 h), 5-FU plus 
ATR inhibitor AZD6738 (24 h) or/and ATM inhibitor KU55933 (24 h), etoposide alone (24 
h), 5-FU or etoposide plus Chk1/Chk2 inhibitor CHIR124 (24 h). Cells were harvested 
after 24 h, washed with PBS and lysed in Triton X-100 cellular lysis buffer for 20 min on 
ice. The lysates were centrifuged at RCF=17000 for 10 min at 4°C. Protein concentration 
was determined by using Pierce® BCA Protein Assay Kit (ThermoScientific) and 
following the manufacturer’s protocol. Equal amounts of protein samples (50 μg of 
protein) were separated in 6%, 10% or 12% SDS-PAGE. Transfer of proteins onto PVDF 
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membrane (GE Healthcare) was performed at 60 mA constant current for 40 min. The 
transfer was visualised by using Ponceau S stain. The PVDF membrane was incubated 
in blocking buffer (3% non-fat dry milk solution TBST buffer) for 1 h at room temperature 
followed by incubation in primary antibody (1:1000 dilution) at 4ºC overnight. Next day, 
the blots were washed in TBST buffer (three times for 5 min) and incubated in secondary 
antibody (1:5000 dilution) for 1 h at room temperature. Following another wash in TBST 
buffer (three times for 5 min), the membrane was incubated in enhanced 
chemiluminescence substrate (SuperSignalä West Pico Trial Kit (ThermoScientific) for 
30 sec and visualised by using Fusion-FX Chemiluminescence System (Vilber Lourmat). 
 
DNA	Hypodiploidy/Nicoletti	Assay	(Apoptosis	Measurement)		
 
Apoptosis measurement was performed according to Nicoletti et al. (1991) (DNA 
hypodiploidy assay). After 48 h of treatment with 5-FU alone, Chk1 inhibitor CHIR124 
alone or in combination with 5-FU, cell culture supernatant, PBS wash-solution and 
trypsinised cells were collected and centrifuged at RCF=2300 for 1 min. The cells were 
resuspended and lysed in 200 μl Nicoletti buffer (50 µg/ml propidium iodide, 0.1% (w/v) 
sodium citrate, 0.1% (w/v) Triton X-100). The fluorescence intensity was measured by 
using BD Accuri C6 flow cytometer (BD Biosciences) and analysed by Venturi One 
software. For each sample, 1000 events were measured, and each measurement was 
repeated three times.  
 
Cloning	into	Expression	Vector	pET-28a	
 
The DDEDs segments of caspase-10, caspase-8 and cFLIP-L genes (hereafter referred 
to as DDEDs caspase-10 (wild type), DDEDs caspase-8 (wild type) and DDEDs cFLIP-
L (wild type)) and the gene of full-length FADD (hereafter referred to as FADD-FL) were 
amplified by PCR. The primers for PCR reactions were designed to generate DNA 
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inserts with desired restriction enzyme sites at their ends. The resulting PCR products 
were subcloned into pGEM-T-Easy vector and transformed into E. coli TOP10 
competent cells. Selected bacteria clones were analysed for the presence of the desired 
inserts, which were then cut from the pGEM-T-Easy constructs by using restriction 
digest.  
 
The DDEDs caspase-10 (wild type), DDEDs caspase-8 (wild type) and DDEDs cFLIP-L 
(wild type) fragments were inserted into the Nde1 and BamH1 sites of pET-28a vector. 
The DDEDs caspase-10 (C401A), DDEDs caspase-10 (D415A), DDEDs caspase-8 
(C360A) and DDEDs caspase-8 (D374A/D384A) variants were then generated by using 
the QuickChange II site-directed mutagenesis kit (Stratagene). The FADD-FL insert was 
cloned into the Nco1 and EcoR1 sites of the pET-28a vector. The constructs were 
validated by sequencing. 
 
Conditions for insert amplifications and site-directed mutagenesis are summarised in 
the Tables 15 and 16, respectively.  	
Table 15. Components list and conditions for insert amplification by using PCR.  
Component 20 μl reaction Conditions 
Nuclease-free water 15 μl Initial denaturation: 95ºC, 2 min 
PCR master mix buffer (10x) 2 μl Denaturation: 95ºC, 30 s 
Forward primer (20 μM) 1 μl Annealing: 58ºC, 30 s 
Reverse primer (20 μM) 1 μl Elongation: 72ºC, 50 s 
DNA template (~20 ng/μl) 1 μl Number of cycles: 25 
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Table 16. Components list and conditions for site-directed mutagenesis.  
Component 30 μl reaction Conditions  
Nuclease-free water 21.6 μl Initial denaturation: 95ºC, 2 min 
Reaction buffer (10x) 3 μl Denaturation: 95ºC, 50 s 
DMSO 1.8 μl Annealing: 60ºC, 1 min 
dNTPs 0.6 μl Elongation: 72ºC, 13 min 
Forward primer (75 ng/μl) 1 μl Final extension: 72ºC, 10 min 
Reverse primer (75 ng/μl) 1 μl Number of cycles: 25 
DNA template (~15 ng/μl) 1 μl  
 
 
Forward (FP) and reverse (RP) primers used for PCR amplification and site-directed 
mutagenesis are listed in the Tables 17 and 18, respectively.  
 
Table 17. Primers list for PCR amplification of DDEDs caspase-10 (wild type), DDEDs 
caspase-8 (wild type), DDEDs cFLIP-L (wild type) and FADD-FL inserts (pET-28a system).  
Construct Restriction sites PCR primers 
pET-28a / DDEDs 
caspase-10 (wild type) 
Nde1, 
BamH1 
FP: CATATGAGTGAATCACAGACTTTGGAC 
RP: GGATCCTCAATCAGAAGGGAAGAC 
pET-28a / DDEDs 
caspase-8 (wild type) 
Nde1, 
BamH1 
FP: CATATGGTTAAGACATTCTTGGAAGCC 
RP: GGATCCCTAGGAAACGCTGCTCCACC 
pET-28a / DDEDs 
cFLIP-L (wild type) 
Nde1, 
BamH1 
FP: CATATGAAAGAACAAAGACTTAAGGAAC 
RP: GGATCCTTATGTGTAGGAGAGGATAAG 
pET-28a / FADD-FL Nco1, EcoR1 
FP: CCATGGACCCGTTCCTGGTGCTGC 
RP: GAATTCGACGCTTCGGAGGTAGATG 
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Table 18. Primers list for site-directed mutagenesis of the DDEDs caspase-10 and DDEDs 
caspase-8 constructs (pET-28a system). 
Construct Site-directed mutagenesis primers 
pET-28a / DDEDs caspase-10 
(C401A) 
FP: ATCCAGGCCGCCCAAGGTGAAGAG 
RP: CTCTTCACCTTGGGCGGCCTGGAT 
pET-28a / DDEDs caspase-10 
(D415A) 
FP: ATCGAAGCAGCCGCTCTGAACCCT  
RP: AGGGTTCAGAGCGGCTGCTTCGAT 
pET-28a / DDEDs caspase-8 
(C360A) 
FP: ATTCAGGCTGCCCAGGGGGATAA 
RP: TTATCCCCCTGGGCAGCCTGAAT 
pET-28a / DDEDs caspase-8 
(D374A/D384A) 
FP (374A): GTTGAGACTGCCTCAGAGGAGCAA 
RP (374A): TTGCTCCTCTGAGGCAGTCTCAAC 
FP (384A): TTAGAAATGGCCTTATCATCACCT 
RP (384A): AGGTGATGATAAGGCCATTTCTAA 
 
 
Cloning	into	Expression	Vector	pGEX-4T-3	
 
Empty pGEX-4T-3 vector was modified by insertion of DNA sequences containing C-
terminal (His)6 tag with thrombin or TEV site into Sal1 and Not1 sites of the plasmid. 
These DNA fragments were generated by hybridization of sense and antisense 
oligonucleotides encoding for the thrombin-(His)6 or TEV-(His)6 peptides. The 
oligonucleotides were designed to generate the respective restriction enzyme 
overhangs after hybridization. The DDEDs caspase-8 (C360A), DDEDs caspase-10 
(C401A), DDEDs caspase-10 (D415A) and DDEDs cFLIP-L (wild type) inserts were 
generated by PCR amplification and subcloned into pGEM-T-Easy in the same manner 
as described for the pET-28a system. The inserts were then cut from the pGEM-T-Easy 
constructs by using restriction digests.  
 
The resulting DDEDs caspase-8 (C360A), DDEDs caspase-10 (C401A), DDEDs 
caspase-10 (D415A) and DDEDs cFLIP-L (wild type) fragments were then cloned into 
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BamH1 and Sal1 sites of the pGEX-4T-3/thrombin-(His)6 and pGEX-4T-3/TEV-(His)6 
backbones. Additionally, DDEDs cFLIP-L (D376A) variants were generated by site-
directed mutagenesis. The constructs were validated by sequencing. 
 
PCR and site-directed mutagenesis were performed as described previously for pET-
28a constructs. Components and conditions for each reaction are summarised in the 
Tables 15 and 16.  
 
Oligonucleotides used for hybridization and primers used for PCR amplification and site-
directed mutagenesis are listed in the Tables 19, 20 and 21, respectively. 
 
Table 19. Oligonucleotides list for generation on thrombin-(His)6 or TEV-(His)6 peptides 
used for modification of the pGEX-4T-3 vector.  
Peptides Restriction sites Oligonucleotides 
Thrombin-
(His)6 Sal1, Not1 
Forward: 
TCGACCTGGTGCCGCGCGGCAGCGGCAGCAGCCATCATCATC
ATCATCACAGCAGC 
Reverse: 
GGCCGCTGCTGTGATGATGATGATGATGGCTGCTGCCGCTGC
CGCGCGGCACCAGG 
TEV-(His)6 Sal1, Not1 
Forward: 
TCGACGGAGAAAATCTTTATTTTCAAGGTGGCAGCAGCCATC
ATCATCATCATCACAGCAGC 
Reverse: 
GGCCGCTGCTGTGATGATGATGATGATGGCTGCTGCCACCTT
GAAAATAAAGATTTTCTCCG 
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Table 20. Primers list for PCR amplification of the DDEDs caspase-8 (C360A), DDEDs 
caspase-10 (C401A and D415A) and DDEDs cFLIP-L (wild type) inserts (pGEX-4T-3 
system). 
Construct Restriction sites PCR primers 
pGEX-4T-3 / DDEDs 
caspase-8 (C360A) BamH1, Sal1 
FP: GGATCCAGTGAATCACAGACTTTGGAC 
RP: GTCGACATCAGAAGGGAAGACAAG 
pGEX-4T-3 / DDEDs 
caspase-10 (C401A 
and D415A) 
BamH1, Sal1 
FP: GGATCCGTTAAGACATTCTTGGAAGCC 
RP: GTCGACGGAAACGCTGCTCCACCTGC 
pGEX-4T-3 / DDEDs 
cFLIP-L (wild type) BamH1, Sal1 
FP: GGATCCAAAGAACAAAGACTTAAGGAAC 
RP: GTCGACTGTGTAGGAGAGGATAAGTTTC 
 
 
Table 21. Primers list for site-directed mutagenesis of the DDEDs cFLIP-L construct (pGEX-
4T-3 system).  
Construct Site-directed mutagenesis primers 
pGEX-4T-3 / DDEDs 
cFLIP-L (D376A) 
FP: GCCTCTTGGAGGTGGCTGGGCCAGCGATGAAG 
RP: CTTCATCGCTGGCCCAGCCACCTCCAAGAGGC 
 
 
Preparation	of	E.	coli	Competent	Cells	
 
The E. coli competent cells were prepared by transferring 200 µl of E. coli TOP10 strain 
preculture grown overnight at 37ºC into 10 ml LB Broth. Following incubation at 37ºC 
for 2 h, the culture was centrifuged at RCF=2103 for 10 min. Bacteria cells were 
resuspended in 5 ml of chilled 100 mM CaCl2. After being incubated for 30 min on ice, 
cells were centrifuged at RCF=2103 for 10 min. Then, the resuspension, incubation and 
centrifugation steps were repeated. Finally, bacteria cells were resuspended in 500 μl 
of 100 mM CaCl2 and incubated on ice for 1 h.  
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Transformation	of	E.	coli	
 
For transformation of E. coli, protein expression vectors or DNA ligations were used. 
The amount of DNA inserts required for ligation reactions was calculated by using the 
following formula:  
 
𝒏𝒈	𝒐𝒇	𝒊𝒏𝒔𝒆𝒓𝒕 = 	𝒏𝒈	𝒐𝒇	𝒗𝒆𝒄𝒕𝒐𝒓	𝒙	𝒊𝒏𝒔𝒆𝒓𝒕	𝒔𝒊𝒛𝒆	(𝒃𝒑)	𝒙	𝑭𝒗𝒆𝒄𝒕𝒐𝒓	𝒔𝒊𝒛𝒆	(𝒃𝒑) 𝒊𝒏𝒔𝒆𝒓𝒕	𝒄𝒐𝒏𝒄𝒆𝒕𝒓𝒂𝒕𝒊𝒐𝒏7 (𝝁𝒈𝝁𝒍 ) 	F	=	vector	to	insert	molar	ratio	
 
DNA ligations were performed using a standard protocol. 100 μl of E. coli competent 
cells and 1 μl of expression vectors (25-50 ng/μl) or 4 μl of DNA ligations were mixed 
and then incubated on ice for 30 min. In order to heat-shock bacteria cells, the bacteria 
and DNA mixture was incubated at 42ºC for 30 s in a water bath. Then, the mixture was 
put back on ice for 2 min. Following addition of 300 μl of SOC medium, the mixture was 
incubated on a shaker at 37ºC for 1 h. Finally, the mixture was plated onto agar plates 
containing ampicillin (pGEM-T-Easy constructs), ampicillin and chloramphenicol 
(pGEX-4-T3 constructs) or kanamycin (pET-28a constructs). The plates were incubated 
at 37ºC overnight.  
 
Protein	Expression	with	pET-28a	Constructs	
 
Cultures of E. coli BL21(DE3) (E. coli strain B F– dcm ompT hsdS(rB– mB–) gal λ(DE3)) 
competent cells were used for expression of the DDEDs caspase-10 (wild type), DDEDs 
caspase-10 (C401A), DDEDs caspase-10 (D415A), DDEDs caspase-8 (wild type), 
DDEDs caspase-8 (C360A), DDEDs caspase-8 (D374A/D384A), DDEDs cFLIP-L (wild 
type) and FADD-FL constructs. Cell cultures were grown at 37ºC for 2-3 h in LB Broth 
containing kanamycin. When cultures density (OD) reached A600 = 0.6-0.8, protein 
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expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to 
the final concentration of 0.02 mM for DDEDs caspase-10 (C401A) and DDEDs caspase-
10 (D415A), and 0.1 mM for DDEDs caspase-10 (wild type), DDEDs caspase-8 (wild 
type), DDEDs caspase-8 (C360A), DDEDs caspase-8 (D374A/D384A), DDEDs cFLIP-L 
(wild type) and FADD-FL. Cell cultures were shaken at 18°C for 15 h (overnight). The 
details of protein expression conditions for each construct are summarised in Table 22. 	
Table 22. List of expression conditions for pET-28a constructs. 
Construct  Medium  IPTG Temp. Time  
DDEDs caspase-10 (wild 
type) LB medium  0.1 mM 18°C 15 h (overnight) 
DDEDs caspase-10 (C401A) LB medium + 1% glucose 0.02 mM 18°C 15 h (overnight) 
DDEDs caspase-10 (D415A) LB medium + 1% glucose 0.02 mM 18°C 15 h (overnight) 
DDEDs caspase-8 (wild type) 
LB medium or 
LB medium + 
1% glucose 
0.1 mM 18°C 15 h (overnight) 
DDEDs caspase-8 (C360A) LB medium  0.1 mM 18°C 15 h (overnight) 
DDEDs caspase-8 
(D374A/D384A) LB medium 0.1 mM 18°C 15 h (overnight) 
DDEDs cFLIP-L (wild type) LB medium 0.1 mM 18°C 15 h (overnight) 
FADD-FL LB medium 0.1 mM 18°C 15 h (overnight) 
 
 
Protein	Expression	with	pGEX-4T-3	Constructs	
  
Cultures of E. coli BL21-RIL (E. coli strain B F– ompT hsdS(rB– mB–) dcm+ Tetr gal endA 
Hte [argU ileY leuW Camr]) competent cells were used for expression of the control 
GST/thrombin-C-(His)6 DDEDs caspase-8 (C360A), DDEDs caspase-10 (C401A), 
DDEDs caspase-10 (D415A), DDEDs cFLIP-L (wild type) and DDEDs cFLIP-L (D376A) 
constructs. Cell cultures were grown at 37ºC for 2-3 h in LB Broth containing 
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chloramphenicol and ampicillin. When cultures density (OD) reached A600 = 0.6-0.8, 
protein expression was induced by addition of IPTG to the final concentration of 0.1 
mM. Cell cultures were shaken at 30°C for 3 h. The details of protein expression 
conditions for each construct are summarised in Table 23. 
 
Table 22. List of expression conditions for pGEX-4T-3 constructs. 
Construct  Medium  IPTG Temp. Time of expression 
GST/thrombin-C-(His)6 LB medium 0.1 mM 30°C 3 h 
DDEDs caspase-8 (C360A) LB medium 0.1 mM 30°C 3 h 
DDEDs caspase-10 (C401A) LB medium 0.1 mM 30°C 3 h 
DDEDs caspase-10 (D415A) LB medium 0.1 mM 30°C 3 h 
DDEDs cFLIP-L (wild type) LB medium 0.1 mM 30°C 3 h 
DDEDs cFLIP-L (D376A) LB medium 0.1 mM 30°C 3 h 
 
 
Lysis	Conditions		
 
Following protein expression, bacteria cultures were harvested by centrifugation at 
RCF=3578 for 10 min, resuspended in cold lysis buffer (50 mM Tris, 100 mM NaCl, 1 
mM EDTA, 50 mM MgCl2), stirred for 30 min and disrupted by sonication (pulsing: 30 s, 
rest: 30 s, number of cycles: 20) at 4°C. The cell debris and inclusion bodies were 
separated from soluble fraction by high-speed centrifugation at RCF=15.821 for 30 min 
at 4°C. In order to determine the level of protein solubility, lysate, supernatant and cell 
pellet samples were analysed on 12% or 15% SDS-PAGE. The gels were stained in 
Coomassie Brilliant Blue buffer for minimum 1 h (up to 15 h overnight) at room 
temperature with gentle agitation. Then, the gels were destained in Coomassie destain 
buffer for a minimum of 1 h (up to 15 h overnight) at room temperature with gentle 
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agitation. Due to accumulation of expressed proteins in insoluble inclusion bodies, cell 
pellets were collected for solubilisation under denaturing conditions. 
 
Inclusion	Bodies	Solubilisation		
 
Bacteria inclusion bodies harbouring desired proteins were resuspended in 25 ml 
solubilisation buffer (6 m GuHCl or 8 M urea, 500 mM NaCl, 20 mM Trizma base, [pH 
8.0]; Table 22) and stirred for 1 h followed by sonication for 10 cycles with 30 s pulsing 
and 30 s rest at 4°C, and centrifugation at RCF=15821 for 20 min at 4°C to separate 
cell debris. After centrifugation, supernatants were collected, and cell pellets were 
resuspended in 25 ml solubilisation buffer followed by sonication and centrifugation 
steps as previously. Supernatants were collected for purification on IMAC (5 ml Ni-NTA 
column, GE Healthcare). 
 
Table 23. List of inclusion bodies solubilisation methods.  
Proteins – pET-28a system Solubilisation method 
DDEDs caspase-10 (wild type) GuHCl 
DDEDs caspase-10 (D415A) GuHCl 
DDEDs caspase-8 (wild type) GuHCl 
DDEDs caspase-8 (C360A) GuHCl or Urea 
DDEDs cFLIP-L (wild type) GuHCl 
FADD-FL GuHCl 
Proteins – pGEX-4T-3 system Solubilisation method 
DDEDs caspase-10 (D415A)/thrombin-C-
(His)6 Urea 
DDEDs cFLIP-L (D376A)/thrombin-C-(His)6 Urea 
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Protein	Purification		
 
Supernatants containing desired proteins were loaded at 1-2 ml/min flow-rate onto IMAC 
(5 ml Ni-NTA) column (GE Healthcare) pre-equilibrated with Buffer D and washed with 
Buffer D at 2-3 ml/min flow-rate using manual pump. Flow-through was collected. The 
column was disconnected and attached to AKTA PrimePlus. Linear urea gradient (100 
ml, 100 % gradient) using Buffers D and A was then carried out to refold the proteins 
immobilised in Ni-NTA matrix. The refolding was performed at 1 ml/min flow-rate. Elution 
was performed with linear imidazole gradient (50 - 100 ml, 100 % gradient) using Buffers 
A and B, which were applied at 2 ml/min until UV plateaus. Protein eluates were collected 
as 5 ml fractions, pooled and dialysed overnight at 4oC in Buffer C. The dialysed 
supernatant was concentrated at RCF=3739 at 4oC in Centricon tubes (Vivaspin 20, 10 
kDa MWCO) to ~10 ml. The N-(His)6 tag (pET-28a system) or N-GST and C-(His)6 tags 
(pGEX-4T-3 system) of successfully purified proteins were removed by adding 125 units 
of thrombin (Sigma) followed by slow rotation overnight at 4oC. The supernatants were 
then re-applied onto IMAC column in the same manner as previously described. The 
flow-through fractions containing the proteins of interest were collected, concentrated to 
2 ml in Centricon tubes (Vivaspin 20, 10 kDa MWCO) and further fractionated at 0.8 
ml/min flow-rate on SEC (120 ml Superdex 75 16/60 column) column (GE Healthcare), 
pre-equilibrated with Buffer C. Selected protein eluates in the major elution peak at 280 
nm were collected as 2 ml fractions, pooled and examined for purity on 12% or 15% 
SDS-PAGE. The gels were stained in Coomassie Brilliant Blue buffer and destained in 
Coomassie destain buffer in the same manner as previously described. In order to further 
confirm the presence of the desired proteins, selected protein fractions were subjected 
to Western blot analysis or mass spectrometry. Fractions containing the proteins of 
interest were concentrated, subjected to circular dichroism spectroscopy and stored as 
200 µl aliquots at -20oC. 
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Mass	Spectrometry	
 
In order to confirm identity of purified proteins, matrix-assisted laser desorption/ionisation 
(MALDI) mass spectrometry analysis was carried out. The protein of interest, which was 
purified using column chromatography and suspended in Buffer C, was loaded and run 
on 12% SDS-PAGE. The gel was stained in Coomassie Brilliant Blue buffer and 
destained in Coomassie destain buffer in the same manner as previously described, 
followed by thorough wash in water. The gel was cut around the band of interest and the 
resulting gel slice was subsequently reduced, followed by digestion into peptides using 
trypsin. The peptides were separated using liquid chromatography (nano-flow LC system 
with reverse phase column). Determination of masses and confirmation of sequences of 
the peptides were carried oud using an Orbitrap Elite MS/MS spectrometer, which was 
coupled to the liquid chromatography device. In order to confirm the identity and origin 
of analysed protein, the detected peptide sequences were then matched against a 
protein database. All MALDI analyses and sample preparations were performed at the 
Functional Genomics and Proteomics Facility, School of Biosciences, University of 
Birmingham.  
 
Circular	Dichroism	Spectroscopy	
 
Chirascan Circular Dichroism Spectrometer (Applied Photophysics) was set up 
according to the manufacturer’s protocol. Required parameters for circular dichroism 
data measurement were set up by using Chirascan software and included: (I) 
temperature at 20oC, (II) wavelength range from high = 245 nm to low = 195 nm and (III) 
wavelength interval at 0.2. In order to determine the spectrum of the sample buffer 
(background), 200 µl of Buffer C was aliquoted into a quartz cuvette (path length = 0.1 
cm) and measured. For sample measurements, 200 µl of purified protein (protein of 
interest in Buffer C) at a concentration between 1 – 200 µM was aliquoted into a quartz 
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cuvette (path length = 0.1 cm). The circular dichroism spectra of the desired protein 
samples were collected in triplicates and averaged by using Chirascan software.  
 
Protein	Concentration	Calculations		
 
Concentrations of the purified proteins were determined spectrophotometrically using 
protein absorbance (A) measurements at 280 nm wavelength and extinction coefficient 
values (e). The absorbance measurements were performed at 20oC using a Cary 60 UV-
visible spectrophotometer (Varian). In order to calibrate the spectrophotometer to zero 
absorbance, 1 ml of Buffer C was transferred into a quartz cuvette (path length = 1cm) 
and measured. Then, 1 ml of purified protein (protein of interest in Buffer C) was 
aliquoted into a quartz cuvette (path length = 1cm) and the absorbance of the sample 
was recorded. The extinction coefficient of the protein of interest was calculated using 
the ProtParam tool (https://web.expasy.org/protparam). Finally, the protein 
concentration was determined using Beer-Lambert formula:  
 	𝑨 = 	e	𝒍	𝒄		 A	–	absorbance	(A280)	
e	-	extinction	coefficient	(M-1	cm-1)	l	–	path	(cm)	c	–	concentration	(M)	
 
FADD	/	Caspase-8	Protein	Pull-Down	Assay	
 
Purified C-(His)6-tagged FADD-FL (bait protein) and untagged DDEDs caspase-8 
(C360A) (prey protein) were mixed at equimolar ratio of 10 µM in a total volume of 1 ml 
of the reaction buffer (50 mM Trizma base, 100 mM NaCl, [pH 7.4]) and incubated for 1 
h at room temperature. The mixture was applied at 1 ml/min flow-rate onto the 5 ml Ni-
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NTA column, pre-equilibrated with Buffer A. The column was attached to AKTA 
PrimePlus and 3-step washing was performed at 1-2 ml/min flow-rate by using: (I) 10 ml 
of Buffer A, (II) 30 ml of linear salt gradient (100% gradient; Buffers A and A*) and 10 ml 
of Buffer A**. Each wash step was collected as a separate fraction and concentrated at 
RCF=3739 at 4oC in Centricon tubes (Vivaspin 20, 10 kDa MWCO) to ~1 ml. Elution was 
performed with linear imidazole gradient (50 ml, 100% gradient) by using Buffers A** and 
B, which were applied at 1-2 ml/min. Protein eluates were collected as 10 ml fractions 
and concentrated in the same manner as wash fractions. Equal volumes (30 µl) of wash 
and elution fractions were loaded on 15% SDS-PAGE and analysed by Western blot.  
 
As a control, purified C-(His)6-GST tag (bait protein) and untagged DDEDs caspase-8 
(C360A) (prey protein) were mixed at equimolar ratio of 10 µM in a total volume of 1 ml 
of the reaction buffer (50 mM Trizma base, 100 mM NaCl, [pH 7.4]) and incubated for 1 
h at room temperature. The protein pull-down assay for the control mixture was 
performed in the same manner as for C-(His)6-tagged FADD-FL and untagged DDEDs 
caspase-8 (C360A), followed by 15% SDS-PAGE and Western blot analysis.  
 
The details of the protein pull-down assay and reagents used are summarised in Table 
25.  
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Table 24. List of proteins and reagents used for FADD / caspase-8 protein pull-down assay.  
Reaction mixture 
• 10 µM C-(His)6-tagged FADD-FL + 10 µM untagged DDEDs 
caspase-8 (C360A) 
• 10 µM C-(His)6-tagged GST + 10 µM untagged DDEDs 
caspase-8 (C360A) – control  
Reaction conditions 50 mM Tris, 100 mM NaCl, [pH 7.4], 1 h, room temperature 
Column details IMAC 5 ml His-trap FF nickel-nitrilotriacetic (Ni-NTA) acid-sepharose column, pre-equilibrated with Buffer A 
Wash 1 10 ml of Buffer A (50 mM Trizma base, 500 mM NaCl, 20 mM imidazole, [pH 7.5] 
Wash 2 30 ml linear salt gradient (100%) – Buffer A and A* (50 mM Trizma base, 1 M NaCl, 20 mM imidazole, [pH 7.5]) 
Wash 3 10 ml Buffer A** (50 mM Trizma base, 500 mM NaCl, 80 mM imidazole, [pH 7.5]) 
Elution 50 ml linear imidazole gradient – Buffers A** and B (50 mM Trizma base, 500 mM NaCl, 500 mM imidazole, [pH 7.5]) 
 
 
Caspase-10	/	Caspase-8	Activity	Assay	
 
1 µM of purified untagged DDEDs caspase-10 (D415A) (enzyme) and 10 µM of purified 
untagged DDEDs caspase-8 (C360A) (substrate) were mixed in a total volume of 250 µl 
of the reaction buffer (50 mM Trizma base, 150 mM NaCl, 10% PEG, 0.1% CHAPS, [pH 
7.4]) and incubated at room temperature. At noted timepoints, 30 µl of the reaction was 
aliquoted into the loading buffer, in order to stop the reaction and prepare samples for 
analysis by using 15% SDS-PAGE and Western blot.  
 
In order to optimise the buffer and reaction conditions for the assay, 1 µM of purified 
untagged DDEDs caspase-10 (D415A) (enzyme) mixed with 10 µM of purified untagged 
DDEDs caspase-8 (C360A) (substrate) were tested at physiological conditions (50 mM 
Trizma base, 100 mM NaCl, [pH 7.4]. 10 µM of purified untagged DDEDs caspase-8 
(C360A) alone was used as a control and tested at physiological conditions (50 mM 
Trizma base, 100 mM NaCl, [pH 7.4], stabilising conditions (50 mM Trizma base, 150 
 101 
mM NaCl, 10% PEG, 0.1% CHAPS, [pH 7.4]) and in the presence of kosmotropic salts 
(50 mM Trizma base, 150 mM NaCl and 1 M sodium citrate, [pH 7.4]). As previously, 30 
µl of the reaction was aliquoted into the loading buffer at noted timepoints, followed by 
analysis on 15% SDS-PAGE and Western blot. 
 
The details of reactions and reagents used are summarised in Tables 26, 27 and 28. 
 
Table 25. Conditions and timepoints list for DDEDs caspase-8 (C360A)/DDEDs caspase-10 
(D415A) control assay. 
Reaction 
1 µM untagged DDEDs caspase-10 
(D415A) + 10 µM untagged DDEDs 
caspase-8 (C360A)  
Timepoints (minutes) 
Physiological 
conditions 
50 mM Trizma base, 150 mM NaCl, 
[pH 7.4] • 0, 10, 40 160  (Fig. 48) 	
	
	
Table 26. Conditions and timepoints list for DDEDs caspase-8 (C360A) control assay. 
Reaction 10 µM untagged DDEDs caspase-8 (C360A) – control Timepoints (minutes) 
Physiological 
conditions 
50 mM Trizma base, 150 mM 
NaCl, [pH 7.4] 
• 0, 10, 40 160       
• 0, 0.5, 1, 1.5, 2, 3, 4, 5, 10 
 
• 0, 0.5, 1, 1.5, 2, 5, 10       
(Fig. 48) 
(Fig. 49A 
and B) 
(Fig. 50) 
Stabilising 
conditions 
50 mM Trizma base, 150 mM 
NaCl, 10% PEG, 0.1% 
CHAPS, [pH 7.4] 
• 0, 0.5, 1, 1.5, 2, 5, 10    (Fig. 49B) 
Addition of 
kosmotropic 
salts 
50 mM Trizma base, 150 mM 
NaCl, 1 M sodium citrate, [pH 
7.4] 
• 0, 0.5, 1, 1.5, 2, 5, 10            (Fig. 50) 									
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Table 27. Conditions and timepoints for DDEDs caspase-10 (D415A) / DDEDs caspase-8 
(C360A) activity assay. 
Reaction 
1 µM untagged DDEDs caspase-10 
(D415A) + 10 µM untagged DDEDs 
caspase-8 (C360A) 
Timepoints (minutes) 
Stabilising 
conditions 
50 mM Trizma base, 150 mM NaCl, 
10% PEG, 0.1% CHAPS, [pH 7.4] • 0, 0.5, 1, 1.5, 2, 5, 10    (Fig. 43) 
 
	
Statistical	Analysis	
 
Collected data sets were summarised in tables by using Microsoft Excel. The data were 
organised and presented based on various factors, such as cell line, cytotoxic drug type 
and dose, treatment duration and date of measurement. The statistical calculations, 
including mean, sum and standard deviation were then performed. Finally, experimental 
data were expressed as mean values ± standard error of mean (S.E.M.).  
 
The following formula was used for calculation of the standard error bars:  
 
𝑺. 𝑬.𝑴.= 	±𝑺𝑫√𝒏 SD	-	standard	deviation	n	–	number	of	samples	or	datapoints		
 
In order to perform significance analyses, the means between two or more groups of 
values were compared by using single-factor analysis of variance (single-factor 
ANOVA). In this analysis, the null hypothesis that “equal means of each sample” was 
tested. The significance was then assessed based on calculated p-values (probability 
values), which express the probability of obtaining a greater or equal mean difference 
between two groups, when compared with the observed values (assuming that the null 
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hypothesis it true). In this analysis, p<0.05 was considered as significant and p<0.001 
as highly significant, meaning that the higher the p-value, the lower the significance.  
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CHAPTER	3	
RESULTS	–	PART	I	
	
Functional	Analysis	of	the	Main	Constituents	of	the	
FADDosome	Complex	In	Vitro		
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 Design	 and	 Establishment	 of	 Protein	 Expression	
Constructs	by	Using	pET-28a	Vector	
 
In order to reconstitute the FADDosome complex and to study the functional 
relationships and interactions of the main molecular constituents of the FADDosome in 
vitro, it was essential to express human caspase-10, caspase-8, cFLIP-L and FADD as 
recombinant proteins in E. coli and to purify them on chromatography columns.  
 
In this study, as suggested by Stennicke and Salvesen (1999), and Denault and 
Salvesen (2002), the pET-expression system was used for recombinant production of 
the proteins of interest. The authors have demonstrated that using the pET vectors led 
to the successful expression of proteins and allowed to obtain very high yields. In this 
study, the pET-28a vector was used in this study due to the presence of N-terminal and 
optional C-terminal (His)6-tags, which allows flexibility when designing and establishing 
expression constructs (Figure 14). In the pET-28a vector, the target genes are subcloned 
downstream of the T7 bacteriophage promoter and the lac operator (Figure 14). The 
vector containing the genes of interest is transformed into bacterial host, which contains 
the T7 polymerase gene controlled by the lacUV5 promoter. Synthesis of the T7 
polymerase and the subsequent expression of genes under the T7 promoted is induced 
by addition of IPTG (Denault and Salvesen (2002).   
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B 
 
 
Figure 14. Schematics of an empty pET-28a vector. 
A. Map of the vector with its main features B. Detailed schematics of the Multiple Cloning Site 
with indication of restrictions sites positions for enzymes used during cloning of desired DNA 
constructs.  
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Caspases and cFLIP-L proteins consist of domains, which include N-terminal death 
effector domains (DED1 and DED2) and active subunits: p18 and p10 for caspase-8, 
p18 and p12 for caspase-10 and caspase-like subunit for cFLIP-L. An adaptor protein 
FADD is composed of one DED domain and death domain (DD) (Figure 15 A, B, C and 
D). It is believed that the DED domains are necessary for interactions between these 
proteins (Carrington et al., 2006; Riley et al., 2015). Thus, in the present study, it was 
hypothesised that within the FADDosome, caspase-10, caspase-8, cFLIP-L and FADD 
would possibly associate in the DED-dependent manner. With respect to this, the initial 
aim was to express full-length recombinant proteins, containing their DED domains and 
active subunits. The recombinant expression of full-length caspase-10 and caspase-8 
was successful and led to production of good levels of the desired proteins (data not 
shown). Nevertheless, purification of the proteins of interest resulted in obtaining very 
poor or no yields (data not shown). It was assumed that this was possibly caused by 
protein instability and/or degradation. With respect to this, a different strategy for 
recombinant protein production was needed.  
 
Therefore, the death effector domains (DEDs) of caspase-10, caspase-8 and cFLIP-L 
were excluded in the DNA constructs (Figure 15A, B and C), similar to the recombinant 
proteins designed and produced by others (Stennicke and Salvesen, 1997; Garcia-Calvo 
et al., 1999; Boatright et al., 2004; Yu et al., 2009; Wachmann et al., 2010). The authors 
have shown that recombinant DED-truncated caspase-10, caspase-8 and cFLIP-L, 
which were expressed in E. coli and purified by liquid chromatography, can be functional 
without their DEDs in vitro. It was demonstrated that caspase-10 and caspase-8, which 
lacked their DEDs remained active and had the ability to process their substrates or other 
proteins in vitro (Stennicke and Salvesen, 1997; Garcia-Calvo et al., 1999; Boatright et 
al., 2004; Yu et al., 2009). Moreover, exclusion of DEDs in the caspase-10, caspas-8 
and cFLIP-L constructs can be advantageous, as it might help facilitate the recombinant 
protein production. It was described that DEDs might undergo oligomerisation, which 
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greatly reduces solubility and increases toxicity levels of the proteins expressed in E. coli 
(Denault and Salvesen, 2002; Keller et al., 2009). 
 
As the aim of this study was to analyse the functional relationships and interactions 
between caspase-10, caspase-8, cFLIP-L and FADD in terms of the FADDosome 
formation, it was crucial to express and purify different variants of the recombinant 
proteins. For this, the following variants were designed: DDEDs caspase-10 (wild type), 
DDEDs caspase-10 (C401A active site mutant), DDEDs caspase-10 (D415A linker 
mutant), DDEDs caspase-8 (wild type), DDEDs caspase-8 (C360A active site mutant), 
DDEDs caspase-8 (D374A/D384A linker mutant), DDEDs cFLIP-L (wild type), DDEDs 
cFLIP-L (D376A cleavage mutant) and FADD-FL (Figure 15A, B, C and D). Depending 
on experimental design, active site mutations allow to study the role of selected proteins 
as substrates in the reaction, whereas linker mutations allow to investigate biologic 
activity of selected proteins and their role as enzymes/activators in the reaction.  
 
Mutation at C401A (active site mutation) abolishes the proteolytic activity of DDEDs 
caspase-10 and thus, prevents processing of other proteins and autocleavage. Mutation 
at D415A (linker mutation) prevents DDEDs caspase-10 from being cleaved by other 
proteins (Figure 15A). For DDEDs caspase-8, substitution at C360A (active site 
mutation) abolishes the proteolytic activity of the protein. This prevents processing of 
other proteins and autocleavage. Two substitutions at D374A/D384A (linker mutation) 
prevent DDEDs caspase-8 from being cleaved by other proteins (Figure 15B). In case of 
DDEDs cFLIP-L, mutation at D376A, which has been demonstrated to function as a 
preferred cleavage site for pro-caspase-8 (Yu et al., 2009), it prevents cFLIP-L from 
being processed by caspase-8 (Figure 15C). The FADD-FL construct does not contain 
any mutations (Figure 15D), as they have not been reported to possess any (auto-) 
proteolytic activity.  
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Figure 15. Schematic representation of human recombinant protein constructs used in this 
study. 
A. The DDEDs caspase-10 construct without mutation and with single amino acid substitution at 
C401A (abolishes the proteolytic activity of DDEDs caspase-10 and therefore, prevents 
processing of other proteins and autocleavage) or at D415A (linker mutation, which prevents 
DDEDs caspase-10 from being cleaved by other proteins). All constructs are compared with wild 
type pro-caspase-10 variant. All subunits are defined as orange rectangles with rounded corners. 
B.  The DDEDs caspase-8 construct without mutation and single amino acid substitutions at 
C360A or D374A/D384A. The substitution at C360A abolishes the proteolytic activity of DDEDs 
caspase-8 and therefore, prevents processing of other proteins and autocleavage. Two 
substitutions at D374A/D384A prevent DDEDs caspase-8 from being cleaved by other proteins. 
All subunits are defined as blue rectangles with rounded corners. C. The DDEDs cFLIP-L 
construct without mutation and with a single amino acid substitution at D376A. The substitution 
at D376A, which has been shown to be a preferred cleavage site for pro-caspase-8 (Yu et al., 
2009) prevents cFLIP-L from being processed by caspase-8. All subunits are defined as grey 
rectangles with rounded corners. D. The FADD-FL construct without mutation. All subunits are 
defined as green rectangles with rounded corners. DED - death effector domain, DD - death 
domain. 
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DDEDs caspase-10 (wild type) DNA fragment was cloned into Nde1 and BamH1 sites of 
the pET-28a vector. The construct was used to generate the DDEDs caspase-10 
(C401A), DDEDs caspase-10 (D415A) variants by site-directed mutagenesis. As a result, 
the N-termini of all proteins were fused to a (His)6 tag, which can be removed by thrombin 
treatment (Figure 16A and B).  
 
A 
 
B 
 
 
Figure 16. Map of the DDEDs caspase-10/pET-28a construct.  
A. The DDEDs caspase-10 (wild type) gene was inserted into Nde1 and BamH1 sites of the pET-
28a vector. The DDEDs caspase-10 (C401A), DDEDs caspase-10 (D415A) variants were 
generated by site-directed mutagenesis. B. Detailed schematics of the DDEDs caspase-10 insert 
with N-terminal (His)6 tag and thrombin site for tag removal.  
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DDEDs caspase-8 (wild type) DNA segment was inserted into Nde1 and BamH1 sites of 
the pET-28a vector. Then, the DDEDs caspase-8 (C360A), DDEDs caspase-8 
(C374A/D384A) variants were generated by site-directed mutagenesis. Thus, the N-
termini of all proteins were fused to a (His)6 tag, which can be removed by addition of 
thrombin (Figure 17A and B).  
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B 
 
 
Figure 17. Map of the DDEDs caspase-8/pET-28a construct. 
A. The DDEDs caspase-8 (wild type) gene was inserted into Nde1 and BamH1 sites of the pET-
28a vector. The DDEDs caspase-8 (C360A), DDEDs caspase-8 (D374A/D384A) variants were 
generated by site-directed mutagenesis.  B. Detailed schematics of the DDEDs caspase-8 insert 
with N-terminal (His)6 tag and thrombin site for tag removal.  
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DDEDs cFLIP-L (wild type) DNA construct was cloned into Nde1 and BamH1 sites of the 
pET-28a vector. As a result, the N-terminus of the protein was fused to a (His)6 tag, which 
can be cleaved off by using thrombin treatment (Figure 18A and B).  
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Figure 18. Map of the DDEDs cFLIP-L/pET-28a construct.  
A. The DDEDs cFLIP-L gene (wild type) was inserted into Nde1 and BamH1 sites of the pET-28a 
vector. B. Detailed schematics of the DDEDs cFLIP-L insert with N-terminal (His)6 tag and 
thrombin site for tag removal.  
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The FADD-FL gene (Figure 19) was cloned into Nco1 and EcoR1 sites of the pET-28a 
vector. In this construct, the C-terminus of the protein is fused to an uncleavable (His)6 
tag (Figure 19).  
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B 
 
 
Figure 19. Map of the FADD-FL/pET-28a construct. 
A. The FADD-FL gene was inserted into Nco1 and EcoR1 sites of the pET-28a vector B. Detailed 
schematics of the FADD-FL insert with C-terminal (His)6 tag. 
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 Expression	of	Human	Recombinant	DDEDs	Caspase-
10	(wild	type),	DDEDs	Caspase-8	(wild	type),	DDEDs	
cFLIP-L	(wild	type)	and	FADD-FL		
 
The main goals of the protein expression procedure are to obtain high yields of protein 
and maximum production of soluble protein per cell. Therefore, it was crucial to test and 
optimise expression conditions for each protein construct to achieve the most efficient 
production. 
As a host for protein expression, E. coli strain BL21(DE3) was used. BL21(DE3) cells 
are known to allow an easy protein expression induction and are suitable for high-level 
protein expression. These bacteria are lysogens of the bacteriophage lDE3 and 
therefore, carry a DNA fragment containing the lacI gene, the lacUV5 promoter, and the 
T7 RNA polymerase gene. Transcription of the T7 RNA polymerase gene is controlled 
by the lacUV5 promoter, which is inducible by addition of IPTG. Initiation of T7 RNA 
polymerase expression leads to expression of recombinant genes inserted downstream 
of the T7 promoter in the pET-28a vector.   
When selecting expression conditions for recombinant proteins production, the following 
parameters were considered: IPTG concentration, temperature and the time of 
expression. High IPTG concentrations (1 mM final concentration or above) and high 
temperature (37°C) allow rapid protein expression in a short period of time, however 
such conditions often lead to production of insoluble or misfolded proteins, which in turn 
aggregate in inclusion bodies. Therefore, induction with low IPTG concentrations and 
expression at lower temperatures for longer period of time (such as 15 h, overnight) are 
recommended in order to facilitate production of soluble proteins (Garcia-Calvo et al., 
1999; Denault and Salvesen, 2002).  
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As a starting point, induction with 0.1 mM (final concentration) of IPTG, and expression 
at 18°C for 3h and 15 h were tested. The constructs that were tested for recombinant 
protein expression included: DDEDs caspase-10 (wild type), DDEDs caspase-8 (wild 
type), DDEDs cFLIP-L (wild type) and FADD-FL.  
 
Tables 29-32 summarise the basic information regarding protein expression constructs 
and expected protein masses after expression and purification. 
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Table 29. Main features of the human recombinant DDEDs caspase-10 (wild type) construct 
with expected protein masses after expression.  
Protein Details 
DNA Construct DDEDs caspase-10 (aa residues 220-521; wild type) pET-28a, 
N-terminal (His)6-tag 
Host Cell Strain BL21(DE3)  
Tagged Protein MW (kDa) 35 
Untagged Protein MW (kDa) 33 
 
 
Table 30. Main features of the human recombinant DDEDs caspase-8 (wild type) construct 
with expected protein masses after expression. 
Protein Details   
DNA Construct DDEDs caspase-8 (aa residues 217-479; wild type) pET-28a, 
N-terminal (His)6-tag 
Host Cell Strain BL21(DE3) 
Tagged Protein MW (kDa) 31 
Untagged Protein MW (kDa) 29 
 
 
Table 31. Main features of the human recombinant DDEDs cFLIP-L (wild type) construct 
with expected protein masses after expression.  
Protein Details 
DNA Construct DDEDs cFLIP-L (aa residues 208-480; wild type), pET-28a, N-
terminal (His)6-tag 
Host Cell Strain BL21(DE3)  
Tagged Protein MW (kDa) 30 
Untagged Protein MW (kDa) 28 
 
 
Table 32. Main features of the human recombinant FADD-FL construct with expected 
protein masses after expression. 
Protein Details 
DNA Construct FADD (aa residues 1-208; wild type), pET28a, C-terminal 
(His)6-tag (non-cleavable) 
Host Cell Strain BL21(DE3)  
Tagged Protein MW (kDa) 25 
Untagged Protein MW (kDa) N/A 
 
 
The DDEDs caspase-10 (wild type), DDEDs caspase-8 (wild type), DDEDs cFLIP-L (wild 
type) and FADD-FL constructs were transformed into BL21(DE3) cells. After reaching 
the required OD (A600 = 0.6-0.8), small aliquots of whole cell extract (WCE) samples were 
taken before induction and saved for analysis. Recombinant protein expression was 
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induced with IPTG, followed by incubation with shaking overnight. In order to analyse 
the protein expression levels, WCE samples were taken 3 h and 15 h post-induction. 
The samples were run on 12% SDS-PAGE and stained with Coomassie Brilliant Blue. 
We observed that the N-(His)6 DDEDs caspase-10 (wild type), N-(His)6 DDEDs caspase-
8 (wild type), N-(His)6 DDEDs cFLIP-L (wild type) and C-(His)6 FADD-FL were 
successfully expressed after 3 h and 15 h. The overnight expression allowed more 
efficient production, when compared to 3 h induction (Figure 20A, B, C and D).  
 
 
 
 
Figure 20. Expression levels of N-(His)6 DDEDs caspase-10 (wild type), N-(His)6 DDEDs 
caspase-8 (wild type), N-(His)6 DDEDs cFLIP-L (wild type) and C-(His)6 FADD-FL proteins. 
A-D. The whole cell extract (WCE) samples were taken before induction as well as 3 h and 15 h 
post-induction for the analysis of the recombinant N-(His)6 DDEDs caspase-10 (wild type), N-
(His)6 DDEDs caspase-8 (wild type), N-(His)6 DDEDs cFLIP-L (wild type) and C-(His)6 FADD-FL 
expression levels on 12% SDS-PAGE followed by staining with Coomassie Brilliant Blue.  
M1 (Marker 1) and M3 (Marker 3) – protein ladders.  
 
 
In order to assess solubility levels of the expressed proteins, 15 h after expression the 
bacteria were lysed by sonication. Soluble and insoluble fractions were separated by 
A              B 
C              D 
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centrifugation. Small aliquots of the lysate, supernatant and resuspended pellet fractions 
were taken for analysis. Our results showed that the highest levels of N-(His)6 DDEDs 
caspase-10 (wild type), N-(His)6 DDEDs caspase-8 (wild type), N-(His)6 DDEDs cFLIP-L 
(wild type) and C-(His)6 FADD-FL were found in the resuspended pellets (Figure 21A, B, 
C, and D), indicative of the formation of inclusion bodies in the bacteria. Therefore, it was 
essential to isolate and purify the recombination proteins from the inclusion bodies by 
solubilisation under denaturing conditions (Watt et al., 1999; Keller et al., 2009). 
 
 
 
Figure 21. Solubility levels of N-(His)6 DDEDs caspase-10 (wild type), N-(His)6 DDEDs 
caspase-8 (wild type), N-(His)6 DDEDs cFLIP-L (wild type) and C-(His)6 FADD-FL proteins. 
A. After 15 h of N-(His)6 DDEDs caspase-10 (wild type) expression, lysate, supernatant and 
resuspended pellet samples were analysed on 12% SDS-PAGE and staining with Coomassie 
Brilliant Blue. WCE samples were used as control. B. After 15 h of N-(His)6 DDEDs caspase-8 
(wild type) expression lysate, supernatant and resuspended pellet samples were analysed on 
12% SDS-PAGE and staining with Coomassie Brilliant Blue. WCE samples were used as control. 
C. After 15 h of N-(His)6 DDEDs cFLIP-L (wild type) expression lysate, supernatant and 
resuspended pellet samples were analysed on 12% SDS-PAGE and staining with Coomassie 
Brilliant Blue. D. After 15 h of C-(His)6 FADD-FL expression lysate, supernatant and resuspended 
pellet samples were analysed on 12% SDS-PAGE and staining with Coomassie Brilliant Blue.  
M1 (Marker 1), M3 (Marker 3) and M4 (Marker 4) – protein ladders, WCE – whole cell extracts, 
Lys – lysed cells, Sup – supernatant, Pel – cell pellet. 
A              B 
C              D 
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 Purification	 of	 N-(His)6	 DDEDs	 Caspase-10	 (wild	
type),	N-(His)6	DDEDs	Caspase-8	(wild	type),	N-(His)6	
DDEDs	cFLIP-L	(wild	type)	and	C-(His)6	FADD-FL	
 
Following solubilisation of inclusion bodies under denaturing conditions, supernatants 
containing N-(His)6 DDEDs caspase-10 (wild type), N-(His)6 DDEDs Caspase-8 (wild 
type), N-(His)6 DDEDs cFLIP-L (wild type) and C-(His)6 FADD-FL were separated from 
cell debris and applied onto 5 ml IMAC (Ni-NTA) column. The immobilised proteins were 
then washed and refolded on the column by using linear urea gradient (8 M – 0 M urea), 
which was based on the methods described by Holzinger et al. (1996) and Ni-NTA 
column manufacturer’s protocol. It was described that refolding of immobilised proteins 
might greatly limit the interactions between the protein molecules and therefore avoid 
their aggregation, which in contrast happens commonly during refolding in solution 
(Holzinger et al. 1996). Following the on-column refolding, the proteins of interest were 
eluted and selected fractions at the major elution peak at 280 nm were pooled and 
assessed for the protein purity. The samples were separated on 15% SDS-PAGE 
followed by staining with Coomassie Brilliant Blue. 
 
We observed that N-(His)6 DDEDs caspase-10 was successfully purified on the Ni-NTA 
column (Figure 22A and B). Interestingly, the analysis of elution fractions in the major 
elution peak unveiled the presence of two protein bands, 18 kDa and 12 kDa. The 
observation was different from the results obtained for the GuHCl supernatant, pellet and 
flow-through samples, which only showed a single narrow 35 kDa band (Figure 22A). 
Sizes of the eluted protein bands are 18 kDa and 12 kDa, what corresponds to the size 
of the active caspase-10 subunits p18 and p12. Such observation argues for self-
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cleavage and activation of N-(His)6 DDEDs caspase-10 (wild type) in the solution after 
purification. 
A 
 
 
B 
 
Figure 22. IMAC (Ni-NTA) purification of N-(His)6 DDEDs caspase-10 (wild type). 
A. Analysis of fractions after purification of N-(His)6 DDEDs caspase-10 (wild type) on IMAC 5 ml 
His-trap FF nickel-nitrilotriacetic (Ni-NTA) column. The fractions show strong bands running at 18 
kDa and 12 kDa. After purification, the following samples were taken for the analysis on SDS-
PAGE: lysate, supernatant and pellet after GuHCl lysis of inclusion bodies containing the protein 
of interest, flow-through after IMAC purification as well as elution fractions number: 10, 11, 12 
and 13. All samples were separated on 15% SDS-PAGE followed by staining with Coomassie 
Brilliant Blue. B. Elution profile of N-(His)6 DDEDs caspase-10 (wild type) on IMAC 5 ml His-trap 
FF nickel-nitrilotriacetic (Ni-NTA) column; blue line represents protein absorbance; orange line 
represents imidazole gradient. Elution fractions taken for the SDS-PAGE analysis are indicated 
by the red arrow.  
M2 (Marker 2) – protein ladder, GuHCl – guanidine hydrochloride, Lys – lysed cells, Sup – 
supernatant, Pel – cell pellet, FT – flow-through. 
 
 
The 15% SDS-PAGE analysis for N-(His)6 DDEDs caspase-8 (wild type) showed a 
successful protein purification (Figure 23A and B). In this case, analysis of elution 
fractions in the major elution peak at 280 nm also revealed the presence of two protein 
bands, 18 kDa and 10 kDa. The observation was in contrast to the results obtained for 
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the control (WCE) samples, which only showed a single 31 kDa band (Figure 23A). The 
molecular weights of both bands are consistent with the sizes of the active caspase-8 
subunits p18 and p10. Similar to N-(His)6 DDEDs caspase-10 (wild type), the result 
argues for self-activation of N-(His)6 DDEDs caspase-8 (wild type) in the solution after 
purification. 
 
A 
 
 
B 
 
Figure 23. IMAC (Ni-NTA) purification of N-(His)6 DDEDs caspase-8 (wild type). 
A. Analysis of fractions after purification of N-(His)6 DDEDs caspase-8 (wild type) on IMAC 5 ml 
His-trap FF nickel-nitrilotriacetic (Ni-NTA) column. The fractions reveal strong bands running at 
18 kDa and 10 kDa. After purification, the following elution fractions were analysed on 15% SDS-
PAGE: 10, 11, 12 and 13. WCE samples were used as controls. All samples were separated on 
15% SDS-PAGE followed by staining with Coomassie Brilliant Blue. B. Elution profile of N-(His)6 
DDEDs caspase-8 (wild type) on IMAC 5 ml His-trap FF nickel-nitrilotriacetic (Ni-NTA) column; 
blue line represents protein absorbance; orange line represents imidazole gradient. Elution 
fractions taken for the SDS-PAGE analysis are indicated by the red arrow. 
M1 (marker 1) – protein ladder, WCE – whole cell extracts. 
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Furthermore, we found that after elution of N-(His)6 DDEDs cFLIP-L (wild type) from Ni-
NTA column, the levels of purified protein were very low, when analysed on 15% SDS-
PAGE and compared with control (WCE) samples (Figure 24A). However, we observed 
that the major elution peak at 280 nm was quite prominent, indicative of co-purification 
of other/host proteins (Figure 24B). Therefore, further processing and purification of the 
N-(His)6 DDEDs cFLIP-L (wild type) sample was not continued.  
 
A 
 
 
B 
 
 
Figure 24. IMAC (Ni-NTA) purification of N-(His)6 DDEDs cFLIP-L (wild type). 
A. Fractions analysed after purification of N-(His)6 DDEDs cFLIP-L (wild type) on IMAC 5 ml His-
trap FF nickel-nitrilotriacetic (Ni-NTA) column. The fractions show very low levels of the purified 
protein at around 30 kDa. Following purification of the desired protein, the WCE (control) samples 
and Ni-NTA elution fractions number 10, 11, 12 and 13 were analysed by using 15% SDS-PAGE 
and subsequent staining with Coomassie Brilliant Blue. B. Elution profile of N-(His)6 DDEDs 
cFLIP-L (wild type) on IMAC 5 ml His-trap FF nickel-nitrilotriacetic (Ni-NTA) column; blue line 
represents protein absorbance; orange line represents imidazole gradient. Elution fractions taken 
for the SDS-PAGE analysis are indicated by the red arrow. 
M3 (marker 3) – protein ladder, WCE – whole cell extracts. 
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Analysis on 15% SDS-PAGE showed that C-(His)6 FADD-FL was successfully 
expressed and purified on Ni-NTA column. Assessed elution fractions in the major 
elution peak at 280 nm (Figure 25A and B) revealed the presence of one major protein 
band. The observed 25 kDa band is consistent with the size of the (His)6-tagged protein 
(Figure 25A). All elution fractions containing the protein of interest were combined into 
one sample, dialysed and concentrated to 2 ml. Small aliquots of the elute, dialysed and 
concentrated samples were run on 15% SDS-PAGE followed by staining with 
Coomassie Brilliant Blue (Figure 25C). Western blot analysis of the same samples 
confirmed the presence of purified C-(His)6 FADD-FL (Figure 25D).  
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Figure 25. IMAC (Ni-NTA) purification of C-(His)6 FADD-FL. 
A. Analysis of fractions after purification of C-(His)6 FADD-FL on IMAC 5 ml His-trap FF nickel-
nitrilotriacetic (Ni-NTA) column. The fractions reveal a strong band running at 25 kDa. Following 
purification of the protein of interest, the WCE (control) samples and Ni-NTA elution fractions 
number 10, 11, 12, 13 and 14 were analysed by using 15% SDS-PAGE and subsequent staining 
with Coomassie Brilliant Blue. B. Elution profile of C-(His)6 FADD-FL on IMAC 5 ml His-trap FF 
nickel-nitrilotriacetic (Ni-NTA) column; blue line represents protein absorbance; orange line 
represents imidazole gradient. Elution fractions taken for the SDS-PAGE analysis are indicated 
by the red arrow. C. Ni-NTA fractions containing the desired protein were pooled, dialysed and 
concentrated for further processing. The elution, dialysed and concentrated protein samples were 
analysed on 15% SDS-PAGE and staining with Coomassie Brilliant Blue. D. The same samples 
were used for Western blot analysis and confirmation of successfully purified C-(His)6 FADD-FL. 
WCE samples were used as controls. An antibody against FADD was used to confirm the 
presence of the desired protein.  
M4 (marker 4) – protein ladder, WCE – whole cell extracts, dial – dialysed, conc – concentrated. 
 
 
The concentrated (2 ml) sample containing C-(His)6 FADD-FL was subjected to further 
purification by using SEC (Superdex 75) column. Protein eluates were collected as 2 ml 
fractions and assessed for purity by using 15% SDS-PAGE followed by staining with 
Coomassie Brilliant Blue (Figure 26A). Assessment of elution fractions in the major 
elution peak at 280 nm showed very high purity levels of C-(His)6 FADD-FL (Figure 26A 
and B). The presence of the desired protein was also confirmed by Western blot (Figure 
26C). Any host proteins that co-purified on Ni-NTA column and co-eluted within the C-
(His)6 FADD-FL peak were not separated by gel filtration and might be present in minimal 
amounts, acceptable for experimental purposes. Elution fractions containg the protein of 
interest were pooled, combined into one sample and concentrated in order to obtain 2 
ml of the final pure protein sample.  
 
In order to assess whether purified C-(His)6 FADD-FL was folded, circular dichroism (CD) 
spectroscopy was carried out. The CD spectrum of the desired protein was obtained 
using 200 µl of purified protein sample (12 µM), which was transferred to an analytic 
cuvette and subjected to CD spectroscopy. The collected experimental spectrum of C-
(His)6 FADD-FL was then compared with a calculated spectrum of FADD, which was 
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obtained using the PDBMD2CD software (Mavridis and Janes, 2016) and the full-length 
human FADD structure (wild type; aa residues 1 – 191; PDB ID: 2GF5) (Figure 26D).  
The plotted CD data showed that the experimental spectrum of C-(His)6 FADD-FL 
exhibited negative peaks from 205 to 225 nm, which was similar to the calculated 
spectrum of FADD (Figure 26D), indicating that the desired protein was folded and could 
be used for experimental purposes. It was also observed that in the experimental CD 
spectrum, the peak at around 208 nm was slightly greater than the peak at round 222 
nm, whereas the calculated spectrum had both peaks of a similar value (Figure 26D). It 
was assumed that such observation was due to a few possible reasons: (I) the presence 
of C-terminal residues in purified C-(His)6 FADD-FL (aa residues 192 – 208, which were 
excluded from human FADD, PDB ID: 2GF5) and/or (II) the possible presence of the 
minimal amounts of host E. coli proteins, which could be co-purified on Ni-NTA and SEC 
within the C-(His)6 FADD-FL peak and affect the CD measurement. Additionally, it was 
considered, whether the presence of the C-terminal (His)6 tag in the purified protein of 
interest could also influence its folding and the CD measurement. It was described that 
(His)6 tag might have some effect on the structure of purified proteins. However, such 
effect is generally not significant and does not affect the functionality of the proteins 
(Carson et al., 2007).  
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Figure 26. Purification of C-(His)6 FADD-FL protein by using SEC. 
A. Fractions analysed after purification of C-(His)6 FADD-FL on SEC 120 ml HiLoad Superdex 75 
16/60 column. The fractions show a strong band running at 25 kDa. After purification, the following 
elution fractions were taken for the analysis on SDS-PAGE: 10, 11, 12, 13, 14 and 15. WCE 
sample was used as control. All samples were separated on 15% SDS-PAGE followed by staining 
with Coomassie Brilliant Blue. B. Elution profile of C-(His)6 FADD-FL on SEC 120 ml HiLoad 
Superdex 75 16/60 column; blue line represents protein absorbance. Elution fractions taken for 
the SDS-PAGE analysis are indicated by the red arrow. C. Fractions containing the desired 
protein were pooled, combined and concentrated. The combined elution and concentrated protein 
samples were subjected to Western blot analysis in order to confirm successful purification of 
FADD-FL. WCE sample was used as positive control. An antibody against FADD was used to 
confirm the presence of the desired protein. D. Comparison of calculated and experimental 
circular dichroism spectra for FADD. The calculated spectrum was obtained using the 
PDBMD2CD software (Mavridis and Janes, 2016) and the full-length human FADD structure (wild 
type; aa residues 1 – 191; PDB ID: 2GF5). The experimental spectrum was obtained using 200 
µl of purified C-(His)6 FADD-FL sample (12 µM), which was transferred to an analytic cuvette and 
subjected to circular dichroism spectroscopy. The orange curve represents the calculated CD 
spectrum of FADD, and the blue curve is the experimental spectrum of purified C-(His)6 FADD-
FL.  
M4 (marker 4) – protein ladder, WCE – whole cell extracts, conc – concentrated. 
 
 
The concentration of purified C-(His)6 FADD-FL sample was calculated below by using 
Beer-Lambert formula, protein extinction coefficient and absorbance result measured by 
spectrophotometer.  
 
Beer–Lambert formula:	𝐴 = 	e	𝑙	𝑐  
 
Extinction coefficient (e) = 18240 
Path (l) = 1 cm 
Absorbance at 280 (A) = 0.02232773 (1 ml, 1/10 dilution) 
Concentration (c) 
 
Calculation:	𝐴 = 	e	𝑙	𝑐 à	𝑐 = !
e
 à 𝑐 = "."$$%$&&%	()$*"	 	× 	10 = 0.00001224 M = 
12.24 µM 
 
Next, the molar concentration of purified C-(His)6 FADD-FL was converted into 
concentration in mg/ml as follows:   
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Formula: concentration (mg/ml) = c (Molar) x MW (Daltons) 
 
Concentration (c) = 0.00001224 M 
Molecular weight (MW) = 25000 Da 
Calculation: concentration = 0.00001224 M x 25000 Da = 0.30602 mg/ml = 
306.02 µg/ml  
 
Finally, purified C-(His)6 FADD-FL was aliquoted into 200 µl samples and stored at -20oC. 
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 Expression	of	Human	Recombinant	DDEDs	Caspase-
10	 (C401A),	 DDEDs	 Caspase-10	 (D415A),	 DDEDs	
Caspase-8	 (C360A)	 and	 DDEDs	 Caspase-8	
(D374A/D384A)		
	
Results obtained for DDEDs caspase-10 (wild type), DDEDs caspase-8 (wild type), 
DDEDs cFLIP-L (wild type) constructs showed successful expression and purification of 
the proteins of interest. Nevertheless, we observed, that purified N-(His)6 DDEDs 
caspase-10 (wild type) and N-(His)6 DDEDs caspase-8 (wild type) were cleaved into 
active subunits after purification.  
 
Purification of the proteins of interest in their single-chained forms is of paramount 
importance for this study. In order to purify such proteins, the following mutated 
constructs were used: DDEDs caspase-10 (C401A), DDEDs caspase-10 (D415A), 
DDEDs caspase-8 (C360A) and DDEDs caspase-8 (D374A/D384A) (Figure 15A, B and 
C; p. 109). These variants were generated by using DDEDs caspase-10 (wild type) 
(Figure 16; p. 110) and DDEDs caspase-8 (wild type) (Figure 17; p. 112) constructs as a 
template and site-directed mutagenesis.  
 
For protein production, induction with 0.1 mM (final concentration) of IPTG, and 
expression at 18°C for 3 h and 15 h were tested as a starting point. The constructs that 
were examined for recombinant protein expression included: DDEDs caspase-10 
(C401A), DDEDs caspase-10 (D415A), DDEDs caspase-8 (C360A) and DDEDs 
caspase-8 (D374A/D384A).  
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Tables 33-34 summarise the basic information regarding protein expression constructs 
and expected protein masses after expression and purification. 
 
Table 33. Main features of the human recombinant DDEDs caspase-10 constructs with 
expected protein masses after expression.  
Protein Details 
DNA Construct DDEDs caspase-10 (aa residues 220-521; C401A active site 
mutant; D415A linker mutant), pET-28a, N-terminal (His)6-tag 
Host Cell Strain BL21(DE3)  
Tagged Protein MW (kDa) 35 
Untagged Protein MW (kDa) 33 
 
 
Table 34. Main features of the human recombinant DDEDs caspase-8 constructs with 
expected protein masses after expression. 
Protein Details   
DNA Construct DDEDs caspase-8 (aa residues 217-479; C360A active site 
mutant; D374A/D384A linker mutant) pET-28a, N-terminal 
(His)6-tag 
Host Cell Strain BL21(DE3) 
Tagged Protein MW (kDa) 31 
Untagged Protein MW (kDa) 29 
 
 
 
 
The DDEDs caspase-10 (C401A), DDEDs caspase-10 (D415A), DDEDs caspase-8 
(C360A) and DDEDs caspase-8 (D374A/D384A) constructs were transformed into 
BL21(DE3) cells. After the OD of the bacteria culture reached A600 = 0.6-0.8, small 
aliquots of whole cell extract (WCE) samples were taken and saved for analysis. 
Induction of recombinant protein expression was initiated by using IPTG, followed by 
incubation with shaking overnight. WCE samples were taken 3 h and 15 h after IPTG-
induction, in order to assess the levels of the protein expression. Analysis of the WCE 
samples was performed on 12% SDS-PAGE and staining with Coomassie Brilliant Blue.  
 
The results showed that the N-(His)6 DDEDs caspase-10 (C401A), N-(His)6 DDEDs 
caspase-10 (D415A), N-(His)6 DDEDs caspase-8 (C360A) and N-(His)6 DDEDs caspase-
8 (D374A/D384A) were successfully expressed after 3 h and 15 h (Figure 27A, B, C and 
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D). Interestingly, we observed that the levels of N-(His)6 DDEDs caspase-10 (C401A) 
and N-(His)6 DDEDs caspase-10 (D415A) were very only slightly increased,  
when compared with uninduced cells. In contrast, the levels of N-(His)6 DDEDs caspase-
8 (C360A) and N-(His)6 DDEDs caspase-8 (D374A/D384A) were markedly increased in 
comparison with the cells before induction.  
 
 
 
Figure 27.  Expression levels of N-(His)6 DDEDs caspase-10 (C401A), N-(His)6 DDEDs 
caspase-10 (D415A), N-(His)6 DDEDs caspase-8 (C360A) and N-(His)6 DDEDs caspase-8 
(D374A/D384A) proteins. 
A-D. The whole cell extract (WCE) samples were taken before induction as well as 3 h and 15 h 
post-induction (IPTG at 0.1 mM final concentration) for the analysis of the recombinant N-(His)6 
DDEDs caspase-10 (C401A), N-(His)6 DDEDs caspase-10 (D415A), N-(His)6 DDEDs caspase-8 
(C360A) and N-(His)6 DDEDs caspase-8 (D374A/D384A) expression levels on 12% SDS-PAGE 
followed by staining with Coomassie Brilliant Blue.  
M4 (marker 4) – protein ladder.  
 
A              B 
C              D 
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Due to the low levels of expressed N-(His)6 DDEDs caspase-10 (C401A) and N-(His)6 
DDEDs caspase-10 (D415A), it was essential to further test and optimise conditions for 
recombinant protein production. For this, higher IPTG concentrations, such as 0.5 and 1 
mM (final concentration) were used. The temperature and time of recombinant protein 
expression remained unchanged. DDEDs caspase-8 (C360A) construct was used as a 
control. WCE samples were taken before induction and saved for analysis. 
Transformation of the constructs and protein expression were performed as described 
previously. Bacteria cultures were incubated and shaken at 18° overnight. In order to 
analyse the levels of the protein expression, the WCE samples were taken 3 h and 15 h 
after IPTG-induction. The samples were run on 12% SDS-PAGE and stained with 
Coomassie Brilliant Blue. 
 
The results obtained for N-(His)6 DDEDs caspase-10 (C401A) (Figure 28A) and N-(His)6 
DDEDs caspase-10 (D415A) (Figure 28B) did not show any noticeable change nor 
increase of the protein expression after induction with both 0.5 and 1 mM final 
concentration of IPTG. The observation was comparable to the previous result (Figure 
27A and B), where 0.1 mM final concentration of IPTG was used for induction. In 
contrast, the control N-(His)6 DDEDs caspase-8 (C360A) production was very abundant 
after expression under the same conditions as for N-(His)6 DDEDs caspase-10 (C401A) 
(Figure 28A) and N-(His)6 DDEDs caspase-10 (D415A) (Figure 28B). 
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Figure 28. Expression levels of N-(His)6 DDEDs caspase-10 (C401A) and N-(His)6 DDEDs 
caspase-10 (D415A) proteins. 
A. The whole cell extract samples were taken before induction as well as 3 h and 15 h post-
induction (IPTG at 0.5 and 1 mM final concentration) for the analysis of the recombinant N-(His)6 
DDEDs caspase-10 (C401A) and the control N-(His)6 DDEDs caspase-8 (C360A) expression 
levels on 12% SDS-PAGE followed by staining with Coomassie Brilliant Blue. B. The whole cell 
extract samples were taken before IPTG-induction (IPTG at 0.5 and 1 mM final concentration) as 
well as 3 h and 15 h after expression of the recombinant N-(His)6 DDEDs caspase-10 (D415A) 
and the control N-(His)6 DDEDs caspase-8 (C360A). The samples were analysed on 12% SDS-
PAGE and stained with Coomassie Brilliant Blue. 
M4 (marker 4) – protein ladder.  
 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Lack of improvement of protein production efficiency after using higher IPTG 
concentrations led to assumption, that N-(His)6 DDEDs caspase-10 (C401A) and N-(His)6 
DDEDs caspase-10 (D415A) were potentially too toxic, when expressed in E. coli. This 
could be caused by cAMP-mediated derepression of the lacUV5 promoter, which 
normally is regulated by the lacI repressor. However, it was demonstrated that 
expression of the lacUV5 promoter can be derepressed in the presence of cAMP, which 
in turn leads to the increase of the basal expression of T7 RNA polymerase (Grossman 
et al., 1998) and “leaky” expression of the inserted genes in their uninduced state. 
Derepression of the lacUV5 promoter can be effectively avoided by addition of 1% (w/v) 
of glucose to the bacteria growth medium and an overnight incubation of the liquid 
culture. Addition of glucose inhibits cAMP production in E. coli.  
 
BL21(DE3) bacteria carrying the DDEDs caspase-10 (C401A), DDEDs caspase-10 
(D415A) and DDEDs caspase-8 (C360A) constructs were grown in LB medium 
supplemented with glucose at 1% final concentration. After reaching the required OD 
(A600 = 0.6-0.8), small aliquots of WCE samples were taken before induction and saved 
for analysis. Recombinant protein expression was induced with 0.1 and 0.02 mM final 
concentration of IPTG, followed by incubation with shaking at 18° overnight.  
 
In this experiment, 0.02 mM final concentration of IPTG was used, which is in line with 
other studies (Stennicke and Salvesen, 1999; Denault and Salvesen, 2002). It was 
suggested that lowering of the IPTG concentration might provide a more controlled, yet 
less stringent recombinant expression conditions, which as a result might lead to a 
successful production of toxic proteins in E. coli. The authors described that addition of 
0.02 mM IPTG (final concentration) was optimal for expression of recombinant caspase-
10 by using pET vectors and E. coli strain BL21(DE3) (Stennicke and Salvesen, 1999; 
Denault and Salvesen, 2002). Thus, it was tested, whether DDEDs caspase-10 (C401A) 
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and DDEDs caspase-10 (D415A) could be successfully expressed after induction with 
0.02 mM IPTG (final concentration).  
 
The WCE samples were taken 3 h and 15 h after induction with IPTG, in order to assess 
the levels of the protein expression. Analysis of the samples was carried out on 12% 
SDS-PAGE and followed by staining with Coomassie Brilliant Blue. We observed that 
the control N-(His)6 DDEDs caspase-8 (C360A) was efficiently expressed, when induced 
with both 0.1 and 0.02 mM final concentration of IPTG in the presence of 1% (w/v) 
glucose (Figure 29A and B). The results obtained for N-(His)6 DDEDs caspase-10 
(C401A) (Figure 29A) and N-(His)6 DDEDs caspase-10 (D415A) (Figure 29B) showed, 
that both proteins were also successfully expressed after supplementation with 1% (w/v) 
glucose and addition of 0.1 and 0.02 mM final concentration of IPTG. Induction with IPTG 
at the final concentration of 0.02 mM contributed to a slightly increased production of the 
recombinant proteins, when compared with the results obtained for proteins expressed 
with 0.1 mM final concentration of IPTG. Although the yield of N-(His)6 DDEDs caspase-
10 (C401A) and N-(His)6 DDEDs caspase-10 (D415A) was reduced, when compared 
with the control N-(His)6 DDEDs caspase-8 (C360A), it was acceptable for proceeding 
with protein purification.  
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Figure 29. Expression levels of N-(His)6 DDEDs caspase-10 (C401A) and N-(His)6 DDEDs 
caspase-10 (D415A) proteins. 
A. The proteins of interest were expressed in BL21(DE3) bacteria grown in LB medium 
supplemented with glucose at 1% (w/v) concentration. The whole cell extract samples were taken 
before induction as well as 3 h and 15 h post-induction (IPTG at 0.1 mM final concentration) for 
the analysis of the recombinant N-(His)6 DDEDs caspase-10 (C401A), N-(His)6 DDEDs caspase-
10 (D415A) (both indicated by red arrows) and the control N-(His)6 DDEDs caspase-8 (C360A) 
expression levels on 12% SDS-PAGE followed by staining with Coomassie Brilliant Blue. B. The 
proteins of interest were expressed in BL21(DE3) bacteria grown in LB medium supplemented 
with glucose at 1% (w/v) concentration. The whole cell extract samples were taken before IPTG-
induction (IPTG at 0.02 mM final concentration) as well as 3 h and 15 h after expression of the 
recombinant N-(His)6 DDEDs caspase-10 (C401A), N-(His)6 DDEDs caspase-10 (D415A) (both 
indicated by red arrows) and the control N-(His)6 DDEDs caspase-8 (C360A). The samples were 
analysed on 12% SDS-PAGE and stained with Coomassie Brilliant Blue. 
M4 (marker 4) – protein ladder.  
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Following the successful expression, bacteria cells harbouring N-(His)6 DDEDs caspase-
8 (C360A), N-(His)6 DDEDs caspase-10 (C401A) and N-(His)6 DDEDs caspase-10 
(D415A) were lysed by using sonication. Soluble and insoluble fractions of the lysates 
were separated by centrifugation. In order to assess the levels of solubility of the 
proteins, small aliquots of the lysate, supernatant and resuspended pellet fractions were 
analysed on 12% SDS-PAGE followed by Coomassie Brilliant Blue staining.  
 
As shown in Figure 30, the highest amounts of N-(His)6 DDEDs caspase-8 (C360A), N-
(His)6 DDEDs caspase-10 (C401A) and N-(His)6 DDEDs caspase-10 (D415A) were found 
in the resuspended pellets, which suggests aggregation of the proteins of interest in 
bacterial inclusion bodies. Therefore, the recombination proteins were isolated from 
inclusion bodies by solubilisation under denaturing conditions. 
 
 
 
Figure 30. Solubility levels of the control N-(His)6 DDEDs caspase-8 (C360A), N-(His)6 
DDEDs caspase-10 (C401A) and N-(His)6 DDEDs caspase-10 (D415A).  
After 15 h of N-(His)6 DDEDs caspase-8 (C360A), N-(His)6 DDEDs caspase-10 (C401A) and N-
(His)6 DDEDs caspase-10 (D415A) expression, lysate, supernatant and resuspended pellet 
samples were analysed on 12% SDS-PAGE followed by staining with Coomassie Brilliant Blue. 
WCE samples were used as controls. N-(His)6 DDEDs caspase-10 (C401A) and N-(His)6 DDEDs 
caspase-10 (D415A) are indicated by red arrows.  
M1 (Marker 1) – protein ladder, WCE – whole cell extracts, Lys – lysed cells, Sup – supernatant, 
Pel – cell pellet. 
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 Purification	of	N-(His)6	 	DDEDs	Caspase-10	 (D415A)	
and	N-(His)6	DDEDs	Caspase-8	(C360A)	
 
In our previous report our group demonstrated that 5-FU-induced upregulation of 
caspase-10 provides a germ for subsequent FADDosome complex assembly. As a core 
driver of the FADDosome formation, upregulated caspase-10 acts as an apoptosis 
regulator, but not as a direct cell death initiator upon the treatment with 5-FU. At the 
FADDosome, caspase-8 is activated and initiates apoptosis (Mohr et al., 2018). 
Therefore, in the current study, the aim was to explore the role of caspase-10 as a 
constituent od the FADDosome and a potential caspase-8 activator. 
 
For this, it was crucial to express and purify N-(His)6 DDEDs Caspase-10 (D415A) – a 
linker mutant of DDEDs Caspase-10, which can act as an enzyme (activator) – and N-
(His)6  DDEDs Caspase-8 (C360A) – an active site mutant, that can play a role of a 
substrate. 
 
After performing solubilisation under denaturing conditions, supernatants containing N-
(His)6 DDEDs Caspase-10 (D415A) and N-(His)6  DDEDs Caspase-8 (C360A) were 
separated from cell debris and loaded onto 5 ml Ni-NTA column. Eluted proteins were 
collected as 5 ml fractions, which were taken for analysis. The samples were separated 
on 12% SDS-PAGE followed by staining with Coomassie Brilliant Blue. 
 
We observed that N-(His)6 DDEDs caspase-10 (D415A) was successfully purified during 
IMAC (Figure 31A). SDS-PAGE analysis and staining with Coomassie Brilliant Blue of 
the elution fractions at the major elution peak at 280 nm revealed the presence of a 35 
kDa protein band, which corresponds to the expected size of the (His)6-tagged protein 
after purification (Figure 31A). Additionally, we observed that the major elution peak was 
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quite prominent (Figure 31B), indicative of co-purification of other/host proteins, possibly 
due to the low levels of purified N-(His)6 DDEDs caspase-10 (D415A).  
 
Elution fractions containing N-(His)6 DDEDs caspase-10 (D415A) were combined into 
one sample, dialysed and concentrated to ~10 ml. Small aliquots of the elute, dialysed 
and concentrated samples were analysed on 12% SDS-PAGE and stained with 
Coomassie Brilliant Blue (Figure 31C). The same samples were subjected to Western 
blot analysis, which confirmed the presence of purified N-(His)6 DDEDs caspase-10 
(D415A) (Figure 31C). Importantly, due to the low levels after purification, the protein 
was hardly detectable in the elution and dialysed fractions by using both Coomassie 
Brilliant Blue staining and Western blot. However, the concentrated fraction showed a 
decent N-(His)6 DDEDs caspase-10 (D415A) band, acceptable for further processing.  
 
After removal of the N-terminal (His)6 tag by thrombin treatment, supernatant containing 
the untagged protein was then re-applied onto an IMAC column as described in the 
Methods Chapter. The flow-through fractions containing untagged DDEDs caspase-10 
(D415A) were collected, combined and concentrated to 2 ml for further purification by 
using a SEC column. Small aliquots of the fractions before and after thrombin treatment 
as well as flow-through and concentrated samples after IMAC were run on 12% SDS-
PAGE and stained with Coomassie Brilliant Blue. We observed a 33 kDa band, which 
confirmed the successful removal of the (His)6 tag and separation of the untagged protein 
(Figure 31D).  
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Figure 31.  IMAC (Ni-NTA) purification of human recombinant N-(His)6 DDEDs caspase-10 
(D415A). 
A. Analysis of fractions after purification of N-(His)6 DDEDs caspase-10 (D415A) on IMAC 5 ml 
His-trap FF nickel-nitrilotriacetic (Ni-NTA) column. The fractions show a strong band running at 
35 kDa. Following purification of the protein, the WCE (control) samples and Ni-NTA elution 
fractions number 6, 7, 10, 11, 12 and 13 were analysed by using 12% SDS-PAGE and subsequent 
staining with Coomassie Brilliant Blue. B. Elution profile of N-(His)6 DDEDs caspase-10 (D415A) 
on IMAC 5 ml His-trap FF nickel-nitrilotriacetic (Ni-NTA) column; blue line represents protein 
absorbance; orange line represents imidazole gradient. Elution fractions taken for the SDS-PAGE 
analysis are indicated by the red arrow. C. Ni-NTA fractions containing the desired protein were 
pooled, dialysed and concentrated for further processing. The elution dialysed and concentrated 
protein samples were analysed on 12% SDS-PAGE and staining with Coomassie Brilliant Blue. 
The same samples were used for Western blot analysis and confirmation of successfully purified 
N-(His)6 DDEDs caspase-10 (D415A). WCE samples were used as controls. An antibody against 
(His)6 tag was used to confirm the presence of the desired protein. D. Cleavage of N-terminal 
(His)6 tag. Supernatant containing N-(His)6 DDEDs caspase-10 (D415A) was subjected to 
treatment with 125 units of thrombin, followed by gentle rotation at 4°C overnight and re-applied 
onto IMAC column. Fractions before and after thrombin treatment, as well as follow-through and 
concentrated samples after IMAC were analysed on 12% SDS-PAGE followed by staining with 
Coomassie Brilliant Blue. WCE and concentrated sample after first purification step were used as 
controls.  
WCE – whole cell extracts, dial – dialysed, conc – concentrated, FT- flow-through. 
 
 
 
Following further purification of untagged DDEDs caspase-10 (D415A) on SEC column, 
protein eluates were collected as 2 ml fractions and examined for purity on 12% SDS-
PAGE and staining with Coomassie Brilliant Blue (Figure 32A). Assessment of elution 
fractions in the major elution peak at 280 nm showed very good purity levels of untagged 
DDEDs caspase-10 (D415A) (Figure 32A and B). Any host proteins that were co-purified 
and co-eluted within the untagged DDEDs caspase-10 (D415A) peak were not separated 
on SEC and may be present in minimal amounts, acceptable for experimental purposes. 
 
The presence of the desired protein was confirmed by mass-spectrometry. The analysis 
identified two caspase-10 peptides, which were compared with the human caspase-10 
sequence (Figure 32C). The protein sequence was retrieved from the National Centre 
for Biotechnology Information (NCBI) webpage by using the following search 
parameters: (I) database: “gene” and (II) keywords: “caspase-10 isoform 2 preproprotein 
[Homo sapiens] (accession number: NP_116756)”. 
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SEC elution fractions containg untagged DDEDs caspase-10 (D415A) were pooled, 
combined into one sample and concentrated in order to obtain 2 ml of the final pure 
protein sample. Untagged DDEDs caspase-10 (D415A) was then subjected to circular 
dichroism (CD) spectroscopy in order to assess, whether it was folded after purification. 
The CD spectrum of the protein of interest was measured using 200 µl of purified protein 
sample (1.4 µM). The obtained CD spectrum of untagged ΔDEDs caspase-10 (D415A) 
was then compared with a calculated spectrum of ΔDEDs caspase-8 (wild type) (Figure 
32D). The calculation of the spectrum was performed using the PDBMD2CD software 
(Mavridis and Janes, 2016) and the ΔDEDs human caspase-8 structure (wild type; aa 
residues 217 – 479; PDB ID: 4PRZ). It is noteworthy, that the experimental CD spectrum 
of untagged ΔDEDs caspase-10 (D415A) was compared to the calculated CD spectrum 
of ΔDEDs caspase-8 (wild type) due to the lack of the crystal structure of caspase-10 
and the fact that caspase-8 and caspase-10 are closely related and their amino acid 
sequences share similarity in 46% (Wachmann et al., 2010).  
 
Due to low levels of the purified untagged ΔDEDs caspase-10 (D415A), obtained CD 
spectrum was slightly noisy, but clear enough for analysis and interpretation. The plotted 
CD data revealed that the experimental spectrum of untagged ΔDEDs caspase-10 
(D415A) and the calculated spectrum of ΔDEDs caspase-8 (wild type) showed negative 
minima from 205 to 225 nm (Figure 32D). The observed results suggested that purified 
untagged ΔDEDs caspase-10 (D415A) was folded following purification and it could be 
used for further experiments. However, it is noteworthy that the minima of the calculated 
spectrum were slightly more distinct and negative than the experimental one (Figure 
32D). Such marginal differences were not unexpected, considering that the experimental 
and calculated CD spectra were determined for two closely related, yet different proteins.  
 
 
 
 144 
A 
 
B 
 
C 
 
  1 MKSQGQHWYS SSDKNCKVSF REKLLIIDSN LGVQDVENLK FLCIGLVPNK  
 51 KLEKSSSASD VFEHLLAEDL LSEEDPFFLA ELLYIIRQKK LLQHLNCTKE  
101 EVERLLPTRQ RVSLFRNLLY ELSEGIDSEN LKDMIFLLKD SLPKTEMTSL  
151 SFLAFLEKQG KIDEDNLTCL EDLCKTVVPK LLRNIEKYKR EKAIQIVTPP  
201 VDKEAESYQG EEELVSQTDV KTFLEALPQE SWQNKHAGSN GNRATNGAPS  
251 LVSRGMQGAS ANTLNSETST KRAAVYRMNR NHRGLCVIVN NHSFTSLKDR  
301 QGTHKDAEIL SHVFQWLGFT VHIHNNVTKV EMEMVLQKQK CNPAHADGDC  
351 FVFCILTHGR FGAVYSSDEA LIPIREIMSH FTALQCPRLA EKPKLFFIQA  
401 CQGEEIQPSV SIEADALNPE QAPTSLQDSI PAEADFLLGL ATVPGYVSFR  
451 HVEEGSWYIQ SLCNHLKKLV PRMLKFLEKT MEIRGRKRTV WGAKQISATS  
501 LPTAISAQTP RPPMRRWSSV S* 
 
D 
 
-2
0
2
4
6
8
30 40 50 60 70 80 90 100 110 120
Ab
so
rb
an
ce
 (a
.u
.)
Volume (ml)
-3500
-2500
-1500
-500
500
1500
2500
3500
195 205 215 225 235 245
M
ol
ar
 e
lip
tic
ity
 θ
 
[d
eg
⋅cm2 ⋅dm
ol
-1
]
Wavelength (nm)
untagged ∆DEDs 
caspase-10 (D415A)
∆DEDs caspase-8 (wild 
type; PDB ID: 4PRZ)
 145 
Figure 32. Purification of untagged DDEDs caspase-10 (D415A) by using SEC. 
A. Fractions analysed after purification of untagged DDEDs caspase-10 (D415A) on SEC 120 ml HiLoad 
Superdex 75 16/60 column. The fractions show good levels of the protein of interest at around 33 kDa. After 
purification, the following elution fractions were taken for the analysis on SDS-PAGE: 10, 11, 12, 13, 14, 15, 
16 and 17. WCE samples were used as controls. All samples were separated on 12% SDS-PAGE followed 
by staining with Coomassie Brilliant Blue. B. Elution profile of untagged DDEDs caspase-10 (D415A) on 
SEC 120 ml HiLoad Superdex 75 16/60 column; blue line represents protein absorbance. Elution fractions 
taken for the SDS-PAGE analysis are indicated by the red arrow. C. Fractions containing the desired protein 
were pooled, combined and concentrated. The purified protein sample was subjected to mass-spectrometry 
analysis in order to confirm successful purification of untagged DDEDs caspase-10 (D415A). Caspase-10 
isoform 2 preproprotein [Homo sapiens] (accession number: NP_116756) was retrieved from NCBI website 
and used to compare two peptides found by mass-spectrometry. Peptides identified by mass spectrometry 
are in blue and red. D. Comparison of calculated and experimental circular dichroism spectra for DDEDs 
caspase-8 (wild type) and untagged DDEDs caspase-10 (D415A), respectively. The calculated spectrum 
was obtained using the PDBMD2CD software (Mavridis and Janes, 2016) and the human DDEDs caspase-
8 structure (wild type; aa residues 217 – 479; PDB ID: 4PRZ). The experimental spectrum was obtained 
using 200 µl of purified untagged DDEDs caspase-10 (D415A) sample (1.4 µM), which was transferred to an 
analytic cuvette and subjected to circular dichroism spectroscopy. The orange curve represents the 
calculated CD spectrum of DDEDs caspase-8 (wild type), and the blue curve is the experimental spectrum 
of purified untagged DDEDs caspase-10 (D415A). 
 
 
The concentration of the purified sample was calculated below by using Beer-Lambert 
formula, protein extinction coefficient and absorbance result measured by 
spectrophotometer. 
 
Beer–Lambert formula:	𝐴 = 	e	𝑙	𝑐  
 
Extinction coefficient (e) = 33460 
Path (l) = 1 cm 
A280 = 0.00459131 (1 ml, 1/10 dilution) 
Concentration (c) 
 
Calculation:	𝐴 = 	e	𝑙	𝑐 à	𝑐 = !
e
 à 𝑐 = ".""*+,(%(	%%*-"	 	× 	10 = 0.000001372 M = 
1.37 µM 
 
 
Next, the molar concentration of purified untagged DDEDs caspase-10 (D415A) was 
converted into concentration in mg/ml as follows:   
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Formula: concentration (mg/ml) = c (Molar) x MW (Daltons) 
 
Concentration (c) = 0.000001372 M 
Molecular weight (MW) = 35000 Da 
 
Calculation: concentration = 0.000001372 M x 35000 Da = 0.04802 mg/ml 
= 48 µg/ml  
 
Finally, purified untagged DDEDs caspase-10 (D415A) was dispensed into 200 µl 
aliquots and stored at -20oC. 
 
Furthermore, results for N-(His)6 DDEDs caspase-8 (C360A) showed that the protein was 
successfully purified during IMAC (Figure 33A and B). Elution fractions at the major 
elution peak at 280 nm were run on 12% SDS-PAGE and stained with Coomassie 
Brilliant Blue. We observed a 31 kDa protein band, which corresponds to the expected 
size of purified N-(His)6 DDEDs caspase-8 (C360A) (Figure 33A). 
 
Elution fractions containing the protein of interest were combined into one sample, 
dialysed and concentrated to ~10 ml. For removal of the N-terminal (His)6 tag, the protein 
of interest was treated with 125 units of thrombin. The sample was rotated at 4°C 
overnight and re-applied onto an IMAC column in the same manner as previously 
described. The flow-through fractions containing N-(His)6 DDEDs caspase-8 (C360A) 
were collected, combined and concentrated to 2 ml for further purification on a SEC 
column.  Small aliquots of the following samples: eluted, dialysed, concentrated, 
fractions before and after thrombin treatment as well as flow-through and concentrated 
flow-through after IMAC were run on 12% SDS-PAGE and stained with Coomassie 
Brilliant Blue. The analysis showed a 29 kDa, indicating a successful removal of the 
(His)6 tag and separation of the untagged protein (Figure 33C).  
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The same samples were examined for the presence of the desired protein by Western 
blot. First, an antibody against (His)6-tag was used. The analysis confirmed the 
successful purification of N-(His)6 DDEDs caspase-8 (C360A). As expected, no protein 
bands were detected in the following samples: after treatment with thrombin and after 
second IMAC purification (Figure 33D). The Western blot membrane was then re-probed 
by using an antibody against caspase-8/p18 subunit. The result revealed the presence 
of caspase-8 in all analysed samples and confirmed successful removal of the N-terminal 
(His)6 tag (Figure 33D).  
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Figure 33. IMAC (Ni-NTA) purification of human recombinant N-(His)6 DDEDs caspase-8 
(C360A). 
A. Fractions analysed after purification of N-(His)6 DDEDs caspase-8 (C360A) on IMAC 5 ml His-
trap FF nickel-nitrilotriacetic (Ni-NTA) column. The fractions reveal a strong band running at 31 
kDa. Following purification of the desired protein, the WCE (control) samples and Ni-NTA elution 
fractions from 10-22 were examined by using 12% SDS-PAGE and stained with Coomassie 
Brilliant Blue. B. Elution profile of N-(His)6 DDEDs caspase-8 (C360A) on IMAC 5 ml His-trap FF 
nickel-nitrilotriacetic (Ni-NTA) column; blue line represents protein absorbance; orange line 
represents imidazole gradient. Elution fractions taken for the SDS-PAGE analysis are indicated 
by the red arrow. C. Cleavage of N-terminal (His)6 tag. Ni-NTA fractions containing the desired 
protein were pooled, dialysed and concentrated for further processing. Supernatant containing N-
(His)6 DDEDs caspase-8 (C360A) was subjected to treatment with 125 units of thrombin, followed 
by gentle rotation at 4°C overnight and re-applied onto IMAC column. The elution, dialysed, 
concentrated, before and after thrombin treatment samples, as well as follow-through and 
concentrated flow-through samples after IMAC were analysed on 12% SDS-PAGE and staining 
with Coomassie Brilliant Blue. D. The same samples were used for Western blot analysis, in order 
to confirm the successful purification of N-(His)6 DDEDs caspase-8 (C360A) and subsequent 
removal of the (His)6 tag. WCE samples were used as controls. An antibody against (His)6-tag 
and caspase-8/p18 subunit were used to confirm the presence of the desired protein.  
M1 (Marker 1) and M4 (marker 4) – protein ladder, WCE – whole cell extracts, dial – dialysed, 
conc – concentrated, FT- flow-through. 
 
 
 
Supernatant containing untagged DDEDs caspase-8 (C360A) was further fractionated 
on SEC column. Eluted protein samples were collected as 2 ml fractions and tested for 
purity by using 12% SDS-PAGE and staining with Coomassie Brilliant Blue (Figure 34A 
and B). The results obtained for the fractions in the major elution peak at 280 nm 
revealed very high purity levels of untagged DDEDs caspase-8 (C360A) (Figure 34A and 
B). Any host proteins that co-purified and co-eluted within the untagged DDEDs caspase-
8 (C360A) peak were not separated on SEC and are present in minimal amounts, 
acceptable for experimental purposes.  
 
SEC eluates containg untagged DDEDs caspase-8 (C360A) were pooled, combined into 
one sample and concentrated to 2 ml. A single  SEC eluate and concentrated SEC 
eluates were subjected to Western blot analysis. First, the sampes were examined by 
using an antibody against (His)6-tag. As expected, no protein was detectable in the 
eluate samples, when compared with the control N-(His)6 DDEDs caspase-8 (C360A). 
Re-probing with an antibody against caspase-8/p18 subunit showed, that caspase-8 was 
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present in all analysed samples, confirming successful purification on SEC column. 
(Figure 34C).  
 
In order to check whether untagged ΔDEDs caspase-8 (C360A) was folded after 
purification, circular dichroism (CD) spectroscopy was performed. The CD spectrum of 
the protein of interest was collected using 200 µl of purified protein sample (48 µM), 
subjected to CD spectroscopy analysis. The collected experimental spectrum of 
untagged ΔDEDs caspase-8 (C360A) was then compared with a calculated spectrum of 
ΔDEDs caspase-8 (wild type) (Figure 34D). The calculated spectrum was obtained using 
the PDBMD2CD software (Mavridis and Janes, 2016) and the ΔDEDs human caspase-
8 structure (wild type; aa residues 217 – 479; PDB ID: 2K7Z).  
 
After plotting the CD data, it was observed that the experimental spectrum of untagged 
ΔDEDs caspase-8 (C360A) showed negative peaks from 205 to 225 nm. This 
observation was comparable to the calculated spectrum of ΔDEDs caspase-8 (wild type) 
(Figure 34D), which suggested that purified untagged ΔDEDs caspase-8 (C360A) was 
folded and could be used for experimental purposes. The result also showed that the 
peaks in the experimental CD spectrum were slightly more negative than the peaks in 
the calculated spectrum (Figure 34D). This could be possibly caused by the presence of 
the point mutation, C360A, in the ΔDEDs caspase-8 protein, which would be in line with 
the observations described by others, as it was demonstrated that mutations might affect 
protein folding to some extent (Hwang et al., 2014). The authors observed that the 
mutated proteins would exhibit less negative CD spectra than the wild type ones. 
Importantly, it was shown that despite the conformational changes, the mutated proteins 
were still functional (Hwang et al., 2014). The slight difference in the values of the 
experimental and calculated peaks could be also possibly caused by host E. coli 
proteins, which could be co-eluted on Ni-NTA and SEC within the untagged ΔDEDs 
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caspase-8 (C360A) peak and present in minimal amounts in the protein sample measure 
by CD spectroscopy. 
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Figure 34. Purification of untagged DDEDs caspase-8 (C360A) by using SEC. 
A. Fractions analysed after purification of untagged DDEDs caspase-8 (C360A) on SEC 120 ml 
HiLoad Superdex 75 16/60 column. The fractions show a strong band running at 29 kDa. After 
purification of the desired protein, the following elution fractions were taken for the analysis on 
SDS-PAGE: 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19. WCE sample was used as control. All 
samples were separated on 12% SDS-PAGE followed by staining with Coomassie Brilliant Blue. 
B. Elution profile of untagged DDEDs caspase-8 (C360A) on SEC 120 ml HiLoad Superdex 75 
16/60 column; blue line represents protein absorbance. Elution fractions taken for the SDS-PAGE 
analysis are indicated by the red arrow. C. Fractions containing the desired protein were pooled, 
combined and concentrated. The elution and concentrated protein samples after SEC were 
subjected to Western blot analysis. An antibody against (His)6-tag and caspase-8/p18 subunit 
were used in order to confirm successful purification of untagged DDEDs caspase-8 (C360A). D. 
Comparison of calculated and experimental circular dichroism spectra for DDEDs caspase-8. The 
calculated spectrum was obtained using the PDBMD2CD software (Mavridis and Janes, 2016) 
and the human DDEDs caspase-8 structure (wild type; aa residues 217 – 479; PDB ID: 2K7Z). 
The experimental spectrum was obtained using 200 µl of purified untagged DDEDs caspase-8 
(C360A) sample (48 µM), which was transferred to an analytic cuvette and subjected to circular 
dichroism spectroscopy. The orange curve represents the calculated CD spectrum of DDEDs 
caspase-8 (wild type), and the blue curve is the experimental spectrum of purified untagged 
DDEDs caspase-8 (C360A). 
 
The concentration of the purified sample was calculated below by using Beer-Lambert 
formula, protein extinction coefficient and absorbance result measured by 
spectrophotometer. 
 
Beer–Lambert formula:	𝐴 = 	e	𝑙	𝑐  
 
Extinction coefficient (e) = 24005 
Path (l) = 1 cm 
A280 = 0.1167048 (1 ml, 1/10 dilution) 
Concentration (c) 
 
Calculation: 	𝐴 = 	e	𝑙	𝑐 à	𝑐 = !
e
 à 𝑐 = ".((-&"*)		$*""+	 	× 	10 = 0.00004862 M = 
48.62 µM 
 
Next, the molar concentration of purified untagged DDEDs caspase-8 (C360A) was 
converted into concentration in mg/ml as follows:   
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Formula: concentration (mg/ml) = c (Molar) x MW (Daltons) 
 
Concentration (c) = 0.00004862 M 
Molecular weight (MW) = 31000 Da 
 
Calculation: concentration = 0.00004862 M x 31000 Da = 1.507 mg/ml 
 
Finally, purified untagged DDEDs caspase-8 (C360A) was aliquoted into 200 µl samples 
and stored at -20oC. 
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 Design	 and	 Establishment	 of	 Alternative	 Protein	
Expression	Constructs	by	Using	pGEX-4T-3	System		
 
By using pET-28a system, we have successfully expressed and purified C-(His)6 FADD-
FL, untagged DDEDs caspase-8 (C360A) and untagged  DDEDs caspase-10 (D415A). 
The yield obtained after purification of the first two proteins was good and satisfactory, 
whereas the yield of the third protein was low and only enough for selected experiments. 
Moreover, purification of N-(His)6 DDEDs cFLIP-L was unsuccessful, when using the 
pET-28a system. Such results suggested two possible scenarios: (I) protein expression 
levels were too low and/or (II) only small parts of proteins were solubilised and isolated 
from inclusion bodies. Upscaling the recombinant protein production and optimisation of 
solubilisation under denaturing conditions did not increase the yield after purification 
(data not shown).  
 
Therefore, it was essential to consider using a different protein production system, which 
could allow higher and more efficient expression as well as increase the level of protein 
solubility, when expressed in E. coli. Aside testing and monitoring different induction and 
expression parameters (such as various IPTG concertation, time and temperature), it is 
common to use a fusion protein technology, which recommends utilising fusion partners 
or tags, also known as solubility enhancer tags (Costa et al., 2014). A wide range of such 
tags is available and one of the most common and well-known ones is glutathione-S-
transferase (GST), which was selected in this study.  
 
pGEX plasmid vectors function as a well-established known expression system, which 
allows production of proteins fused to the GST tag. In this system, protein expression is 
controlled by the IPTG-inducible tac promoter. Expression of the insert is tightly 
regulated by the presence of the product of the lacIq gene and lac operator, which are 
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also engineered in the vector (Figure 35A). The lacIq gene product functions as the tac 
repressor, which can be outcompeted by addition of IPTG, leading to expression of an 
inserted gene.  
In this study, the pGEX-4T-3 vector was used for establishment of the protein expression 
constructs (Figure 35A and B).  
A 
 
B 
 
 
Figure 35. Schematics of an empty pGEX-4T-3 vector. 
A. Map of the vector with its main features B. Detailed schematics of the Multiple Cloning Site 
with N-terminal GST tag and indication of restrictions sites positions for enzymes used during 
cloning of desired constructs.  
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The first step was to modify the pGEX-4T-3 vector, in order to add the (His)6 tag 
downstream of the Multiple Cloning Site (MCS) (Figure 36A and 37A). This would result 
in expression of the proteins with the N-terminal GST and C-terminal (His)6 tag. The 
second tag was added to facilitate purification on the Ni-NTA column and to utilise an 
already established protocol from the pET-28a system, so only minor optimisations to 
the protein expression conditions would need to be made for the new system.  
 
Empty pGEX-4T-3 vector was modified by cloning of DNA inserts containing C-terminal 
(His)6 tag with thrombin or TEV cleavage site into the Sal1 and Not1 sites of the plasmid 
(Figure 36A and B; Figure 37A and B). Usage of the pGEX-4T-3 / thrombin-(His)6 
requires only one treatment with thrombin in order to remove both N-GST and C-(His)6 
tags, whereas usage of pGEX-4T-3 / TEV-(His)6 allows to remove N-GST and to leave 
C-(His)6 tag after the thrombin treatment. When necessary, C-(His)6 tag can be cut off 
with TEV protease.  
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A 
 
 
B 
 
 
Figure 36. Schematics of the pGEX-4T-3 vector with additional (His)6 tag and thrombin site. 
A. Map of the vector with its main features. Additional (His)6 tag with thrombin site (indicated by 
the red arrow) for tag removal was inserted into Sal1 and Not1 sites of the pGEX-4T-3 vector. B. 
Detailed schematics of the Multiple Cloning Site with N-terminal GST, C-terminal (His)6 tag and 
indication of restriction sites positions for enzymes used during cloning of desired constructs.  
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A 
 
 
B 
 
 
Figure 37. Schematics of the pGEX-4T-3 vector with additional (His)6 tag and TEV site. 
A. Map of the vector with its main features. Additional (His)6 tag with TEV site (indicated by the 
red arrow) for tag removal was inserted into Sal1 and Not1 sites of the pGEX-4T-3 vector. B. 
Detailed schematics of the Multiple Cloning Site with N-terminal GST, C-terminal (His)6 tag and 
indication of restriction sites positions for enzymes used during cloning of desired constructs.  
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For establishment of the pGEX-4T-3-based protein expression constructs, the same 
DNA fragments were used as for the pET-28a system and were described in detail on p. 
88-89. The schematics of the constructs is shown in Figure 15A, B and C (p. 109).  
Additionally, a construct containing the cleavage mutant of cFLIP-L with a single amino 
acid substitution at D376A was generated (Figure 15C, p. 109). Mutation at this site, 
which has been described as a preferred cleavage site for pro-caspase-8 (Yu et al., 
2009), prevents cFLIP-L from being processed by caspase-8.  
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DDEDs caspase-8 (C360A) DNA fragment was cloned into BamH1 and Sal1 sites of the 
pGEX-4T-3/thrombin-(His)6 vector. As a result, the N-terminus and C-terminus of the 
protein were fused to the GST tag and the (His)6 tag, respectively. Both tags can be 
removed by thrombin treatment (Figure 38A and B).  
 
A 
 
 
B 
 
 
Figure 38.  Map of the DDEDs caspase-8 (C360A) pGEX-4T-3/thrombin-(His)6 construct.  
A. The DDEDs caspase-8 gene (C360A) was inserted into BamH1 and Sal1 sites of the pGEX-
4T-3/thrombin-(His)6 vector B. Detailed schematics of the DDEDs caspase-8 (C360A) insert with 
N-terminal GST and C-terminal (His)6 tag with thrombin sites for tags removal.  
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DDEDs caspase-10 (C401A) and DDEDs caspase-10 (D415A) DNA segments were 
inserted into BamH1 and Sal1 sites of the pGEX-4T-3/thrombin-(His)6 vector. Therefore, 
the N-termini and C-termini of the proteins were fused to the GST tag and the (His)6 tag, 
respectively. Both tags can be removed by addition of thrombin (Figure 39A and B). 
 
A 
 
 
 
B 
 
 
Figure 39.  Map of the DDEDs caspase-10/pGEX-4T-3/thrombin-(His)6 construct.  
A. The DDEDs caspase-10 gene (containing either C401A or D415A mutation) was inserted into 
BamH1 and Sal1 sites of the pGEX-4T-3/thrombin-(His)6 vector. B. Detailed schematics of the 
DDEDs caspase-10 insert with N-terminal GST and C-terminal (His)6 tag with thrombin sites for 
tags removal.  
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DDEDs caspase-10 (C401A) and DDEDs caspase-10 (D415A) DNA genes were 
engineered into BamH1 and Sal1 sites of the pGEX-4T-3/TEV-(His)6 plasmid. This 
resulted in fusion of the N-termini and C-termini of the proteins to the GST tag and the 
(His)6 tag, respectively. The N-GST tag can be removed by thrombin treatment, whereas 
the C-(His)6 can be cut off with TEV (Figure 40A and B). 
 
A 
 
 
B 
 
 
Figure 40. Map of the caspase-10/pGEX-4T-3/TEV-(His)6 construct.  
A. The DDEDs caspase-10 gene (containing either C401A or D415A mutation) was inserted into 
BamH1 and Sal1 sites of the pGEX-4T-3/TEV-(His)6 vector. B. Detailed schematics of the DDEDs 
caspase-10 insert with N-terminal GST with thrombin site and C-terminal (His)6 tag with TEV site 
for tags removal.  
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DDEDs cFLIP-L (wild type) and DDEDs cFLIP-L (D376A) DNA fragments were cloned 
into BamH1 and Sal1 sites of the pGEX-4T-3/thrombin-(His)6 vector. In these constructs, 
the N-termini and C-termini of the proteins were fused to the GST tag and the (His)6 tag, 
respectively. Both tags can be cut off by using thrombin (Figure 41A and B). 
 
A 
 
 
 
B  
 
 
Figure 41.  Map of the DDEDs cFLIP-L/pGEX-4T-3/thrombin-(His)6 construct.  
A. The DDEDs cFLIP-L gene (wild type or D376A mutant) was inserted into BamH1 and Sal1 
sites of the pGEX-4T-3/thrombin-(His)6 vector B. Detailed schematics of the DDEDs cFLIP-L 
insert with N-terminal GST and C-terminal (His)6 tag with thrombin sites for tags removal.  
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DDEDs cFLIP-L (wild type) and DDEDs cFLIP-L (D376A) DNA segments were 
engineered into BamH1 and Sal1 sites of the pGEX-4T-3/TEV-(His)6 vector. As a result, 
the N-termini and C-termini of the proteins were fused to the GST tag and the (His)6 tag, 
respectively. The N-GST tag can cut off by thrombin treatment, whereas C-(His)6 can be 
removed with TEV (Figure 42A and B). 
 
A 
 
 
B 
 
 
Figure 42.  Map of the DDEDs cFLIP-L/pGEX-4T-3/TEV-(His)6 construct.  
A. The DDEDs cFLIP-L gene (wild type or D376A mutant) was inserted into BamH1 and Sal1 
sites of the pGEX-4T-3/TEV-(His)6 vector B. Detailed schematics of the DDEDs cFLIP-L insert 
with N-terminal GST and C-terminal (His)6 tag with TEV site for tag removal.  
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As a host for protein expression, E. coli strain BL21-RIL was used. These bacteria are 
derivatives of the BL21 E. coli strain, which is known to enable high-level protein 
expression, as they are engineered to contain genes encoding for rare tRNAs. BL21-RIL 
cells were selected due to the fact, that the protein expression with the pGEX-4T-3 
plasmid is driven by the tac promoter, therefore it was not necessary to employ a DE3 
lysogen as host.  
 
As a starting point, induction with 0.1 mM (final concentration) of IPTG, and expression 
at 30°C for 3h and 15 h were tested. The constructs that were assessed for recombinant 
protein expression included: empty pGEX-4T-3/thrombin-C-(His)6 vector (used to 
express GST as a control for protein assays), DDEDs caspase-8 (C360A)/thrombin-
(His)6 (control for expression conditions) as well as DDEDs caspase-10 (C401A), DDEDs 
caspase-10 (D415A), DDEDs cFLIP-L (wild type) and DDEDs cFLIP-L (D376A) 
constructs with both thrombin-(His)6 and TEV-(His)6 tags.  
 
Tables 35-38 summarise the basic information regarding protein expression constructs 
and expected protein masses after expression and purification. 
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Table 35. Main features of the pGEX-4T-3/thrombin-(His)6 control construct with expected 
protein masses after expression 
Protein Details   
DNA Construct None; the expression product is the N-terminal GST tag fused 
with C-terminal (His)6-tag 
Host Cell Strain BL21-RIL 
Tagged Protein MW (kDa) 26 
 
 
Table 36. Main features of the human recombinant DDEDs caspase-8 constructs with 
expected protein masses after expression. 
Protein Details   
DNA Construct DDEDs caspase-8 (aa residues 217-479; C360A active site 
mutant), pGEX-4T-3, N-terminal GST tag and C-terminal 
(His)6-tag 
Host Cell Strain BL21-RIL 
Tagged Protein MW (kDa) 58 
Untagged Protein MW (kDa) 29 
 
 
Table 37. Main features of the human recombinant DDEDs caspase-10 constructs with 
expected protein masses after expression. 
Protein Details 
DNA Construct DDEDs caspase-10 (aa residues 219-521, C401A active site 
mutant; D415A linker mutant), pGEX-4T-3, N-terminal GST 
tag and C-terminal (His)6-tag 
Host Cell Strain BL21-RIL 
Tagged Protein MW (kDa) 62 
Untagged Protein MW (kDa) 33 
 
 
Table 38. Main features of the human recombinant DDEDs cFLIP-L constructs with 
expected protein masses after expression. 
Protein Details 
DNA Construct DDEDs cFLIP-L (aa residues 208-480; wild type and D376A 
cleavage mutant), pGEX-4T-3, N-terminal GST tag and C-
terminal (His)6-tag 
Host Cell Strain BL21-RIL 
Tagged Protein MW (kDa) 57 
Untagged Protein MW (kDa) 28 
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 Expression	of	Human	Recombinant	DDEDs	Caspase-
10	 (C401A),	DDEDs	Caspase-10	 (D415A)	and	DDEDs	
cFLIP-L	(wild	type	and	D376A)	Constructs	
 
The constructs were transformed into BL21-RIL cells. After reaching the required OD 
(A600 = 0.6-0.8), small aliquots of whole cell extract (WCE) samples were taken before 
induction and saved for analysis. Recombinant protein expression was induced with 
IPTG, followed by incubation with shaking overnight. In order to analyse the protein 
expression levels, WCE samples were taken 3 h and 15 h post-induction. The samples 
were run on 12% SDS-PAGE and stained with Coomassie Brilliant Blue.  
 
As shown in Figure 35A, B, C, D, E and F, GST/thrombin-C-(His)6, N-GST DDEDs 
caspase-8 (C360A)/thrombin-C-(His)6 as well as N-GST DDEDs caspase-10 (C401A), 
N-GST DDEDs caspase-10 (D415A), N-GST DDEDs cFLIP-L (wild type) and N-GST 
DDEDs cFLIP-L (D376A) with both thrombin-(His)6 and TEV-(His)6 tags were 
successfully expressed after 3 h and 15 h. The 3h expression enabled more efficient 
production, when compared to 15 h induction (Figure 43A, B, C, D, E and F).  
 
The levels of N-GST DDEDs caspase-10 (C401A), N-GST DDEDs caspase-10 (D415A), 
N-GST DDEDs cFLIP-L (wild type) and N-GST DDEDs cFLIP-L (D376A) with both 
thrombin-(His)6 and TEV-(His)6 tags (Figure 35C, D, E and F) were comparable with the 
results obtained for the control GST/thrombin-C-(His)6, N-GST and DDEDs caspase-8 
(C360A)/thrombin-C-(His)6 (Figure 35A and B). 
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Figure 43.   Expression levels of the proteins produced by using the pGEX-4T-3 system. 
A-F. The whole cell extract (WCE) samples were taken before induction as well as 3 h and 15 h 
post-induction (IPTG at 0.1 mM final concentration) for the analysis of the expression levels of 
the following proteins: N-GST DDEDs caspase-10 (C401A), N-GST DDEDs caspase-10 (D415A), 
N-GST DDEDs cFLIP-L (wild type) and N-GST DDEDs cFLIP-L (D376A) with both thrombin-(His)6 
and TEV-(His)6. GST/thrombin-C-(His)6 and N-GST DDEDs caspase-8 (C360A)/thrombin-C-
(His)6 were used as controls. The samples were analysed on 12% SDS-PAGE followed by 
staining with Coomassie Brilliant Blue.  
M3 (Marker 3) and M4 (marker 4) – protein ladders.  
 
 
 
 
A                B 
C                D 
E                F 
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In order to examine solubility levels of the expressed proteins, 3 h after expression the 
bacteria were harvested and lysed by sonication. Supernatants and insoluble fractions 
were separated by centrifugation. The lysate, supernatant and resuspended pellet 
fractions were aliquoted and taken for analysis by using 12% SDS-PAGE and staining 
with Coomassie Brilliant Blue.  
 
We observed that the highest levels of N-GST DDEDs caspase-10 (C401A), N-GST 
DDEDs caspase-10 (D415A), N-GST DDEDs cFLIP-L (wild type) and N-GST DDEDs 
cFLIP-L (D376A) with both thrombin-(His)6 and TEV-(His)6 tags were found in the 
resuspended pellets (Figure 44A, C, D, E and F). As previously, the expressed proteins 
were aggregated in inclusion bodies. The observation was comparable with the result 
obtained for the control N-GST DDEDs caspase-8 (C360A)/thrombin-C-(His)6, which was 
also most abundant in the resuspended pellet fraction. In contrast and as expected, the 
control GST/thrombin-C-(His)6 was mostly found in the supernatant. 
 
As previously, solubilisation under denaturing conditions was used to isolate and purify 
the recombination proteins from the inclusion bodies. The solubilisation was performed 
in the same manner, as described for the pET-28a system.  
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Figure 44.  Solubility levels of the proteins expressed by using the pGEX-4T-3 system. 
A. After 3 h of GST/thrombin-C-(His)6 expression, the lysate, supernatant and resuspended pellet 
samples were analysed on 12% SDS-PAGE and stained with Coomassie Brilliant Blue. WCE 
samples were used as control. B. After 3 h of N-GST DDEDs caspase-8 (C360A)/thrombin-C-
(His)6 expression, the lysate, supernatant and resuspended pellet samples were analysed on 12% 
SDS-PAGE followed by staining with Coomassie Brilliant Blue. WCE samples served as controls. 
C. After 3 h expression of N-GST DDEDs caspase-10 (C401A) with both thrombin-(His)6 and TEV-
(His)6 tags, the lysate, supernatant and resuspended pellet samples were analysed on 12% SDS-
PAGE and stained with Coomassie Brilliant Blue. WCE samples were utilised as controls.  D. 
After 3 h expression of N-GST DDEDs caspase-10 (D415A) with both thrombin-(His)6 and TEV-
(His)6 tags, the lysate, supernatant and resuspended pellet samples were analysed on 12% SDS-
PAGE followed by staining with Coomassie Brilliant Blue. E. After 15 h expression of N-GST 
DDEDs cFLIP-L (wild type) with both thrombin-(His)6 and TEV-(His)6 tags, the lysate, supernatant 
and resuspended pellet samples were analysed on 12% SDS-PAGE and stained with Coomassie 
Brilliant Blue. WCE samples were used as controls. F. After 15 h expression of N-GST DDEDs 
cFLIP-L (D376A) with both thrombin-(His)6 and TEV-(His)6 tags, the lysate, supernatant and 
resuspended pellet samples were analysed on 12% SDS-PAGE and stained with Coomassie 
Brilliant Blue. WCE samples served as controls.  
M4 (marker 4) – protein ladder, WCE – whole cell extracts, Lys – lysed cells, Sup – supernatant, 
Pel – cell pellet. 
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 Purification	 of	 the	 Control	 GST/thrombin-C-(His)6	
Protein	
 
Soluble (His)6-tagged GST was purified on IMAC column by following the manufacturer’s 
protocol. Analysis on 15% SDS-PAGE and subsequent staining with Coomassie Brilliant 
Blue showed that the protein was successfully purified. Assessed elution fractions in the 
major elution peak at 280 nm (Figure 45A and B) revealed the presence of one major 
protein band. The observed 26 kDa band is consistent with the size of the (His)6-tagged 
GST (Figure 45A). All elution fractions containing the protein of interest were combined 
into one sample, dialysed and concentrated to 2 ml. Small aliquots of the elute, dialysed 
and concentrated samples were run on 15% SDS-PAGE followed by staining with 
Coomassie Brilliant Blue. The analysis further confirmed the presence of the purified 
protein (Figure 45C).  
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A 
 
 
B 
 
C 
 
 
Figure 45.  IMAC (Ni-NTA) purification of GST/thrombin-C-(His)6. 
A. Analysis of fractions after purification of GST/thrombin-C-(His)6 on IMAC 5 ml His-trap FF 
nickel-nitrilotriacetic (Ni-NTA) column. The fractions reveal a strong band running at 26 kDa. 
Following purification of the protein, the WCE (control) samples and Ni-NTA elution fractions 
number 10, 11, 12, 13, 14 and 15 were analysed by using 15% SDS-PAGE and subsequent 
staining with Coomassie Brilliant Blue. B. Elution profile of GST/thrombin-C-(His)6 on IMAC 5 ml 
His-trap FF nickel-nitrilotriacetic (Ni-NTA) column; blue line represents protein absorbance; 
orange line represents imidazole gradient. Elution fractions taken for the SDS-PAGE analysis are 
indicated by the red arrow. C. Fractions containing the desired protein were pooled, dialysed and 
concentrated for further processing. The elution dialysed and concentrated protein samples were 
analysed on 15% SDS-PAGE and staining with Coomassie Brilliant Blue. WCE samples were 
used as controls.  
M3 (Marker 3) – protein ladder, WCE – whole cell extracts, dial – dialysed, conc – concentrated. 
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The concentrated (2 ml) sample containing (His)6-tagged GST was further purified on 
SEC column. Protein eluates were collected as 2 ml fractions and examined for purity by 
using 15% SDS-PAGE followed by staining with Coomassie Brilliant Blue (Figure 46A 
and B). Analysis of elution fractions in the major elution peak at 280 nm showed very 
high purity levels of (His)6-tagged GST (Figure 46A). Any host proteins that co-purified 
on IMAC column and co-eluted within the (His)6-tagged GST peak were not separated 
by SEC and were present in minimal amounts, acceptable for experimental purposes. 
 
A 
 
 
B 
 
 
Figure 46. Purification of (His)6-tagged GST protein by using SEC. 
A. Analysis of fractions after purification of (His)6-tagged GST on SEC 120 ml HiLoad Superdex 
75 16/60 column. The fractions reveal a strong band running at 26 kDa. After purification, the 
SEC elution fractions from 9 to 20 were taken for analysis. WCE sample was used as control. All 
samples were separated on 15% SDS-PAGE followed by staining with Coomassie Brilliant Blue. 
B. Elution profile of (His)6-tagged GST on SEC 120 ml HiLoad Superdex 75 16/60 column; blue 
line represents protein absorbance. Elution fractions taken for the SDS-PAGE analysis are 
indicated by the red arrow. 
M4 (Marker 4) – protein ladder.  
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Elution fractions containg the protein of interest were pooled, combined into one sample 
and concentrated in order to obtain 2 ml of the final pure protein sample. The 
concentration of purified (His)6-tagged GST sample was calculated below by using Beer-
Lambert formula, protein extinction coefficient and absorbance result measured by 
spectrophotometer.  
 
 
Beer–Lambert formula:	𝐴 = 	e	𝑙	𝑐  
 
Extinction coefficient (e) = 42860 
Path (l) = 1 cm 
A280 = 0.08838008 (1 ml, 1/100 dilution) 
Concentration (c) 
 
Calculation: 	𝐴 = 	e	𝑙	𝑐 à	𝑐 = !
e
 à 𝑐 = "."))%)"")		*$)-"	 	× 	100 = 0.00020621 M = 
206.21 µM 
 
Next, the molar concentration of purified untagged DDEDs caspase-8 (C360A) was 
converted into concentration in mg/ml as follows:   
 
Formula: concentration (mg/ml) = c (Molar) x MW (Daltons) 
 
Concentration (c) = 0. 00020621 M 
Molecular weight (MW) = 26000 Da 
 
Calculation: concentration = 0.00020621 M x 26000 Da = 5.361 mg/ml 
 
Finally, purified (His)6-tagged GST was separated into 200 µl aliquots and prepared for 
storage at -20oC. 
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 Purification	 of	 N-GST	 DDEDs	 Caspase-10	
(D415A)/thrombin-C-(His)6	
 
Following solubilisation under denaturing conditions, supernatant containing N-GST 
DDEDs aspase-10 (D415A)/thrombin-C-(His)6 was applied onto IMAC column and 
purified as described for the pET-28a system.  
 
The results obtained for N-GST DDEDs caspase-10 (D415A)/thrombin-C-(His)6 showed 
that the protein was successfully purified (Figure 47A and B). The fractions at the major 
elution peak at 280 nm were analysed on 12% SDS-PAGE and stained with Coomassie 
Brilliant Blue. We observed a 62 kDa protein band, which corresponds to the expected 
size of the purified protein (Figure 47). 
 
Elution fractions containing the protein of interest were combined into one sample, 
dialysed and concentrated to ~10 ml. in order to remove the N-terminal GST and C-
terminal (His)6 tag, the protein of interest was treated with 125 units of thrombin. The 
sample was rotated at 4°C overnight and re-applied onto IMAC column in the same 
manner as previously described. The flow-through fractions containing N-GST DDEDs 
caspase-10 (D415A)/thrombin-C-(His)6 were collected, combined and concentrated to 2 
ml for further purification on SEC column.  Small aliquots of the following samples: eluted, 
dialysed and concentrated as well as flow-through, wash and concentrated flow-through 
after IMAC were run on 12% SDS-PAGE and stained with Coomassie Brilliant Blue 
(Figure 47C). The analysis revealed the presence of two protein bands, 33 kDa and 26 
kDa, in the concentrated fraction after tags removal and second IMAC purification 
(Figure 47C). The 33 kDa and 26 kDa bands corresponded to the sizes of untagged 
DDEDs caspase-10 (D415A) and GST, respectively, indicating a successful removal of 
the GST and (His)6 tags as well as separation of the untagged protein. Surprisingly, the 
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levels of untagged DDEDs caspase-10 (D415A) in the concentrated fraction after second 
IMAC purification were considerably reduced, when compared with the fraction obtained 
and concentrated after the first purification step (Figure 47C).  
 
Moreover, further purification on the SEC column showed that the protein of interest 
eluted at the end of the purification process (indicated by the red arrow in Figure 47D), 
which was not in line with the expected elution at 45 ml, observed previously for untagged 
DDEDs caspase-10 (D415A) (Figure 32A, p. 144). Therefore, it was assumed, that the 
protein of interest was not stable and could not be used for experimental purposes.  
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Figure 47. IMAC (Ni-NTA) and SEC purification of N-GST DDEDs caspase-10 
(D415A)/thrombin-C-(His)6. 
A. Analysis of fractions after purification of N-GST DDEDs caspase-10 (D415A)/thrombin-C-(His)6 
on IMAC 5 ml His-trap FF nickel-nitrilotriacetic (Ni-NTA) column. The fractions show a strong 
band running at 62 kDa. Following purification of the protein of interest, the WCE (control) sample 
and Ni-NTA elution fractions number 10, 11, 12, 13 and 14 were analysed by using 12% SDS-
PAGE and subsequent staining with Coomassie Brilliant Blue. B. Elution profile of N-GST DDEDs 
caspase-10 (D415A)/thrombin-C-(His)6 on IMAC 5 ml His-trap FF nickel-nitrilotriacetic (Ni-NTA) 
column; blue line represents protein absorbance; orange line represents imidazole gradient. 
Elution fractions taken for the SDS-PAGE analysis are indicated by the red arrow. C. Cleavage 
of C-terminal (His)6. Fractions containing the desired protein were pooled, dialysed and 
concentrated for thrombin treatment. The elution dialysed and concentrated protein samples as 
well as flow-through, wash and concentrated flow-through after addition of thrombin and second 
IMAC purification were analysed on 12% SDS-PAGE and staining with Coomassie Brilliant Blue. 
WCE sample and supernatant after urea lysis were used as controls. The fractions show very low 
levels of the desired protein at around 33 kDa. D. Elution profile of N-GST DDEDs caspase-10 
(D415A)/thrombin-C-(His)6 on SEC 120 ml HiLoad Superdex 75 16/60 column; blue line 
represents protein absorbance. Fractions that possibly contain the protein of interest are indicated 
by the red arrow.  
M3 (Marker 3) – protein ladder, WCE – whole cell extracts, sup – supernatant, dial – dialysed, 
conc – concentrated. 
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 Investigation	of	Caspase-10-Mediated	Processing	of	
Caspase-8	in	Vitro	
 
As mentioned, in the current study we were interested in investigation of the role of 
caspase-10 as a component of the FADDosome and a potential caspase-8 activator. In 
order to assess, whether caspase-10 has the ability to activate caspase-8 in vitro, we 
performed an activity assay for purified untagged DDEDs caspase-10 (D415A) and 
untagged DDEDs caspase-8 (C360A), which were expressed by using the pET-28a 
system followed by purification on the IMAC and SEC columns, as described earlier in 
this Chapter. The roles of untagged DDEDs caspase-10 (D415A) and untagged DDEDs 
caspase-8 (C360A) in the reaction was to act as an enzyme and substrate, respectively. 
 
First, the purified untagged DDEDs caspase-10 (D415A) and untagged DDEDs caspase-
8 (C360A) were mixed at the concentrations of 1 µM and 10 µM, respectively, and 
incubated at physiological conditions (50 mM Trizma base, 150 mM NaCl [pH 7.4]) in a 
total volume of 250 µl of the reaction buffer. The mixture was incubated at room 
temperature. At the 0, 10, 40 and 160 minutes, 30 µl of the reaction was aliquoted into 
the loading buffer. As a control, 10 µM of untagged DDEDs caspase-8 (C360A) alone 
was used and subjected to the same conditions as the mixture. At the 0, 10, 40 and 160 
minutes, 30 µl of samples were aliquoted into the loading buffer. The control and assay 
samples were run on 15% SDS-PAGE and analysed by Western Blot.  
 
As shown in Figure 46, after performing the DDEDs caspase-10 (D415A) and DDEDs 
caspase-8 (C360A) assay, the levels of the single-chained DDEDs caspase-8 (C360A) 
decreased slightly and gradually after 10 and 40. After 160 minutes, the levels of the 
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protein were markedly decreased. However, we observed the same phenomenon for the 
control DDEDs caspase-8 (C360A).  
 
 
Figure 48. Caspase-10 / caspase-8 activity assay in physiological conditions. 
1 µM of untagged DDEDs caspase-10 (D415A) (enzyme) and 10 µM of purified untagged DDEDs 
caspase-8 (C360A) (substrate) were mixed in a total volume of 250 µl of the reaction buffer (50 
mM Trizma base, 150 mM NaCl, [pH 7.4]) and incubated at room temperature. 10 µM of purified 
untagged DDEDs caspase-8 (C360A) was used as a control and subjected to the same reaction 
conditions. At noted timepoints, 30 µl of the control and reaction were aliquoted into the loading 
buffer. The samples were analysed by 15% SDS-PAGE and Western blot. An antibody against 
caspase-8/p18 subunit was used to detect the protein of interest.  
 
 
It was assumed, that the observed decrease of the control DDEDs caspase-8 (C360A) 
was caused by one of the following possible scenarios: (I) instability or (II) self-cleavage 
of the protein into smaller fragments, which increased proportionally to the time of 
incubation. In order to examine the stability of DDEDs caspase-8 (C360A), we used 10 
µM of untagged DDEDs caspase-8 (C360A) alone, which was incubated at room 
temperature and at physiological conditions. To test the DDEDs caspase-8 (C360A) 
stability in more detail, the samples were taken after 0, 0.5, 1, 1.5, 2, 3, 4, 5 and 10 
minutes of incubation and aliquoted into the loading buffer. The Western blot result 
showed, that the levels of single-chained DDEDs caspase-8 (C360A) were gradually 
reduced, proportionally to the time of incubation (Figure 49A). This indicated that the 
protein becomes unstable or cleaves itself after a short period of time. Therefore, it was 
essential to optimise buffer and reaction conditions for the assay. 
 
For this, 10 µM of purified untagged DDEDs caspase-8 (C360A) alone was used and 
assessed for its stability by using 50 mM Trizma base, 150 mM NaCl, 10% PEG, 0.1% 
 183 
CHAPS [pH 7.4] buffer, which provided stabilising conditions for caspases reactions. As 
previously, 10 µM of untagged DDEDs caspase-8 (C360A) alone at physiological 
conditions was used as a control. The samples were taken and aliquoted into the loading 
buffer after 0, 0.5, 1 1.5, 2, 5 and 10 minutes and analysed by Western blot. As expected, 
the levels of control DDEDs caspase-8 (C360A) were gradually decreasing with time 
(Figure 49B). In contrast, at stabilising conditions, the levels of single-chained DDEDs 
caspase-8 (C360A) were not reduced, indicating that the protein remained stable in the 
tested conditions (Figure 49B).  
 
A 
 
 
 
B 
 
Figure 49. Stability test for DDEDs caspase-8 (C360A). 
A. 10 µM of purified untagged DDEDs caspase-8 (C360A) was incubated at room temperature in 
a total volume of 250 µl of the physiological buffer (50 mM Trizma base, 150 mM NaCl, [pH 7.4]). 
At noted timepoints, 30 µl of the control and reaction were aliquoted into the loading buffer. The 
samples were analysed 15% SDS-PAGE and Western blot. An antibody against casapase-8 p18 
subunit was used, in order to assess the levels of DDEDs caspase-8 (C360A). B. 10 µM of purified 
untagged DDEDs caspase-8 (C360A) was incubated at room temperature in a total volume of 
250 µl of the stabilising buffer (50 mM Trizma base, 150 mM NaCl, 10% PEG, 0.1% CHAPS, [pH 
7.4]). 10 µM of purified untagged DDEDs caspase-8 (C360A) incubated at physiological 
conditions was used as control. At noted timepoints, 30 µl of the control and reaction were 
aliquoted into the loading buffer. The samples were run on 15% SDS-PAGE and examined for 
DDEDs caspase-8 (C360A) stability by Western blot. An antibody against casapase-8 p18 subunit 
was used, in order to assess the levels of DDEDs caspase-8 (C360A). 
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In order to assess, whether DDEDs caspase-8 (C360A) has the ability to cleave itself, 
we performed an assay in the presence of kosmotropic salts, which are known to 
accelerate dimerization and subsequently, proteolysis and activation of proteins 
(Boatright et al., 2004). For this, we used 10 µM of purified untagged DDEDs caspase-8 
(C360A) alone, which was incubated in the reaction buffer containing kosmotropic salts 
(50 mM Trizma base, 150 mM NaCl, 1 M sodium citrate, [pH 7.4]) As previously, 10 µM 
of untagged DDEDs caspase-8 (C360A) alone was incubated at physiological conditions 
was used as a control. 
 
The control and tested samples were aliquoted into the loading buffer after 0, 0.5, 1, 1.5, 
2, 5 and 10 minutes and analysed on 15% SDS-PAGE followed by Western blot. As 
shown in Figure 50 (right), the levels single-chained of DDEDs caspase-8 (C360A) were 
not decreased in the presence of 1 M sodium citrate after 0.5, 1, 1.5, 2, 5 and 10 minutes 
and were comparable with the results obtained for the control (Figure 50; left), ruling out 
the ability of DDEDs caspase-8 (C360A) to cleave itself.  
 
 
Figure 50. Self-cleavage test for DDEDs caspase-8 (C360A) in the presence of kosmotropic 
salts.  
10 µM of purified untagged DDEDs caspase-8 (C360A) alone was incubated at room temperature 
in a total volume of 250 µl of the buffer containing kosmotropic salts (50 mM Trizma base, 150 
mM NaCl, 1 M sodium citrate, [pH 7.4]). 10 µM of purified untagged DDEDs caspase-8 (C360A) 
incubated in physiological conditions was used as a control. At noted timepoints, 30 µl of the 
control and reaction were aliquoted into the loading buffer. The samples were run on 15% SDS-
PAGE and examined for DDEDs caspase-8 (C360A) stability by Western blot. An antibody against 
casapase-8 p18 subunit was used, in order to assess the levels of DDEDs caspase-8 (C360A). 
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Next, we performed the caspase-10 / caspase-8 activity assay by using the stabilising 
conditions. For this, we mixed 1 µM of purified untagged DDEDs caspase-10 (D415A) 
and 10 µM of purified untagged DDEDs caspase-8 (C360A) and incubated in the 
stabilising reaction buffer (50 mM Trizma base, 150 mM NaCl, 10% PEG, 0.1% CHAPS, 
[pH 7.4]) for 0, 0.5, 1 1.5, 2, 5 and 10 minutes. As a control we used 10 µM of untagged 
DDEDs caspase-8 (C360A) alone incubated at stabilising conditions. At indicated 
timepoints, 30 µl of the control and mixture were aliquoted and analysed by 15% SDS-
PAGE and Western blot. We observed that the levels of single chained DDEDs caspase-
8 (C360A) were decreasing gradually and proportionally to the time of incubation and 
were markedly reduced, when compared with the control samples taken at compared 
timepoints (Figure 51). Thus, our data indicated that DDEDs caspase-10 (D415A) could 
proteolytically process DDEDs caspase-8 (C360A) in vitro.  
 
 
Figure 51. Caspase-10 / caspase-8 activity assay in stabilising conditions. 
1 µM of untagged DDEDs caspase-10 (D415A) (enzyme) and 10 µM of purified untagged DDEDs 
caspase-8 (C360A) (substrate) were mixed in a total volume of 250 µl of the reaction buffer (50 
mM Trizma base, 150 mM NaCl, 10% PEG, 0.1% CHAPS [pH 7.4]) and incubated at room 
temperature. 10 µM of purified untagged DDEDs caspase-8 (C360A) was used as a control and 
subjected to the same reaction conditions. At noted timepoints, 30 µl of the control and reaction 
were aliquoted into the loading buffer. The samples were analysed by 15% SDS-PAGE and 
Western blot. An antibody against caspase-8/p18 subunit was used to detect the protein of 
interest.  
 
 
 
 
 
 186 
 Investigation	 of	 Interaction	Relationship	Between	
Caspase-8	and	FADD	in	Vitro	
 
Conventionally, FADD is known to be involved in formation of the DISC complex, which 
initiates the extrinsic apoptotic pathway. As an adaptor molecule, FADD binds to a death 
receptor and recruits caspase-8, which is cleaved and activated at the DISC, leading to 
induction of apoptosis. It is believed that FADD and caspase-8 interact via homotypic 
interaction between the DEDs, which are present in the structure of both proteins. 
Currently, there is only one report describing the molecular mechanism responsible for 
such interaction, which is based on investigation of the FADD/pro-caspase-8 binding in 
the context of the DISC assembly (Carrington et al., 2006). The authors also proposed 
a model for such interaction by studying the crystal structure of MC159, also known as 
vFLIP. DEDs of this protein are structurally similar to DEDs of FADD and caspase-8. 
Therefore, the evidence of the FADD/caspase-8 interaction in the context of formation 
of the intracellular apoptosis-inducing protein complexes, such as FADDosome, which 
do not require involvement of the death receptors, is still missing.  
 
Furthermore, in the previous report our group has demonstrated that FADD plays a 
central role in the FADDosome formation and acts as a functional partner in caspase-8 
activation at the complex. The FADD-dependent caspase-8 activation was confirmed by 
examination of FADD-silenced HCT116 cells. Upon 5-FU treatment, both apoptosis and 
caspase-8 activation were inhibited in HCT.shFADD cells (Mohr et al., 2018).  
 
Thus, we examined the interaction between FADD and caspase-8 by performing an pull-
down assay (Figure 52). C-(His)6 FADD-FL (bait protein) and untagged DDEDs caspase-
8 (C360A) (prey protein) were expressed by using pET-28a system and purified on the 
IMAC and SEC columns, as shown earlier in this Chapter. The purified proteins were 
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mixed at equimolar ratio of 10 µM and incubated in the reaction buffer (50 mM Trizma 
base, 100 mM NaCl, [pH 7.4]) at room temperature. The mixture was applied onto the 5 
ml IMAC (Ni-NTA) column followed by the washing and protein elution steps as 
described in the Methods Chapter. The wash and elution fraction were collected, 
concentrated to ~ 1ml and analysed for the presence of FADD-FL and DDEDs caspase-
8 (C360A) by using 15% SDS-PAGE and Western blot.  
 
Additionally, a pull-down assay was performed for the control GST/thrombin-C-(His)6 and 
untagged DDEDs caspase-8 (C360A). The control protein was expressed by using the 
pGEX-4T-3 system followed by purification on the IMAC and SEC columns, as described 
earlier in this Chapter. In principle, the assay was carried out in the same manner as for 
C-(His)6-tagged FADD-FL and untagged DDEDs caspase-8 (C360A), followed by 15% 
SDS-PAGE and Western blot analysis (Figure 52).   
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Figure 52.  The principle and steps of the FADD / caspase-8 pull-down assay. 
For this assay, C-(His)6 FADD-FL (bait protein) and untagged DDEDs caspase-8 (C360A) (prey 
protein) were used. The bait protein contains the C-terminal (His)6 tag, which can bind to the Ni-
NTA resin. The prey protein remains untagged, thus it can only bind to the bait protein, if an 
interaction between the proteins of interest occurs. C-(His)6 FADD-FL and untagged DDEDs 
caspase-8 (C360A) were mixed at equimolar ratio of 10 µM and incubated in the reaction buffer 
(50 mM Trizma base, 100 mM NaCl, [pH 7.4]) at room temperature. The mixture was applied onto 
the IMAC (Ni-NTA) column. Next, the column was washed in order to remove any excess or 
unbound proteins. Then, the bound proteins of interest were eluted from the column. The wash 
fractions and protein eluates were collected separately and concentrated. Equal volumes (30 µl) 
of the wash and elution fractions were loaded onto 15% SDS-PAGE and analysed by Western 
blot.14 
 
 
As shown in Figure 53A, C-(His)6-tagged FADD-FL eluted in fraction 2 and 3, whereas 
untagged DDEDs caspase-8 (C360A) eluted in fraction 2. The levels of the eluted 
proteins were similar to the levels of their controls. Interestingly, the amount of untagged 
 
14 Image created with BioRender.com 
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DDEDs caspase-8 (C360A) that eluted in fraction 2 was comparable with the amount of 
C-(His)6-tagged FADD-FL, which eluted in the same fraction. The proteins of interest 
were not detected in the wash fractions. The results obtained for the control assay 
showed that C-(His)6 GST and untagged DDEDs caspase-8 (C360A) eluted in fraction 2 
(Figure 53B). The levels of C-(His)6 GST were similar to the amount of the controls in 
lanes 1 and 2. Importantly, the levels of eluted untagged DDEDs caspase-8 (C360A) 
were decreased, when compared with the controls in lanes 2 and 3, as well as control 
C-(His)6 GST (Figure 53B). the proteins of interest were not detected in the wash 
fractions. 
 
Additionally, we performed the Western blot analysis for elution fractions obtained from 
both assays, which were run on one SDS-PAGE. The analysis was carried out in order 
to compare the levels of eluted untagged DDEDs caspase-8 (C360A) during both assays 
(Figure 53C) and to confirm the reliability of the C-(His)6 FADD-FL / untagged DDEDs 
caspase-8 (C360A) experiment. We observed that amount of eluted protein (indicated 
by the red arrow) during the control C-(His)6 GST / untagged DDEDs caspase-8 (C360A) 
assay was markedly reduced, when compared with the protein levels eluted during the 
C-(His)6 FADD-FL / untagged DDEDs caspase-8 (C360A) pull-down assay and the 
controls in lanes 1, 2 and 3 (Figure 53C). Thus, our data suggest that C-(His)6 FADD-FL 
and DDEDs caspase-8 (C360A) were capable to bind in vitro.  
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Figure 53. FADD / caspase-8 pull-down assay with controls and comparison blot.  
A. Purified C-(His)6-tagged FADD-FL (bait protein) and untagged DDEDs caspase-8 (C360A) 
(prey protein) were mixed at equimolar ratio of 10 µM and incubated in the reaction buffer (50 mM 
Trizma base, 100 mM NaCl, [pH 7.4]) at room temperature. The mixture was applied onto the 5 
ml IMAC (Ni-NTA) column, which was then attached to AKTA PrimePlus. The column was 
washed, and the proteins were eluted. The wash and elution fraction were collected, concentrated 
and analysed for the presence of FADD and DDEDs caspase-8 (C360A) by using 15% SDS-
PAGE and Western blot. The antibodies against FADD and aspase-8 p18 subunit were used in 
order to detect the proteins of interest. B. The control GST/thrombin-C-(His)6 and untagged 
DDEDs caspase-8 (C360A) assay and analysis were carried out in the same manner as for C-
(His)6-tagged FADD-FL and untagged DDEDs caspase-8 (C360A). The antibodies against GST 
tag and aspase-8 p18 subunit were used in order to detect the proteins of interest. C. Comparison 
blot for elution fractions obtained during both C-(His)6-tagged FADD-FL / untagged DDEDs 
caspase-8 (C360A) (middle), and GST/thrombin-C-(His)6 / untagged DDEDs caspase-8 (C360A) 
(right; elution fraction 2 indicated by the red arrow) assays. The eluates were analysed for the 
levels of caspase-8. An antibody against caspase-8/p18 subunit was used to detect the protein. 
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CHAPTER	4	
RESULTS	–	PART	II	
	
Regulation	of	the	FADDosome	Formation	in	
Response	to	Chemotherapeutic	Drugs15	
 
 
 
 
 
15 Some results from this Chapter have been published in:  
Mohr, A., Deedigan, L., Jencz, S., Mehrabadi, Y., Houlden, L., Albarenque, S.-M. and 
Zwacka, R.M. (2018). Caspase-10: a molecular switch from cell-autonomous apoptosis 
to communal cell death in response to chemotherapeutic drug treatment. Cell Death & 
Differentiation, 25(2), 340–352. 
 192 
4.1 ATR	 But	 Not	 ATM	 is	 Phosphorylated	 in	 HCT.shctrl	
Cells	Exposed	to	5-FU	
 
The ATR and ATM kinases play a crucial role in the conventional DNA damage response 
machinery. Induction of the DNA lesions contributes to autocatalytic phosphorylation of 
ATR and ATM, which is a hallmark of their active state. Activation of these kinases leads 
to phosphorylation of a wide range of proteins involved in the DNA damage response 
signalling. Thus, we wondered, whether these kinases could be involved in translation 
of the 5-FU-induced DNA damage into apoptotic signals and the subsequent 
FADDosome formation. With respect to this, our first aim was to test, whether ATR and 
ATM were phosphorylated in response to 5-FU in cancer cells.  
 
To examine this, we used HCT.shctrl cells, a stable control knockdown, derived from 
HCT116 human colorectal cancer cells. This derivative was generated with an empty 
knockdown plasmid and was subjected to the same experimental procedure, that was 
used for generation of the other stable knockdowns used in this study. In principle, 
HCT.shctrl and HCT116 cells respond in the same way to treatment with 5-FU. 
HCT.shctrl cells were exposed to 5-FU for 2 h, 4 h, 8 h, 15 h and 24 h. The untreated 
cells (0 h) serves as a control. The cells were analysed for ATR and ATM activation by 
using antibodies against the Thr1989 and Ser1981 phosphorylation sites, respectively. 
Moreover, the cells were assessed for the endogenous levels of ATR and ATM using the 
total ATR and ATM antibodies, respectively.  
 
The results obtained by Western blot revealed that ATR was phosphorylated in 
HCT.shctrl cells in response to 5-FU. We observed that the ATR phosphorylation levels 
were gradually increasing after 2 h, 4 h and 8 h treatment with 5-FU and slightly 
decreasing after 15 h and 24 h exposure to the drug. it was also found that 
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phosphorylation of ATM was not elevated in HCT.shctrl cells subjected to the anti-tumour 
drug. Furthermore, the levels of total ATR and ATM were increased in HCT.shctrl cells 
untreated and treaded with 5-FU.  
 
The chemotherapeutic drug-induced cytotoxic stress typically contributes to 
accumulation of proteins involved in regulation of the cell cycle, such as p53. Thus, 
HCT.shctrl cells were examined for the levels of p53 in response to 5-FU. As expected, 
p53 levels were gradually increasing after exposure to 5-FU (Figure 54). 
 
The obtained results indicate that ATR, but not ATM, undergoes phosphorylation after 
the treatment with 5-FU, which suggest that this kinase acts as the key sensor of the 
DNA damage cause by 5-FU in HCT.shctrl cells. Moreover, the results showed that p53 
was accumulated in response to 5-FU, which indicated that HCT.shctrl cells were able 
to respond to 5-FU-inflicted DNA damage. 
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Figure 54.  Treatment with 5-FU promotes ATR phosphorylation in HCT.shctrl cells. 
Exposure to 5-FU causes an increase of ATR phosphorylation after 2 h, 4 h and 8 h and its slight 
decrease after 15 h and 24 h, whereas ATM phosphorylation was not elevated in response to the 
anti-tumour drug. Upon treatment with 5-FU, the levels of p53 induction were gradually elevating 
and proportionally to the time of incubation. Moreover, the levels of total ATR and ATM were 
elevated in HCT.shctrl cells untreated and treated with 5-FU. The protein extracts of HCT.shctrl 
cells untreated and treated with 5-FU (200 µM) for 0, 2, 4, 8, 15 and 24 h were subjected to 
Western blot analysis and assessed for the phosphorylation status of ATR and ATM. Additionally, 
the cells were examined for the p53 levels in response to the same treatment. Total ATR, total 
ATM and CuZnSOD were used as loading controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(no increase) 
(loading control) 
 195 
4.2 Inhibition	 and	 Silencing	 of	 ATR	 Strongly	 Decreases	
Chk1	and	Chk2	Phosphorylation	Levels	 in	Response	
to	5-FU	
 
Activation of Chk1 and Chk2 kinases via ATR- and ATM-mediated phosphorylation, 
respectively, has been widely described in the context of the conventional DNA damage 
response model and DNA repair. Similar to ATR and ATM, our knowledge of the roles 
of Chk1 and Chk2 in the genotoxic stress-induced apoptosis remains sparse. Moreover, 
it remains unknown, whether activation of Chk1 and Chk2 is regulated by ATR and/or 
ATM, respectively, in response to chemotherapeutic drug-induced apoptosis. In order to 
clarify this, we used HCT.shctrl cells, which were pre-treated with ATR kinase inhibitor 
(AZD6738) or/and ATM kinase inhibitor (KU55933) 30 min prior to the addition of 5-FU.  
The HCT.shctrl cells, that were exposed to DMSO only or DMSO plus 5-FU served as a 
control. The cells were then incubated for 24 h and analysed by Western blot for Chk1 
and Chk2 activation using antibodies against the Ser317 and Thr68 phosphorylation 
sites, respectively. Antibodies against total Chk1 and Chk2 were used to assess the 
endogenous levels of Chk1 and Chk2, respectively.  
 
The results showed that upon exposure to 5-FU, the Chk1 and Chk2 phosphorylation 
levels were strongly increased in HCT.shctrl cells. Moreover, we observed that in the 
presence of ATR inhibitor the levels of phosphorylated Chk1 and Chk2 were 
considerably reduced in HCT.shctrl cells after treatment with 5-FU, when compared to 
HCT.shctrl cells subjected to the anti-tumour drug alone. Moreover, after application of 
the ATM inhibitor, the levels of phosphorylated Chk1 were increased to the same degree 
in response to 5-FU as in HCT.shctrl cells exposed to the chemotherapeutic alone. 
Interestingly, we observed that Chk2 phosphorylation was elevated in the HCT.shctrl 
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cells treated with 5-FU alone, whereas it was strongly reduced in the cells exposed to 
ATR or ATM inhibitor combined with 5-FU (Figure 55). 
 
As expected, we observed that application of both ATR and ATM inhibitors lead to 
reduction of Chk1 and Chk2 phosphorylation levels in HCT.shctrl cells treated with 5-FU. 
These results showed that ATM was dispensable for 5-FU-induced phosphorylation of 
Chk1, however both ATR and ATM were required for Chk2 phosphorylation in response 
to 5-FU. Interestingly, the levels of total Chk1 and total Chk2 were markedly reduced in 
response to treatment with 5-FU plus ATR and ATM inhibitors (Figure 55).  
 
As previously, the cells were examined for the levels of p53. As shown in Figure 55, 
inhibition of ATR, but not ATM blocked the 5-FU-induced increase in p53. The same 
event was observed in response to exposure to 5-FU combined with ATR and ATM 
inhibitors. Thus, the results indicate, that activation of Chk1 and induction of p53 are 
ATR-dependent, whereas activation of Chk2 is mediated by both ATR and ATM.  
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Figure 55.  Chk1 and Chk2 phosphorylation status in HCT.shctrl cells exposed to 5-FU 
alone or 5-FU plus ATR inhibitor or/and ATM inhibitor. 
Treatment with 5-FU caused a strong increase of Chk1 and Chk2 phosphorylation in the control 
(HCT.shctrl plus DMSO) cells. Addition of the ATR inhibitor AZD6738 led to considerable 
decrease of the Chk1 and Chk2 phosphorylation in response to 5-FU. Exposure to the ATM 
inhibitor KU55933 caused a strong reduction of Chk2, but not Chk1 phosphorylation after 
treatment with 5-FU. Application of both ATR and ATM inhibitors led to decrease of the Chk1 and 
Chk2 phosphorylation as well as total Chk1 and Chk2 levels in response to 5-FU. Moreover, the 
levels of p53 induction were markedly increased in the 5-FU-induced control cells. Application of 
the ATR inhibitor alone or ATR and ATM inhibitors blocked the p53 induction in response to 5-
FU. In contrast, addition of the ATM inhibitor alone did not block the p53 induction after treatment 
with 5-FU. HCT.shctrl cells were exposed to ATR inhibitor AZD6738 (2 µM) or/and ATM inhibitor 
KU55933 (2 µM) and then untreated or treated with 5-FU followed by incubation for 24 h. The 
HCT.shctrl cells, that were exposed to DMSO only or DMSO plus 5-FU served as a control. The 
cells were checked for Chk1 and Chk2 phosphorylation by using Western blot. Additionally, the 
cells were assessed for the levels of p53 protein. Total Chk1, total Chk2 and CuZnSOD served 
as loading controls.  
 
 
To further examine the role of ATR in phosphorylation of its downstream targets in 5-FU-
induced cell death, we generated a stable ATR knockdown clone of HCT116 cells named 
HCT.shATR. It was confirmed by Western blot that HCT.shATR cells harboured no 
detectable ATR levels (Figure 56A).  
 
After being treated with 5-FU, HCT.shctrl and HCT.shATR cells were subjected to 
Western blot and analysed for the levels of phosphorylated Chk1 and Chk2. Our results 
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showed that Chk1 phosphorylation was strongly increased in HCT.shctrl cells treated 
with 5-FU. In contrast, we observed an almost complete inhibition of Chk1 
phosphorylation in HCT.shATR cells in response to the anti-tumour drug (Figure 56B). 
Moreover, while the chemotherapeutic drug-induced phosphorylation of Chk2 was 
slightly increased in HCT.shctrl cells, HCT.shATR cells showed almost no detectable 
phosphorylated Chk2. As expected, p53 levels were strongly decreased in 5-FU-treated 
cells with knocked down ATR. These results further confirm the requirement of ATR for 
phosphorylation of both Chk1 and Chk2 as well as induction of p53 in response to 5-FU. 
(Figure 56B). 
 
Therefore, the obtained results indicate that, similar to ATR, the Chk1 and Chk2 kinases 
undergoes phosphorylation upon exposure to 5-FU and play a role in the DNA damage 
signalling in 5-FU-induced apoptosis in HCT.shctrl cells. Moreover, these findings 
indicate that Chk1 activation and p53 accumulation are regulated by ATR, whereas Chk2 
activation is mediated by both ATR and ATM in response to 5-FU. Thus, the above 
observations suggest that upon the 5-FU-induced DNA damage, activated ATR signals 
towards its downstream targets, Chk1/Chk2 and p53, leading to their subsequent 
activation and accumulation, respectively.  
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   A     B 
 
 
Figure 56.  Levels of 5-FU-induced Chk1 and Chk2 phosphorylation in HCT.shATR cells. 
A. HCT.shATR cells are unable to express ATR protein, when compared to HCT.shctrl cells. The 
cell extracts were subjected to Western blot analysis and assessed for the levels of ATR. 
CuZnSOD served as a loading control. B. Treatment with 5-FU led to considerable increase of 
Chk1 and Chk2 phosphorylation as well as p53 induction in HCT.shctrl cells. On the contrary, 
knocking down of ATR caused an almost complete inhibition of Chk1 and Chk2 phosphorylation 
as well as p53 induction in 5-FU-treated HCT.shATR cells. The HCT.shctrl (control) and 
HCT.shATR cells were untreated or treated with 5-FU for 24 h followed by Western blot analysis. 
The blots were assessed for the levels of phosphorylated Chk1 and Chk2. Additionally, the cells 
were examined for the p53 levels in response to the same treatment. Total Chk1, total Chk2 and 
CuZnSOD were used as loading controls. 
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4.3 Inhibition	 and	 Silencing	 of	 ATR	 Lead	 to	 a	 Strong	
Reduction	 of	 Caspase-10	 Upregulation	 Levels	 After	
the	5-FU	Treatment	
 
Next, we wondered, whether ATR and/or ATM could regulate the 5-FU-induced 
upregulation of caspase-10 and subsequent FADDosome formation. In order to elucidate 
that, we used HCT.shctrl cells, which were pre-treated with ATR inhibitor (AZD6738) 
or/and ATM inhibitor (KU55933) for 30 min and then incubated with or without 5-FU for 
24 h. The HCT.shctrl cells, that were exposed to DMSO only or DMSO plus 5-FU were 
utilised as a control. The cells were analysed by Western blot and assessed for capsase-
10 upregulation levels. 
 
The results showed that caspase-10 upregulation was strongly elevated in the control 
(HCT.shctrl plus DMSO) cells in response to 5-FU. Interestingly, we found that blocking 
of ATR led to a complete abrogation of caspase-10 upregulation after treatment with 5-
FU. Moreover, the results unveiled, that in the presence of ATM inhibitor, caspase-10 
was upregulated to a similar degree as in the HCT.shctrl cells. Additionally, like the result 
obtained for the ATR inhibitor plus 5-FU treatment, blocking of both ATR and ATM 
contributed to a strong reduction of caspase-10 upregulation in response to 5-FU (Figure 
57). Our data indicate that 5-FU-induced caspase-10 upregulation is ATR-dependent 
and ATM-independent in apoptosis triggered by 5-FU.  
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Figure 57. Levels of upregulated caspase-10 in HCT.shctrl cells treated with 5-FU alone or 
5-FU plus ATR inhibitor or/and ATM inhibitor. 
Upon treatment with 5-FU, upregulation of caspase-10 was strongly increased in the control 
(HCT.shctrl plus DMSO) cells. Exposure to the ATR inhibitor alone or ATR and ATM inhibitors 
markedly reduced the caspase-10 upregulation levels in response to 5-FU. In contrast, addition 
of the ATM inhibitor alone did not decrease the caspase-10 upregulation after treatment with 5-
FU. HCT.shctrl cells were exposed to ATR inhibitor AZD6738 (2 µM) or/and ATM inhibitor 
KU55933 (2 µM) with or without 5-FU and then incubated for 24 h. The HCT.shctrl cells, that were 
exposed to DMSO only or DMSO plus 5-FU were utilised as a control. The cells were assessed 
for the levels of upregulated caspase-10 by using Western blot. CuZnSOD was used as a loading 
control. 
 
 
 
In order to further elucidate the role of ATR in anti-cancer drug-induced caspase-10 
upregulation, we used HCT.shATR cells and assessed them for the caspase-10 levels 
in response to 5-FU. The results obtained by Western blot showed that caspase-10 was 
no longer upregulated in HCT.shATR cells subjected to the chemotherapeutic drug 
treatment (Figure 58). Such observation confirmed the results obtained for HCT.shctrl 
cells treated with combination of 5-FU and ATR inhibitor (Figure 57). Thus, these findings 
further confirm the requirement of ATR for caspase-10 upregulation in 5-FU-induced 
apoptosis. 
 
The obtained results demonstrate that the signal form the 5-FU-induced DNA damage is 
transduced by activated ATR towards caspase-10, leading to its upregulation and 
subsequent apoptosis-inducing FADDosome complex formation.   
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Figure 58. Induction of caspase-10 upregulation by ATR kinase in response to 5-FU. 
Treatment with was 5-FU contributed to elevation of caspase-10 upregulation in HCT.shctrl cells. 
In contrast, caspase-10 was no longer upregulated in cells with knocked down ATR, namely 
HCT.shATR, after treatment with 5-FU. The HCT.shctrl (control) and HCT.shATR cells were 
untreated or treated with 5-FU. After incubation for 24 h, the cells were analysed for caspase-10 
upregulation levels by Western blot. CuZnSOD was used as a loading control.  
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4.4 Loss	of	p53	and	Caspase-10	Does	Not	affect	Chk1	and	
Chk2	Phosphorylation	Levels	in	Response	to	5-FU	
 
In this study, it was found that when ATR was inhibited or silenced, phosphorylation of 
Chk1 and Chk2, induction of p53 and upregulation of caspase-10 were strongly reduced 
in response to 5-FU. In order to explore the DNA-damage initiated signalling pathway 
and examine the order of molecular events downstream of ATR in more detail, the cells 
that were knocked out for p53 (HCT.p53-/-) and knocked down for caspase-10 
(HCT.shC10) were used. The HCT.p53-/- cells were a gift from Bert Vogelstein, whereas 
the HCT.shCaspase-10 cells were generated using RNA interference (RNAi), as 
described in the Methods. It was confirmed by Western blot that HCT.p53-/- and 
HCT.shCaspase-10 cells harboured no detectable p53 and caspase-10, respectively 
(Figure 59A and B). 
 
A      B 
 
Figure 59. Validation of the p53 knockout (HCT.p53-/-) and caspase-10 knockdown 
(HCT.shC10) cells. 
A. The levels of p53 are considerably increased HCT.shctrl (control cells) in response to 5-FU. 
Untreated and 5-FU-treated HCT.p53-/- cells are unable to express p53 protein, when compared 
to HCT.shctrl cells. The cell extracts were subjected to Western blot analysis and assessed for 
the levels of p53. CuZnSOD served as a loading control. B. Upregulation of caspase-10 is 
markedly elevated HCT.shctrl (control cells) after exposure to 5-FU. Untreated and 5-FU-treated 
HCT.shC10 cells are unable to express caspase-10, when compared to HCT.shctrl cells. The cell 
extracts were analysed using Western blot and assessed for the levels of caspase-10. CuZnSOD 
was utilised as a loading control. 
C10 – caspase-10. 
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The HCT.shctrl, HCT.p53-/- and HCT.shC10 cells were untreated and treated with 5-FU 
for 24 h and subjected to Western blot analysis, in order to assess the Chk1 and Chk2 
phosphorylation levels in response to 5-FU. As illustrated in Figure 58, the Chk1 and 
Chk2 phosphorylation levels were not increased in the untreated HCT.p53-/- cells. In 
contrast, exposure to 5-FU led to considerable elevation of the Chk1 and Chk2 
phosphorylation in HCT.p53-/- cells (Figure 60). These observations were comparable 
with the results obtained for HCT.shctrl cells untreated and treated with the anti-cancer 
drug. The obtained results suggest that in 5-FU-induced apoptosis Chk1 and Chk2 
activation is triggered in the p53-dependent manner.  
 
 
 
 
Figure 60. Levels of 5-FU-induced Chk1 and Chk2 phosphorylation in HCT.p53-/- cells. 
In untreated HCT.shctrl and HCTp53-/- cells, the levels of Chk1 and Chk2 phosphorylation were 
not increased, whereas treatment with 5-FU contributed to a strong elevation of phosphorylated 
Chk1 and Chk2 in these cell lines. The HCT.shctrl (control) and HCT.p53-/- cells were untreated 
and treated with 5-FU for 24 h followed by Western blot analysis. The blots were assessed for 
the levels of phosphorylated Chk1 and Chk2. Total Chk1, total Chk2 and CuZnSOD served as 
loading controls. 
 
 
 
Moreover, it was observed that the phosphorylation of Chk1 and Chk2 was not elevated 
in untreated HCT.shC10 cells. In contrast, it was found that both Chk1 and Chk2 were 
phosphorylated in HCT.shC10 cells in response to 5-FU. Importantly, the levels of Chk1 
and Chk2 phosphorylation in the absence of caspase-10 were increased to the same 
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degree as in HCT.shctrl cells subjected to treatment with the chemotherapeutic drug. 
(Figure 61). This suggest that Chk1 and Chk2 activation occurs upstream of caspase-
10.  
 
In order to check, whether HCT.shC10 cells mounted the same response to treatment 
with 5-FU as the HCT.shctrl cells, the cells were assessed for the levels of p53 and p21. 
We observed that induction of p53 and p21 was strongly increased in HCT.shC10 cells 
exposed to 5-FU. The observation was comparable to the results obtained for HCT.shctrl 
cells subjected to the same treatment (Figure 61). This suggests that there is no 
fundamental difference in the action of 5-FU in parental and caspase-10-silenced cells, 
i.e. p53 upregulation is not caspase-10-dependent. 
 
 
 
Figure 61. Levels of Chk1 and Chk2 phosphorylation in 5-FU-treated HCT.shC10 cells. 
In untreated HCT.shctrl and HCT.shC10, the levels of Chk1 and Chk2 phosphorylation were not 
increased, whereas treatment with 5-FU contributed to a strong elevation of phosphorylated Chk1 
and Chk2 in these cell lines. The HCT.shctrl (control) and HCT.shC10 cells were untreated and 
treated with 5-FU for 24 h. The whole cell extracts were analysed for Chk1 and Chk2 
phosphorylation levels by Western blot. The cells were also assessed or the levels of 5-FU-iduced 
p53 and p21. Total Chk1, total Chk2 and CuZnSOD were utilised as loading controls.  
C10 – caspase-10. 
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The above findings suggest that upon the 5-FU-induced DNA damage, activation of 
Chk1 and Chk2 occurs independently of p53 and upstream of caspase-10. Moreover, it 
was found that caspase-10 was dispensable for induction of p53 in 5-FU-induced 
apoptosis. Taken these and our previous results showing that caspase-10 upregulation 
and FADDosome formation were p53-independent (Mohr et al., 2018), it appears that 
p53 possibly regulates a different pathway of apoptosis in HCT.shctrl cells treated with 
5-FU.  
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4.5 Treatment	with	the	Chk	Inhibitor,	CHIR-124,	Blocks	
Chk1	and	Chk2	Phosphorylation	After	Exposure	to	5-
FU	or	Etoposide	
 
Next, it was asked, whether Chk1 and Chk2 play a role in the anti-cancer drug-induced 
apoptosis. To be more specific, the question arised, whether these kinases could act 
downstream of ATR to signal to caspase-10 and FADDosome-mediated cell death and 
whether they could be involved in determining the mode of apoptosis (FADDosome vs. 
FLIPosome).  
 
In order to find out, HCT.shctrl cells were used and treated with 5-FU or etoposide alone 
as well as the combination of CHIR-124 and 5-FU or etoposide. The HCT.shctrl cells, 
that were exposed to DMSO only or DMSO plus 5-FU or etoposide were used as a 
control. The cells were incubated for 24 h and analysed by Western blot for Chk1 and 
Chk2 phosphorylation levels in order to validate the action of the kinase inhibitor.  
 
The Western blot analysis showed that in response to CHIR-124 plus 5-FU the levels of 
phosphorylated Chk1 and Chk2 were markedly decreased in HCT.shctrl cells, when 
compared to the control (HCT.shctrl plus DMSO) cells exposed to the chemotherapeutic 
drug. The observation was comparable to the results obtained for HCT.shctrl cells 
subjected to the CHIR-124 plus etoposide treatment, which also showed a considerable 
reduction of Chk1 and Chk2 phosphorylation levels (Figure 62). These findings indicate 
that CHIR-124 can block phosphorylation of both Chk1 and Chk2.  
 
Additionally, it was checked, whether the HCT.shctrl cells stimulated with CHIR-124 plus 
5-FU or etoposide mount the same response to the treatment as the HCT.shctrl cells 
exposed to 5-FU or etoposide alone. We observed that induction of p53 and p21 was 
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highly elevated in HCT.shctrl cells treated with CHIR-124 plus 5-FU or etoposide. The 
observation was comparable to the results obtained for HCT.shctrl cells subjected to the 
5-FU or etoposide treatment alone (Figure 62). This indicates that there is no 
fundamental difference in the action between CHIR-124 combined with 5-FU or 
etoposide and 5-FU or etoposide alone.  
 
Therefore, these results demonstrate the functionality of the CHIR-124 inhibitor, which 
effectively blocked Chk1 and Chk2 phosphorylation upon exposure to 5-FU or etoposide.  
 
 
Figure 62. . Levels of phosphorylated Chk1 and Chk2 in HCT.shctrl cells exposed to 5-FU 
or etoposide alone and CHIR-124 plus 5-FU or etoposide. 
Upon treatment with 5-FU or etoposide, Chk1 and Chk2 undergo phosphorylation in HCT.shctrl 
cells. Application of CHIR-124 blocked the Chk1 and Chk2 phosphorylation in HCT.shctrl cells 
exposed to 5-FU or etoposide. HCT.shctrl cells were treated with the combination of Chk1/Chk2 
inhibitor CHIR-124 (250 nM) plus 5-FU or etoposide. HCT.shctrl cells exposed to DMSO only or 
DMSO plus 5-FU or etoposide were utilised as a control. The cells were incubated for 24 h and 
tested for Chk1 and Chk2 phosphorylation by using Western blot. Additionally, the cells were 
assessed for the levels of induced p53 and p21 in response to the treatments. Total Chk1, total 
Chk2 and CuZnSOD served as loading controls.  
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4.6 Inhibition	 with	 CHIR-124	 Reduces	 Caspase-10	
Upregulation	Levels	After	the	Treatment	with	5-FU	
 
To examine, whether Chk1 and Chk2 kinases could be involved in signal transduction 
leading to caspase-10 upregulation and FADDosome-mediated apoptosis, HCT.shctrl 
cells were used and stimulated with 5-FU or etoposide alone as well as the combination 
of CHIR-124 and 5-FU or etoposide. The HCT.shctrl cells exposed to DMSO only or 
DMSO plus 5-FU or etoposide served as a control. It was necessary to examine the roles 
of Chk1 and Chk2 in caspase-10 upregulation in HCT.shctrl cells treated with both 
chemotherapeutic drugs, as the aim was to determine, whether these kinases could be 
involved in caspase-10 upregulation specifically in response to 5-FU or whether such 
molecular event was important for apoptosis induced by other anti-tumour drugs as well. 
Etoposide is described as a topoisomerase inhibitor, forming a complex with 
topoisomerase II, which leads to DNA damage and gives rise to DNA double strand 
breaks. In contrast, 5-FU is believed to cause DNA damage by giving rise to single-
strand breaks. 
 
The HCT.shctrl cells subjected to the respective treatments were incubated for 24 h and 
assessed for the levels of upregulated caspase-10 by using Western blot. As illustrated 
in Figure 54, caspase-10 upregulation was markedly increased in the control (HCT.shctrl 
plus DMSO) cells treated with 5-FU (Figure 63). Importantly, the results showed that 
application of CHIR-124 led to a considerable reduction of caspase-10 upregulation in 
response to 5-FU (Figure 63). Furthermore, it was observed observed that caspase-10 
upregulation levels were not elevated in response to etoposide (Figure 63). In this 
context, treatment with CHIR-124 and etoposide did not affect the caspase-10 levels. 
These findings indicate that caspase-10 upregulation is Chk1/Chk2-dependent in 5-FU-
induced apoptosis and that this molecular event is specific for 5-FU.  
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Therefore, the obtained results suggest that, similar to ATR, activated Chk1 and Chk2 
are responsible for signal transduction from the 5-FU-induced DNA damage site towards 
upregulation of caspase-10 and thereby acts as regulators of the FADDosome formation 
in HCT.shctrl cells.   
 
 
Figure 63. Caspase-10 upregulation status in HCT.shctrl cells exposed to 5-FU or 
etoposide alone and CHIR-124 plus 5-FU or etoposide. 
In the control HCT.shctrl cells exposed to DMSO, caspase-10 upregulation was strongly 
increased in response to treatment with 5-FU, but not etoposide. Treatment with Chk1/Chk2 
inhibitor CHIR-124 considerably reduced the caspase-10 upregulation levels after stimulation with 
5-FU. Exposure to CHIR-124 and etoposide did not affect the caspase-10upregulation levels in 
HCT.shctrl cells. HCT.shctrl cells were stimulated with Chk1/Chk2 inhibitor CHIR-124 (250 nM) 
plus 5-FU or etoposide. The HCT.shctrl cells exposed to DMSO only or DMSO plus 5-FU or 
etoposide served as a control. After incubation for 24 h, the cell lysates were examined for the 
levels of caspase-10 by using Western blot. CuZnSOD was utilised as a loading control. 
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4.7 Inhibition	 with	 CHIR-124	 Significantly	 Increases	
Apoptosis	Levels	in	Response	to	5-FU		
 
In order to assess the role of Chk1 and Chk2 in the regulation anti-cancer drug-induced 
apoptosis, HCT.shctrl cells were used and treated with 5-FU alone and the 5-FU/CHIR-
124 combination. The cells were incubated for 24 and 48 h and analysed by DNA 
hypodiploidy assay for apoptosis measurement. The obtained measurement data were 
plotted as average apoptosis and specific apoptosis results. The average apoptosis is 
represented by absolute cell death levels of untreated and treated cells. The specific 
apoptosis was obtained by subtraction of the basal cell death values from the apoptosis 
levels of cells exposed to treatments. Both average and specific apoptosis are expressed 
as mean values.  
 
As illustrated in Figure 55A, the levels of average apoptosis in HCT.shctrl cells treated 
with 5-FU alone and HCT.shctrl cells exposed to CHIR-124 inhibitor plus 5-FU were 
about 10.3% and 25.8%, respectively, after 24 h treatment. The levels of average 
apoptosis in 5-FU-treated HCT.shctrl cells and HCT.shctrl cells subjected to CHIR-124 
inhibitor plus 5-FU treatment were about 36.8% and 42.5%, respectively after 48 h 
treatment. The specific apoptosis results showed that for HCT.shctrl cells treated with 5-
FU alone and HCT.shctrl cells exposed to 5-FU plus CHIR-124 inhibitor, the levels of cell 
death were about 5.4% and 19.6%, respectively, after 24 h treatment. Moreover, for 5-
FU-treated HCT.shctrl cells and HCT.shctrl cells subjected to 5-FU plus CHIR-124 
inhibitor treatment, the specific apoptosis values were about 31.6% and 36.3% (Figure 
64B).  
 
These results indicate that application of CHIR-124 plus 5-FU led to a significant increase 
of cell death after 24 h, when compared with the 5-FU treatment alone (Figure 64A and 
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B). Following 48 h exposure to the CHIR-124/5-FU combination, the levels of apoptosis 
in HCT.shctrl cells were also strongly elevated, however such observation was 
comparable with the results obtained for HCT.shctrl cells stimulated with 5-FU alone 
(Figure 64A and B). We observed the same phenomenon in HCT116 cells, that were 
knocked down for ATR, caspase-10, RIP1, and TRAF2 and treated with 5-FU (Mohr et 
al., 2018). Further analysis revealed that these cells were able to switch to an alternative 
cell death mechanism, which required assembly of the FLIPosome platform (Mohr et al., 
2018).  
 
Thus, similar to our previous findings, the results obtained for HCT.shctrl cells exposed 
to CHIR-124 plus 5-FU suggest that the cells are might be able to switch to an alternative 
mode of apoptosis.  
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Figure 64. Levels of the average and specific apoptosis in HCT.shctrl cells treated with 
combination of CHIR-124 and 5-FU after 24 h and 48 h. 
A. Average apoptosis levels in HCT.shctrl cells after treatment with 5-FU only and CHIR-124 plus 
5-FU. The cells were exposed to the treatments for 24 and 48 h. The cell death was measured 
by using flow cytometry. Data are shown as mean values ± S.E.M, n=6. B. Levels of specific 
apoptosis in HCT.shctrl cells stimulated with 5-FU only and CHIR-124 plus 5-FU. The cells were 
subjected to the treatments for 24 and 48 h. The cell death measurements were performed by 
using flow cytometry. Data are shown as mean values ± S.E.M, n=6. 
 
B 
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4.8 Inhibition	 with	 CHIR-124	 Leads	 to	 Degradation	 of	
cIAP1	in	Response	to	5-FU	
 
Our group demonstrated previously that in the absence of ATR, caspase-10, RIP1 or 
TRAF2, the cells were able to switch to the FLIPosome-mediated apoptosis, of which 
one of the key features was the degradation of cIAP1 (Mohr et al., 2018). Moreover, the 
results obtained in this study have shown that apoptosis was significantly increased in 
the cells treated with CHIR-124/5-FU combination, suggesting an initiation of the 
FLIPosome-mediated cell death. In order to confirm that the cells were indeed able to 
switch to the FLIPosome, it was assessed, whether cIAP1 was degraded in response to 
Chk1/Chk2 inhibition. 
 
In order to test this hypothesis, HCT.shctrl cells were used and treated with a 
combination of CHIR-124 plus 5-FU. The HCT.shctrl cells exposed to DMSO only or 
DMSO plus 5-FU were used as a control. The cells were incubated for 24 h and checked 
for the levels of cIAP1 by Western blot. It was observed that the levels of cIAP1 were 
slightly decreased and almost completely lost in the cells treated with CHIR-124 alone 
and with CHIR-124 plus 5-FU, respectively, which was in contrast to the result obtained 
for HCT.shctrl cells treated with 5-FU (Figure 65). These observations confirmed that 
blocking of Chk1/Chk2 contributed to cIAP1 degradation in response to the 5-FU and 
indicated that the cells were able to switch to the FLIPosome-mediated mode of 
apoptosis in the absence of Chk1 and Chk2.  
 
Therefore, the described findings indicate that HCT.shctrl cells can switch to the 
alternative mechanisms of apoptosis, the FLIPosome, upon inhibition of Chk1 and Chk2 
activation and 5-FU treatment. Moreover, similar to the results obtained for the cells 
lacking caspase-10, ATR, RIP1 or TRAF2 (Mohr et al., 2018), the hallmark of the 
 215 
FLIPosome mode of apoptosis in HCT.shctrl cells with blocked Chk1 and Chk2 is that 
cIAP1 undergoes degradation in response to 5-FU.   
 
 
 
Figure 65. Levels of cIAP1 in HCT.shctrl cells stimulated with 5-FU alone and CHIR-124 
plus 5-FU. 
In the untreated and 5-FU-treated control (HCT.shctrl plus DMSO) cells, the levels of cIAP1 were 
considerably increased. The levels of cIAP1 were slightly decreased in response to CHIR-124 
alone and almost completely lost in the cells treated with CHiR-124 plus 5-FU. HCT.shctrl cells 
were stimulated with the combination of Chk1/Chk2 inhibitor CHIR-124 (250 nM) plus 5-FU. The 
HCT.shctrl cells exposed to DMSO only or DMSO plus 5-FU were used as a control. The cells 
were incubated for 24 h and assessed for cIAP1 levels by using Western blot. CuZnSOD was 
utilised as a loading control.  
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5.1 Discussion	
 
Application of 5-FU in anti-tumour therapies can improve the survival of patients with 
colorectal cancer. Nevertheless, acquisition of 5-FU-resitstance is still a common issue 
and a major cause of the limited clinical use of this chemotherapeutic agent (Longley et 
al., 2003). Moreover, our knowledge of the molecular mechanisms responsible for 
development of such resistance is still poor. Therefore, it is crucial to examine the factors 
and pathways involved in 5-FU-induced apoptosis in order to increase its therapeutic 
potential.  
 
Chemotherapeutic drugs exert their anti-tumour effect by induction of apoptosis, 
including initiation of the intrinsic and extrinsic cell death networks (Petak and Houghton, 
2001). A few novel apoptotic pathways and cell death-inducing protein complexes have 
been identified recently, which like the conventional intrinsic and extrinsic networks, have 
been reported to initiate apoptosis in cancer cells treated with chemotherapeutic drugs. 
It was described by Feokistova et al. (2011) and Tenev et al. (2011) that cell death can 
be triggered by the protein complex named RIPoptosome, which consists of caspase-8, 
FADD and RIP1. The authors reported that formation of this protein platform occurs in 
response to the treatment with IAP inhibitor alone or in combination with anti-tumour 
agents.  
 
Recently, our group has shown that apoptosis can be induced by caspase-8, but not 
caspase-9 upon stimulation with 5-FU, irinotecan or raltitrexed (Mohr et al., 2018). 
Moreover, we have demonstrated that caspase-8 activation does not require 
involvement of the death receptors, including TRAIL-R1/2, CD95 and TNF-R1, but is 
mediated by the novel, apoptosis-inducing signalling platform we termed FADDosome, 
which consists of caspase-10, caspase-8, FADD, cFLIP-L, RIP1 and TRAF2. The 
complex formation is driven by caspase-10, which is upregulated in a p53-independent 
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manner upon treatment with anti-tumour agents. Loss of ATR, caspase-10, RIP1 or 
TRAF2 contribute to the switch to an alternative cell death mechanism in cancer cells, 
which requires assembly of another, novel apoptosis-inducing protein complex, we 
termed FLIPosome, consisting of caspase-8 and cFLIP-L (Mohr et al., 2018).  
 
Thus, in this study it was asked, what is the biological importance and the exact roles of 
the main FADDosome constituents in terms of the complex formation and caspase-8 
activation. Moreover, it was asked, how the signal from the 5-FU-induced DNA-damage 
site is translated into cell death signals in cancer cells and what molecular factors are 
involved in this process. Therefore, it was set out to elucidate and better understand the 
functions of the main FADDosome components as well as to investigate the molecular 
details of the 5-FU-induced signalling pathway transducing signals from the DNA 
damage site towards the FADDosome.  
 
Part I of this study was focused on investigation of the functional relationships and 
interactions between its main FADDosome components, encompassing caspase-10, 
caspase-8, FADD and cFLIP-L, in the context of the complex formation and caspase-8 
activation. Firstly, the aim of the present research was to establish the expression 
constructs for human recombinant proteins of these factors, namely DDEDs caspase-10, 
DDEDs caspase-8, FADD-FL and DDEDs cFLIP-L, followed by establishment of the 
optimal expression and purification protocols for the respective proteins. The next aim 
was to express and purify the proteins of interest, followed by the analysis of their 
functional relationships and interactions in the context of the FADDosome.   
 
Part II of this study focused on examination of the molecular pathways responsible for 
transduction of the signal from 5-FU-induced DNA damage sites towards the apoptosis-
inducing protein complex, the FADDosome. It has been described that induction of 
genotoxic stress can activate the ATR/Chk1- and ATM/Chk2-mediated DNA damage 
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responses, including initiation of DNA repair and cell survival or apoptosis (Woods and 
Turchi, 2013; Weber and Ryan, 2015). In this context, ATR, ATM, Chk1 and Chk2 
seemed to be the most promising candidates, which we hypothesised could be involved 
in the 5-FU-induced DNA damage signalling as well as contribute to FADDosome 
formation followed by initiation of apoptosis in cancer cells. Thus, the aim of the present 
research was to examine the functions of the ATR/Chk1- and ATM/Chk2-signalling axes 
in terms of the anti-tumour drug-induced FADDosome assembly and apoptosis 
regulation in 5-FU-treated tumour cells. 
 
In summary, a better understanding of the roles of the main FADDosome constituents in 
the context of the complex formation and caspase-8 activation as well as of the molecular 
events of the DNA damage signalling towards the FADDosome, induced by 
chemotherapeutic agents, is a critical step towards designing new and more effective 
anti-tumour strategies, which can help bypass the drug resistance and defeat cancer. 
 
5.2 Expression	of	Human	Recombinant	Proteins	by	Using	
the	pET-28a	System	and	Their	Purification	
 
In order to reconstitute the FADDosome complex as well as to investigate the functional 
relationships and interactions between the main complex components in vitro, it was 
necessary to express these components, namely caspase-10, caspase-8, FADD and 
cFLIP-L, as recombinant proteins by using E. coli and to purify them by column 
chromatography. 
 
Firstly, it was focused on the cloning strategy and establishment of the protein expression 
constructs for human recombinant DDEDs caspase-10, DDEDs caspase-8, DDEDs 
cFLIP-L and FADD-FL, including the wild-type and mutated variants of the selected 
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proteins. The next step was to establish the most optimal protein expression and 
purification protocols for the respective proteins.  
 
By using the pET-28a system, the following expression constructs were successfully 
generated: DDEDs caspase-10 (wild-type, C401A active site and D415A linker mutants), 
DDEDs caspase-8 (wild type, C360A active site and D374A/D384A linker mutants), 
DDEDs cFLIP-L (wild-type) and FADD-FL (wild type, full-length). The DEDs of caspase-
10, caspase-8 and cFLIP-L were excluded in the DNA expression constructs as 
proposed by Denault and Salvesen (2002).  
 
Firstly, the expression levels of the wild type variants of the recombinant protein 
constructs were tested. The recombinant production was induced by using 0.1 mM (final 
concentration) IPTG and was carried out at 18°C overnight. We observed that N-(His)6 
DDEDs caspase-10 (wild-type), N-(His)6 DDEDs caspase-8 (wild-type), N-(His)6 DDEDs 
cFLIP-L (wild-type) and C-(His)6 FADD-FL were successfully expressed in the host 
BL21(DE3) cells. The analysis of the bacterial whole cell extracts revealed that the levels 
of expressed proteins of interest were decent and satisfactory, indicating that the chosen 
expression system and conditions for the recombinant production were good.  
 
Nevertheless, after the IMAC purification of N-(His)6 DDEDs caspase-10 (wild-type) and 
N-(His)6 DDEDs caspase-8 (wild-type) we found that the proteins were processed into 
smaller fragments. Since we were interested in purification of the desired proteins in their 
uncleaved forms, the cleaved N-(His)6 caspase-10 (wild-type) and N-(His)6 DDEDs 
caspase-8 (wild-type) could not be used for the purpose of this study. As expected, C-
(His)6 FADD-FL was purified in its full-length form, thus further processing and 
purification of this protein was performed. This resulted in obtaining a very good level of 
a highly pure C-(His)6 FADD-FL protein, satisfactory enough for experimental purposes.  
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Due to some unknown limitation(s), we were unable to purify N-(His)6 DDEDs cFLIP-L 
(wild-type) by using IMAC chromatography. The protein was not detectable in the elution 
fractions collected at the major elution peak at 280 nm. Undoubtedly, a self-processing 
of cFLIP-L was excluded, as this protein is not capable to proteolytically process itself 
like caspases. This is due to the fact that the cysteine residue, which is crucial for the 
enzymatic activity of caspases, is not present in the cFLIP-L structure. Shorter variants 
of cFLIP-L, such as cFLIP-S or cFLIP-R, are generated via alternative mRNA splicing, 
resulting in the smaller or lacking caspase-like domain, whereas the DEDs remain intact 
(Golks et al., 2005; Riley et al., 2015). Other variants of cFLIP, such as cFLIP-p43 and 
cFLIP-p22, are generated by the caspase-8-mediated cleavage (Tsuchiya et al., 2015). 
Thus, it was assumed that N-(His)6 DDEDs cFLIP-L (wild-type) could not be purified due 
to a few possible scenarios: (I) protein expression levels, which initially were satisfactory, 
were still too low to produce a good amount of the protein and/or (II) only a small part of 
the protein of interest was solubilised and isolated from inclusion bodies. Expanding the 
scale of the recombinant protein production and optimisation of solubilisation under 
denaturing conditions did not improve nor increase the yield after purification of N-(His)6 
DDEDs cFLIP-L (wild-type). Thus, a different protein expression system was considered.  
 
Next, the expression levels of DDEDs caspase-10 (C401A), DDEDs caspase-10 
(D415A), DDEDs caspase-8 (C360A) and DDEDs caspase-8 (D374A/D384A) constructs 
was examined. The recombinant production was induced by using 0.1 mM (final 
concentration) IPTG and incubated at 18°C overnight. Surprisingly, the levels of N-(His)6 
DDEDs caspase-10 (C401A) and N-(His)6 DDEDs caspase-10 (D415A) were very low, 
when expressed in the host BL21(DE3) cells. Further optimisation of the recombinant 
production conditions, such as an increased final concentration of IPTG (0.5 and 1 mM), 
did not improve the yield of the proteins of interest. After considering that these protein 
variants could be too toxic, when expressed in E. coli, we added glucose to a final 
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concentration of 1% to the bacteria medium. The role of glucose is to enable a more tight 
and controlled expression of the genes, when using the pET-28a system (or other pET 
vectors), which prevents the “leaky” expression of the inserted genes in their uninduced 
state and as a result, reduces the toxic effect on the host cells. As suggested by Denault 
and Salvesen (2002), a lower 0.02 mM (final concentration) of IPTG was used. These 
adjustments resulted in an increased expression levels of N-(His)6 DDEDs caspase-10 
(C401A) and N-(His)6 DDEDs caspase-10 (D415A), when compared with the previous 
method, which were satisfactory enough to process with purification steps. These results 
indicate, that addition of glucose and lowering of the IPTG concentration provided a more 
controlled, yet less stringent recombinant production conditions, which seemed to be 
preferable for N-(His)6 DDEDs caspase-10 (C401A) and N-(His)6 DDEDs caspase-10 
(D415A). 
 
Furthermore, similar to the N-(His)6 DDEDs caspase-8 (wild-type), N-(His)6 DDEDs 
caspase-8 (C360A) and N-(His)6 DDEDs caspase-8 (D374A/D384A) were successfully 
expressed in the host BL21(DE3) cells. The assessment of the bacterial whole cell 
extracts showed that the levels of the produced proteins were very high, when compared 
with the expression of the wild-type construct. This indicates that the chosen expression 
system and conditions for the recombinant production was optimal and that the 
expression of mutated variants was more efficient than the wild-type one.   
 
The selected N-(His)6 DDEDs caspase-10 (D415A) and N-(His)6 DDEDs caspase-8 
(C360A) were purified as full-length proteins, thus they were subjected to further 
processing (N-terminal (His)6 tag removal) and purification on SEC. Similar to C-(His)6 
FADD-FL, this resulted in obtaining a decent level of a highly pure DDEDs caspase-8 
(C360A), which could be used for experimental purposes. Purification of DDEDs 
caspase-10 (D415A) was also successful, however it resulted in a much lower yield, 
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which was only enough for selected experiments. Similar to N-(His)6 DDEDs cFLIP-L 
(wild-type), upscaling the recombinant protein expression and optimisation of 
solubilisation under denaturing conditions did not lead to obtaining higher yields after 
purification of DDEDs caspase-10 (D415A). Therefore, it was necessary to utilise a 
different system for protein production. 
 
In the case of all expressed constructs, the assessment of the protein solubility revealed 
that the proteins of interest were aggregated in inclusion bodies formed by the bacteria, 
which happens very commonly during expression of eukaryotic proteins in bacterial 
systems. Our observation was in contrast to some reports, which showed that caspases, 
including caspase-8 and -10, could be expressed as soluble proteins in E. coli (Blanchard 
et al., 1999; Denault and Salvesen, 2002; Yu et al., 2008). Moreover, Denault and 
Salvesen (2002) proposed a basic protocol and described a procedure for recombinant 
production and purification of caspases by using the IPTG-inducible pET expression 
system and BL21(DE3) cells. Even though in the present study we tested the same 
expression system as proposed by Denault and Salvesen (2002), the recombinant 
production of N-(His)6 DDEDs caspase-10 (wild type), N-(His)6 DDEDs caspase-10 
(D415A), N-(His)6 DDEDs caspase-8 (wild-type) and N-(His)6 DDEDs caspase-8 (C360A) 
resulted in formation of inclusion bodies. The same phenomenon was observed for N-
(His)6 DDEDs cFLIP-L (wild-type) and C-(His)6 FADD-FL. The temperature used for the 
protein expression was lower than suggested by Denault and Salvesen (2002), however 
it still did not prevent aggregation of the proteins in inclusion bodies.  
 
Some studies reported that expression of caspases, including caspase-8, resulted in a 
production of insoluble proteins (Garcia-Calvo et al., 1999; Watt et al., 1999; Keller et al., 
2009), which is consistent with our results. Similar to Garcia-Calvo et al. (1999), Watt et 
al. (1999) and Keller et al. (2009) we performed the solubilisation of inclusion bodies 
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under denaturing conditions by using a buffer containing 6M GuHCl (or 8M urea), which 
currently is the most commonly used technique for the protein isolation from inclusion 
bodies. It was described that alternatively, buffers containing detergents (such as Triton 
X-100 or sarkosyl) can be used to solubilise proteins form inclusion bodies or other fusion 
tags can be utilised to enhance the protein solubility after expression (such as the well-
known MBP (Maltose-binding protein), TrxA (thioredoxin), SUMO (Small ubiquitin 
modified) or NusA (N-utilization substance) (Costa et al., 2014). 
 
In the current study, using a buffer containing 6M GuHCl (or 8M urea) enabled the 
solubilisation of N-(His)6 DDEDs caspase-8 (wild-type), N-(His)6 DDEDs caspase-8 
(C360A), N-(His)6 DDEDs caspase-10 (wild-type), N-(His)6 DDEDs caspase-10 (D415A) 
and C-(His)6 FADD-FL with different effects and efficiency, but overall resulted in 
obtaining supernatants containing soluble proteins. Moreover, the circular dichroism 
analysis revealed that C-(His)6 FADD-FL, DDEDs caspase-8 (C360A) and DDEDs 
caspase-10 (D415A) were folded after purification, indicating a successful refolding of 
the proteins, which is critical to restore their functionality and/or activity.  
 
5.3 Expression	of	Human	Recombinant	Proteins	by	Using	
the	pGEX-4T-3	System	and	Their	Purification	
 
In the present study, several proteins, including C-(His)6 FADD-FL, untagged DDEDs 
caspase-8 (C360A) and untagged DDEDs caspase-10 (D415A) were successfully 
expressed by using the pET-28a system and purified. Purification of the first two proteins 
led to obtaining a good and satisfactory yield, whereas the yield of the third protein was 
low and only enough for selected experiments. When using the pET-28a system, 
purification N-(His)6 DDEDs cFLIP-L (wild type) was unsuccessful. It was assumed that 
this could be caused by too low protein expression levels and/or not efficient 
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solubilisation and isolation of the desired proteins from inclusion bodies. Moreover, a 
higher scale for the recombinant protein production and optimisation of solubilisation 
under denaturing conditions did not improve nor increase the yield of the proteins of 
interest after purification.  
 
In response to these findings, using a different protein expression system was 
considered, namely pGEX-4-T3 vector. Using this system could enable more efficient 
recombinant production and it allows expression of the proteins fused to the GST tag, 
which can act as the solubility enhancer (Costa et al., 2014). For this, an empty pGEX-
4T-3 vector was modified by inserting of DNA fragments containing C-terminal (His)6 tag 
with thrombin or TEV cleavage site. The (His)6 tag was added to facilitate purification on 
the Ni-NTA column and to utilise an already established protocol for the pET-28a system 
as a starting point. Therefore, only minor adjustments to the protein expression 
conditions would be required, when testing the pGEX-4-T3 system.  
 
By using the pGEX-4-T3 system, the expression vectors containing the same DNA 
constructs as designed for the pET-28a system were established. Additionally, the 
cleavage mutant of cFLIP-L (D376A) was generated. This resulted in a successful 
establishment of the following vectors: DDEDs caspase-10 (C401A), DDEDs caspase-
10 (D415A), DDEDs cFLIP-L (wild type) and DDEDs cFLIP-L (D376A) with both 
thrombin-(His)6 and TEV-(His)6 tags. Empty pGEX-4-T3/thrombin-(His)6 and DDEDs 
caspase-8 (C360A)/thrombin-(His)6 were generated to serve as controls.  
 
All established protein constructs were tested for the expression levels. The recombinant 
production was induced by using 0.1 mM (final concentration) IPTG and was carried out 
at 30°C for 3 h and 15 h (overnight). We observed that N-GST DDEDs caspase-10 
(C401A), N-GST DDEDs caspase-10 (D415A), N-GST DDEDs cFLIP-L (wild type) and 
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N-GST DDEDs cFLIP-L (D376A) with both thrombin-(His)6 and TEV-(His)6 tags as well 
as the control GST/thrombin-C-(His)6 and N-GST DDEDs caspase-8 (C360A)/thrombin-
C-(His)6 were successfully expressed in the host BL21-RIL cells. The examination of 
bacterial whole cell extracts unveiled that the levels of expressed proteins of interest 
were high and satisfactory, which indicated that the pGEX-4-T3 expression system and 
the chosen conditions for the recombinant production were optimal.  
 
Unexpectedly, the expression of the recombinant proteins fused with the GST tag did 
not result in their increased solubility. The only exception was the control GST/thrombin-
C-(His)6, which as expected was found in the supernatant. Considering that the 
conditions with a low stringency were chosen for the protein expression and despite that 
it still did not prevent the formation of inclusion bodies, it was assumed that there might 
be other parameters that need optimisation in order to facilitate the production of soluble 
proteins. Nevertheless, in the present study, solubilisation under denaturing conditions 
to isolate and purify the proteins of interest from the inclusion bodies was performed, as 
it allowed to utilise the already established protocol for the pET-28a system.  
 
As expected, purification of GST/thrombin-C-(His)6 was successful and led to obtaining 
of an exceptionally high yield of a pure protein, which could be used as a control in 
experimental assays. The first step of purification of N-GST DDEDs caspase-10 
(D415A)/thrombin-(His)6 by using IMAC was also successful and the levels of purified 
proteins were good and satisfactory to further process and purify the protein of interest. 
Surprisingly, after the GST and (His)6 tag removal followed by the second IMAC 
purification, we found that the levels of untagged DDEDs caspase-10 (D415A) were 
considerably reduced, when compared with the fraction obtained and concentrated after 
the first purification step. Purification on the SEC column revealed that the untagged 
DDEDs caspase-10 (D415A) eluted at the end of the purification process, as opposed to 
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the expected elution at 45 ml. Thus, it was concluded that the protein of interest was not 
stable/underwent degradation after the tags removal and/or purification. However, the 
exact mechanism responsible for such instability and/or degradation still remains 
enigmatic. Purification of N-GST DDEDs caspase-10 (D415A)/thrombin-(His)6 was 
attempted several times and detailed analyses were performed after each purification 
step in order to address this issue, nevertheless the possible point leading to the protein 
instability is yet to be identified.  
 
Due to the yet unknown limitation(s) of the purification of the proteins expressed by using 
the pGEX-4-T3 system, the purification of the remaining proteins of interest, including N-
GST DDEDs caspase-10 (C401A), N-GST DDEDs cFLIP-L (wild type) and N-GST 
DDEDs cFLIP-L (D376A) with both thrombin-(His)6 and TEV-(His)6 tags, remains 
unravelled. Therefore, it was assumed that optimisation of the parameters for the fusion 
tag removal and/or the following purification process could possibly address this issue. 
Additionally, possibly a new method and further research are needed to identify the 
differences or issues related to the fusion tag removal and unsuccessful purification of 
the proteins expressed by using the pGEX-4-T3 system. Alternatively, a new system for 
the protein expression and purification could be tested. 
 
5.4 Caspase-10	Cleaves	Caspase-8	In	Vitro	
 
The present study was focused examination of the functions and interactions between 
the main FADDosome components, namely caspase10, caspase-8, FADD and cFLIP-
L. In particular, it was asked, whether caspase-10, which acts as the core driver of the 
FADDosome formation in 5-FU-induced apoptosis (Mohr et al., 2018), could function as 
a potential caspase-8 activator. In order to elucidate that, an activity assay in vitro was 
performed. For this, purified untagged DDEDs caspase-10 (D415A) and untagged 
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DDEDs caspase-8 (C360A), which played the role of potential enzyme and substrate, 
respectively, were used.  
 
Initially, the activity assay by using physiological conditions was performed. It was 
observed that the levels of single-chained DDEDs caspase-8 (C360A) were considerably 
decreased, proportionally to the time of incubation. However, the same event was 
observed for the control. Thus, it was assumed, that the observed reduction of the control 
DDEDs caspase-8 (C360A) was caused by one of the following possible scenarios: (I) 
instability or (II) self-processing of the protein, which increased proportionally to the time 
of incubation. In order to address these issues, DDEDs caspase-8 (C360A) alone was 
tested by using different conditions, such as a stabilisation buffer, which has been 
described as the optimal reaction buffer for the caspases (Garcia-Calvo et al., 1999), 
and kosmotropic salts buffer, which promotes dimerization and subsequently, proteolysis 
and activation of proteins (Boatright et al., 2004). It was found that DDEDs caspase-8 
(C360A) was unable to cleave itself in stabilising conditions and after addition of the 
kosmotropic salts, as no decrease of the protein, proportional to the time of incubation, 
was observed. Thus, these results suggested that the levels of single-chained DDEDs 
caspase-8 (C360A) were decreased previously due to its instability rather than the self-
cleavage.  
 
With respect to that, the activity assay by using stabilising conditions	was	performed. The	obtained results revealed that DDEDs caspase-10 (D415A) was capable of cleaving 
DDEDs caspase-8 (C360A) in vitro. Thus, it was concluded that processing and 
activation of caspase-8 could be mediated by caspase-10 in vitro. Nevertheless, at this 
stage it was not possible to assess, whether such event could be affected, either 
positively or negatively, by FADD and/or cFLIP-L in terms of reconstitution of the 
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FADDosome complex. Moreover, the stoichiometry of the FADDosome constituents 
remains unclear and is yet to be resolved.  
 
Moreover, it is noteworthy that another reason for the considerable decrease of the 
single-chained DDEDs caspase-8 (C360A) levels in the control assay could be a 
possibility of contamination with other proteinases, which was not tested in this study. 
Thus, in the next stages of this research, it would be beneficial to perform a screening 
for and detection of potential contaminating proteases, which could be present in the 
purified protein samples. Such experiments can be performed using commercially 
available kits that are able to detect primary or trace protease activity using fluorometric 
or colorimetric assays and contain all necessary controls, standards and buffers to 
perform these assays. The range of proteases, that can be detected using the 
commercial kits include serine, aspartic, cysteine and metalloproteases (Mohan et al., 
2018). Based on the class of identified protease(s), appropriate inhibitors can be added 
to protect the purified proteins from proteinase degradation.  
 
Moreover, in the next stages of this study, it would be necessary to test the functionality 
of DDEDs caspase-10 (D415A) using activity assays, as described by Watchmann et al. 
(2010). In order to perform the activity assays, the authors used the following caspase-
10 substrates: Ac-DEVD-AFC, Ac-LEHD-AFC and Ac-IETD-AFC, which were mixed with 
various variants of purified human recombinant caspase-10, including DDEDs caspase-
10 (wild type) and DDEDs caspase-10 (D415A). The activity of the desired proteins was 
then measured by monitoring the levels of hydrolysis of these substrates (Wachmann et 
al., 2010). Therefore, testing the activity of purified DDEDs caspase-10 (D415A) used in 
this study would provide a positive control for the DDEDs caspase-10 (D415A) / DDEDs 
caspase-8 (C360A) activity assay and serve as a confirmation for the functionality of 
DDEDs caspase-10 (D415A). 
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Caspases belong to the family of conserved cysteine proteases, which preferably cleave 
other caspases or substrates after an aspartate residue. Caspase-10 and -8 are known 
as initiator caspases, which conventionally are involved in the DISC formation and 
initiation of the extrinsic apoptotic pathways. Nevertheless, the most recent findings have 
demonstrated that, upon cytotoxic stress induced by anti-tumour drugs, caspase-8 is 
able to form intracellular complexes, such as FADDosome (Mohr et al., 2018) or 
RIPoptosome (Feoktistova et al., 2011; Tenev et al., 2011) and act as an initiator of the 
intrinsic apoptotic network. We have found that, at the FADDosome, caspase-8 
undergoes activation which in turn leads to triggering of apoptosis in response to 5-FU. 
However, the exact mechanism of the caspase-8 activation at the complex remains 
unknown. For activation of the initiator caspase two model have been proposed, 
including the induced proximity model (Salvesen and Dixit, 1999) and proximity-induced 
dimerization model (Boatright and Salvesen, 2003, Wachmann et al., 2010). The first 
model suggests that bringing initiator caspases into close proximity drives the proteolytic 
processing of the molecules. The second model proposes that the force driving the 
cleavage of the initiator caspases requires dimerization of the molecules and this 
happens as a result of bringing caspases into close proximity (Boatright and Salvesen, 
2003; Wachmann et al., 2010). The models and molecular mechanisms responsible for 
caspases activation was investigated and clarified a few years later by Keller et al., 
(2009). The authors demonstrated that the proximity-induced dimerization model was 
responsible for promoting the dimerization of caspase-8, which was found to be 
necessary for subsequent cleavage of the protein. This indicated that caspase-8 can 
only be processed after successful dimerization.  
 
Conventionally, initiator caspases are believed to activate themselves via auto-cleavage. 
They can also proteolytically process the effector (executioner) caspases and other 
substrates. To date, it has not been reported that one initiator caspase could cleave and 
activate another initiator caspase. Moreover, it still remains controversial whether 
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caspase-10 can functionally substitute caspase-8 in death receptor-induced signalling 
pathways (Kischkell et al., 2001; Sprick et al., 2002). However, it has been described 
that caspase-8 and -10 share substrate specificity and therefore, their functions may 
partially overlap (Parrish et al., 2013; Riley et al., 2015).  
 
Interestingly, in contrast to the findings presented in this research, the most recent study 
by Horn et al., (2017) has demonstrated that caspase-10 negatively regulates activation 
of caspase-8 in HeLa cells. In particular, the authors have shown that caspase-10 
abolishes the caspase-8 activation at the CD95-DISC, which in turn leads to inhibition of 
apoptosis. Instead, the NF-kB pathway is activated, which as a result, contributes to cell 
survival. Nevertheless, it is noteworthy that our group has investigated the role of 
caspase-10 in caspase-8 activation in terms of the FADDosome complex, without 
involvement of the death receptors. Whereas Horn et al., (2017) studied the effect of 
caspase-10 functions on caspase-8 activity in terms of the CD95-DISC assembly. Thus, 
this indicates that caspase-10 can perform different functions and affect the caspase-8 
activity depending on the context (death receptor independent FADDosome vs. CD95-
DISC). Therefore, further studies are necessary to investigate and clarify in more detail 
the exact roles of caspase-10 in caspase-8 activation with respect to both the intrinsic 
and extrinsic apoptotic pathways.  
 
5.5 Caspase-8	 and	 FADD	 Possibly	 Interact	 via	 a	 Novel	
DED-Independent	Mechanism		
 
FADD is an adaptor molecule, which was identified and first characterised by Chinnaiyan 
et al. (1995). This protein is known to play a role in the DISC assembly, which is involved 
in initiation of the extrinsic apoptotic network. Following binding to a death receptor, 
FADD associates with caspase-8, which in turn undergoes cleavage and activation at 
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the DISC. Subsequently, these events lead to the initiation of the cell death (Grunert et 
al., 2012). It is believed that FADD and caspase-8 can associate through a homotypic 
interaction between their DEDs (Riley et al., 2015). To date, there has only been one 
study, which described the underlying mechanism of such interaction. Carrington et al. 
(2006) proposed a model for the FADD/caspase-8 interaction, based on studying 
different FADD mutants and their binding abilities to pro-caspase-8 in the context of the 
CD95-DISC assembly. The authors performed a CD95 co-immunoprecipitation, which 
allowed to identify the FADD binding surface for pro-caspase-8 within the FADD DED. 
These results were supported by examination of the crystal structure of MC159 protein, 
also known as vFLIP, which contains DEDs, structurally resembling the DEDs of FADD 
and zymogen caspase-8 (Carrington et al., 2006). However, to date, it has not been 
demonstrated, how FADD and caspase-8 interact in the context of the apoptosis-
inducing protein complexes assembly, such as FADDosome, which are formed without 
engagement of the death receptors. 
 
Thus, in order to examine the interaction between FADD and caspase-8 in the context 
of the FADDosome formation, a pull-down assay was performed. In this experiment, 
purified C-(His)6-tagged FADD-FL (bait protein) and untagged DDEDs caspase-8 
(C360A) (prey protein) were used. Additionally, a control assay by using purified 
GST/thrombin-C-(His)6 and untagged DDEDs caspase-8 (C360A) was performed. The 
obtained results revealed that both C-(His)6 FADD-FL and untagged DDEDs caspase-8 
(C360A) eluted in the same fraction and their levels were comparable. Additionally, iy 
was observed that C-(His)6 FADD-FL eluted in the next fraction, whereas DDEDs 
caspase-8 (C360A) was not detectable in this fraction.  
 
Interestingly, the control assay has revealed that both C-(His)6 GST and DDEDs 
caspase-8 (C360A) eluted in the same fraction, however the levels of DDEDs caspase-
 233 
8 (C360A) were lower, when compared with the C-(His)6 FADD-FL / untagged DDEDs 
caspase-8 (C360A) results. In order to assess and compare the levels of eluted DDEDs 
caspase-8 (C360A) in both experiments, the elution fractions from the C-(His)6 FADD-
FL / untagged DDEDs caspase-8 (C360A) and the control C-(His)6 GST and DDEDs 
caspase-8 (C360A) assays were examined. The fractions were run together on one 
SDS-PAGE and analysed by Western blot. Such analysis was necessary to provide a 
better view at the levels of eluted DDEDs caspase-8 (C360A) in both assays and to 
confirm the reliability of the C-(His)6 FADD-FL / untagged DDEDs caspase-8 (C360A) 
experiment.  
 
The results showed that the levels of eluted DDEDs caspase-8 (C360A) during the 
control C-(His)6 GST and DDEDs caspase-8 (C360A) assay was considerably 
decreased, when compared with the protein levels eluted during the C-(His)6 FADD-FL / 
untagged DDEDs caspase-8 (C360A) assay. Thus, these data indicated that C-(His)6 
FADD-FL and DDEDs caspase-8 (C360A) were capable to associate, however the exact 
mechanism responsible for such interaction and the stoichiometry of bound C-(His)6 
FADD-FL and DDEDs caspase-8 (C360A) remain unravelled and require further 
investigation.  
 
Thus, it was concluded that FADD and caspase-8 can possibly interact via a novel, DED-
independent mechanism in vitro. Nevertheless, at this stage it still remains unclear, 
whether the presence of caspase-10 and/or cFLIP-L could affect, either positively or 
negatively, the FADD/caspase-8 binding in the context of the FADDosome 
reconstitution. Moreover, the possible preferences and/or competition for binding 
between the FADDosome components in the context of the complex formation as well 
as their role in the switch between the FADDosome and FLIPosome, still remain 
unravelled.  
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Importantly, considering that DDEDs caspase-8 (C360A) did not contain its pro-domains, 
the question arises, what force and/or molecular mechanisms could possibly drive such 
interaction. Moreover, considering that the findings presented in this study are not in line 
with other reports, which describe that DEDs are believed to be necessary to associate 
with FADD (Carrington et al., 2006; Riley et al., 2015) and therefore, refute the classical 
model of the FADD/caspase-8 interaction, it is crucial to investigate the possible DED-
independent interaction of FADD/caspase-8 in more detail and to find, which residues 
might be responsible for such interaction. Therefore, using a different experimental 
method and further research are required to address this matter.  
 
5.6 ATR,	 Chk1	 and	 Chk2	 Regulate	 the	 5-FU-Induced	
Apoptosis	
 
Another aim of this study was to investigate the pathways and factors involved in the 
DNA damage signal transduction towards the 5-FU-induced caspase-10 upregulation 
and subsequent FADDosome formation. It was hypothesised that the ATR and/or ATM 
kinases could act as the 5-FU-induced DNA damage sensors and, together with Chk1 
and/or Chk2, can translate the sensed lesion into the apoptotic signals in HCT116 cells 
(HCT.shctrl cells were used in this study, as they provided control cells for other HCT116 
knockdown clones. HCT.shctrl and HCT116 cells respond in the same way to 5-FU).   
 
First of all, it was focused on examination of the ATR and ATM phosphorylation status 
in HCT.shctrl cells after the treatment with 5-FU. The cells were examined for ATR and 
ATM activation by using antibodies against the Thr1989 and Ser1981 phosphorylation 
sites, respectively. We found that only ATR was phosphorylated in HCT.shctrl cells in 
response to 5-FU. Importantly, we observed that ATR was phosphorylated at Thr1989 
after exposure to the anti-tumour drug. Other studies have also reported that ATR 
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undergoes phosphorylation at Thr1989 in cancer cells subjected to various treatments. 
Nam et al. (2011) demonstrated that upon treatment with hydroxyurea, ATR could be 
phosphorylated at Ser428 and Thr1989 in HeLa cells. Similar results were described in 
the study by Liu et al. (2011), which showed that ATR underwent phosphorylation at 
Thr1989 in 293T cells treated with hydroxyurea. Glanzer et al. (2014) also reported the 
same phosphorylation event in UMSCC30 cells subjected to treatment with etoposide. 
Interestingly, these reports emphasised the fact that the Thr1989 site is believed to 
function as a hallmark of an active state of ATR (Liu et al., 2011; Nam et al., 2011; 
Glanzer et al., 2014). Thus, the results obtained in the present research indicate that 
ATR, but not ATM, is activated in response to 5-FU and suggest that this kinase acts as 
the key sensor of the anti-tumour drug-induced DNA damage in HCT.shctrl cells (Figure 
66).  
 
 
 
Figure 66. ATR is the key sensor of the 5-FU-induced DNA damage in cancer cells.  
Treatment with 5-FU leads to DNA damage in colon cancer cells, which in turn contributes to the 
recruitment of ATR, but not ATM, to the damage site. As a result, ATR undergoes phosphorylation 
at Thr1981 and subsequent activation. Therefore, this indicates that ATR acts as the critical 
sensor of the 5-FU-induced DNA damage in colon cancer cells.16 
 
 
In the present study, it was found that both Chk1 and Chk2 were phosphorylated in 
HCT.shctrl cells in response to 5-FU. We have demonstrated that Chk1 underwent 
 
16 Image created with BioRender.com 
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phosphorylation at Ser317 site, which is believed to be the critical site for activation of 
this kinase (Smith et al., 2010; Zhang and Hunter, 2013). Such observation was 
consistent with the results described in other studies, which reported that Chk1 was 
phosphorylated in response to 5-FU in HCT116 and SW480 cells (Martino-Echarri et al., 
2014). Additionally, the Western blot results revealed that in HCT.shctrl cells exposed to 
5-FU, Chk2 was phosphorylated at the Thr68 site, which is considered as crucial for its 
full activation (Smith et al., 2010). Such observation was similar to the results reported 
by Huelsenbeck et al. (2012), which described that Chk2 underwent phosphorylation in 
response to anti-tumour agents, such as doxorubicin and etoposide. These findings 
indicate that, similar to ATR, Chk1 and Chk2 kinases are activated in response to 5-FU 
and are involved in DNA damage signalling in 5-FU-induced apoptosis in HCT.shctrl 
cells. 
 
Moreover, a very recent study by Jaarsveld et al. (2019) also reported an elevation of 
the Chk1 and Chk2 activation in response to chemotherapeutic drugs, such as cisplatin 
or doxorubicin. Interestingly, the authors suggested that the activation of these kinases 
contributes to resistance development in tumour cells rather than apoptosis induction 
(Jaarsveld et al., 2019). Thus, taken these and our findings together, it is noteworthy, 
that the roles of activated Chk1 and Chk2 in determining of the cell fate (survival vs. 
apoptosis) are very likely to be cell type- and/or stimulus-specific. 
 
5.7 ATR	 Mediates	 Chk1	 Activation	 and	 p53	 Induction,	
Whereas	 Both	 ATR	 and	 ATM	 Regulate	 Chk2	
Activation	
 
As described in the classical DNA damage response model, ATR and ATM are involved 
in phosphorylation and activation of Chk1 and Chk2, respectively (Zinkel et al., 2005; 
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Matsuoka et al., 2007; Shiloh and Ziv, 2013; Zhang and Hunter, 2013). Thus, it was 
asked, whether the same molecular events were triggered in response to 5-FU in cancer 
cells. The Western blot analysis revealed that application of 5-FU in combination with 
ATR inhibitor AZD6738 led to a complete block of Chk1 phosphorylation at Ser317 in 
HCT.shctrl cells. In contrast, in the presence of ATM inhibitor KU55933, 
chemotherapeutic agent treated HCT.shctrl cells were able to phosphorylate Chk1 to the 
same degree as the control cell line, suggesting that ATR, but not ATM, was involved in 
the anti-tumour drug induced Chk1 activation (Figure 67).  
 
Interestingly, treatment with 5-FU plus ATR or ATM inhibitor led to a strong reduction of 
the Chk2 phosphorylation at Thr68, when compared with the control cell line. These 
results suggest that both ATR and ATM were required for the Chk2 activation in 
HCT.shctrl cells treated with 5-FU. Initially, our findings ruled out the involvement of ATM 
in 5-FU-induced DNA damage signalling and apoptosis, as this kinase was not found to 
be phosphorylated in response to 5-FU. Nevertheless, finding out that ATM was involved 
in the Chk2 phosphorylation upon the 5-FU treatment, led to a conundrum, that requires 
further experiments with respect to the role of ATM in 5FU-treated HCT.shctrl cells.  
 
In order to further investigate the role of ATR in phosphorylation and regulation of its 
substrates in 5-FU-induced apoptosis, a stable ATR knockdown clone of HCT116 cells, 
namely HCT.shATR, was generated. This cell line was checked for Chk1 and Chk2 
activation by analysis of their phosphorylation status in response to 5-FU. In contrast to 
HCT.shctrl cells, we found that treatment of HCT.shATR with 5-FU led to an almost 
complete attenuation of Chk1 and Chk2 phosphorylation. Thus, these data further 
confirmed the requirement of ATR for 5-FU-induced Chk1 and Chk2 activation in cancer 
cells (Figure 67). 
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Induction of genotoxic stress typically contributes to accumulation of the tumour 
suppressor p53, which plays a crucial role in prevention of cancer development and 
regulation of numerous processes, including cell cycle, cellular responses to DNA 
damage and induction of apoptosis (Russo et al., 2005; Ju et al., 2007; Collavin et al., 
2010; Li et al., 2015). Many studies reported that upon the genotoxic stress, p53 is 
activated and acts as transcriptional activator and can regulate a wide range of 
substrates, that are also involved in the above processes (Heeren et al., 2004; Balmer 
et al., 2014).  
 
Thus, as expected, it was observed that the levels of p53 were strongly increased in 
HCT.shctrl cells in response to 5-FU. Moreover, we found that application of the ATR 
inhibitor blocked the 5-FU-induced elevation in p53. In contrast, the attenuation of the 5-
FU-induced increase in p53 was not observed in response to 5-FU combined with ATM 
inhibitor alone or with both ATR and ATM inhibitors. Furthermore, our results showed 
that the levels of p53 were markedly reduced in 5-FU-treated HCT.shATR cells, when 
compared with the control HCT.shctrl cells subjected to the same treatment. Thus, we 
concluded that ATR functions as a key regulator of the Chk1 and Chk2 activation as well 
as p53 induction in 5-FU-initiated apoptosis in cancer cells (Figure 67).  
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Figure 67. Regulation of Chk1 and Chk2 phosphorylation and p53 induction in cancer cells 
treated with 5-FU.  
Upon 5-FU-induced DNA damage, activated ATR mediates phosphorylation of Chk1 at Ser317 
and accumulation of p53. Moreover, Chk2 undergoes phosphorylation at Thr68 and therefore, 
also undergoes activation in response to 5-FU. However, this process is positively regulated by 
both ATR and ATM. 17 
 
 
Moreover, many studies have correlated the p53 status with therapy responses (Longley 
et al., 2003; Boyer et al., 2004; Sui et al., 2014). As mentioned above, we observed that 
blocking and knocking-down of ATR led to a strong reduction of p53 levels in the cells 
treated with 5-FU. In our previous report we described that HCT.p53-/- cells were 
protected from 5-FU-induced apoptosis (Mohr et al., 2018). Such observation was in line 
with the results obtained by others, which demonstrated that the absence of p53 strongly 
decreases the sensitivity of HCT.p53-/- cells to 5-FU (Longley et al., 2003; Boyer et al., 
2004; Sui et al., 2014). Additionally, we found that caspase-9 was not required for 5-FU-
induced apoptosis (Mohr et al., 2018). Therefore, considering that the resistance of 
HCT.p53-/- cells to 5-FU was not associated with inhibition of the conventional apoptotic 
pathway, we proposed a model of 5-FU-induced apoptosis and the alternative functions 
of p53 therein.  
 
17 Image created with BioRender.com 
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With respect to that, it was shown by our group that 5-FU-induced apoptosis was 
modulated by the p53-driven TRAIL-R2/JNK axis, which we assumed would signal to 
mitochondria (Mehrabadi, 2018). It was demonstrated that p53 was responsible for the 
transcriptional regulation of TRAIL-R2 (DR5) in 5-FU-treated HCT116 cells. Moreover, 
our group discovered, that in 5-FU-induced apoptosis, DR5 was not involved in caspase-
8 activation, as described in the classical model of apoptosis, but in activation of JNK 
(Mehrabadi, 2018). Moreover, other molecular factors, which were associated with DR5 
and responsible for the 5-FU-induced JNK activation, namely, caspase-8 and FADD, 
were also identified (Mehrabadi, 2018). The obtained data indicated that upon treatment 
with 5-FU, DR5 can form a complex with caspase-8 and FADD, without caspase-8 
activation function, that mediates activation of JNK. This complex was termed JIST (JNK-
inducing signal transduction complex). Thus, it was concluded that DR5 functions as the 
molecular platform for JNK activation in cancer cells treated with 5-FU (Mehrabadi, 
2018). Since it was assumed that the p53-driven TRAIL-R2/JNK axis most likely signals 
to mitochondria, the initial apoptosis signal emitted by activated caspase-8 at the 
FADDosome would be amplified via the mitochondria leading to the release of pro-
apoptotic factors, such as Smac/DIABLO (Mehrabadi, 2018). In the light of these 
findings, the question arises, whether ATR could regulate the TRAIL-R2/JNK pathway 
via p53 in response to 5-FU. Nevertheless, this remains to be resolved.    
 
5.8 ATR	 is	 Required	 for	 Caspase-10	 Upregulation	 and	
FADDosome	Formation	
 
Next, it was asked, whether the ATR- and ATM-mediated signalling pathways were 
involved in 5-FU-induced upregulation of caspase-10, which we showed to act as the 
core molecular driver of the FADDosome complex formation (Mohr et al. 2018). The 
results obtained by Western blot showed that in the presence of ATR inhibitor AZD6738, 
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upregulation of caspase-10 was strongly attenuated in HCT.shctrl cells treated with 5-
FU. On the contrary, blocking of ATM with KU55933 had no effect on caspase-10 
upregulation in the 5-FU treated cells, ruling out the role of ATM in controlling the anti-
cancer drug-induced caspase-10 upregulation.  
 
In order to further investigate the involvement of ATR in regulation of caspase-10 levels 
in response to 5-FU, it was tested the HCT.shATR cells, which were analysed for 
caspase-10 upregulation by using Western blot and compared them with the results 
obtained for HCT.shctrl cells. Similar to the findings observed for HCT.shctrl cells treated 
with 5-FU plus ATR inhibitor, caspase-10 was not detectable in HCT.shATR cells after 
exposure to 5-FU. Thus, it was concluded that, upon treatment with 5-FU, caspase-10 is 
upregulated in ATR-dependent manner, whereas ATM is dispensable for this process 
(Figure 68).  
 
5.9 Activated	 Chk1	 and	 Chk2	Act	 Independently	 of	 p53	
and	Are	 Required	 for	 Caspase-10	Upregulation	 and	
FADDosome	Formation	
 
in this study, it was demonstrated that blocking and knocking-down of ATR contributed 
to a strong decrease of the Chk1 and Chk2 phosphorylation, p53 induction and caspase-
10 upregulation after treatment with 5-FU. Next, we investigated the order of molecular 
events downstream of ATR in more detail by using HCT.p53-/- and HCT.shC10 cells, 
which were examined for Chk1 and Chk2 phosphorylation levels after exposure to the 
chemotherapeutic drug.  
 
It was observed that phosphorylation of Chk1 and Chk2 was markedly elevated in both 
HCT.p53-/- and HCT.shC10 cells stimulated with 5-FU, which was comparable with the 
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results obtained for the control HCT.shctrl cells subjected to the same treatment. Thus, 
it was concluded, that activation of Chk1 and Chk2 in 5-FU-induced apoptosis is p53-
independent and occurs upstream of caspase-10. Additionally, the results obtained by 
Western blot revealed that the loss of caspase-10 did not affect the levels of p53 and 
p21 in response to 5-FU. It was observed that these proteins were induced in HCT.shC10 
cells to the same degree as in HCT.shctrl cells treated with the anti-tumour drug. These 
results indicated that the cells lacking caspase-10 showed the same molecular response 
to the chemotherapeutic as HCT.shctrl cells as far as p53 and p21 activation was 
concerned. Thus, both cell types were principally able to respond to cytotoxic drug-
inflicted stress and damage. 
 
Next, it was asked, whether activated Chk1 and Chk2 were involved in the signal 
transduction towards the 5-FU-induced caspase-10 upregulation and FADDosome 
formation. Prior to the analysis, we examined the action of a potent and selective inhibitor 
CHIR-124, which primarily attenuates the activity of Chk1, however it can also block 
activation of Chk2 (Tse et al., 2007). The Western blot analysis revealed that after 
application of CHIR-124, the Chk1 and Chk2 phosphorylation was considerably reduced 
in HCT.shctrl cells treated with 5-FU or etoposide. Moreover, it was found that the 
HCT.shctrl cells exposed to CHIR-124 plus 5-FU or etoposide combination mounted the 
same molecular response to the treatment as HCT.shctrl cells stimulated with 5-FU or 
etoposide alone, as we observed that the levels of p53 and p21 were increased to the 
same degree in the control and treated cells.  
 
Next, HCT.shctrl cells treated with CHIR-124 plus 5-FU or etoposide were checked for 
the levels of caspase-10. The results obtained by Western blot unveiled that application 
of the inhibitor led to a strong decrease of caspase-10 in response to 5-FU. Additionally, 
it was observed that upon treatment with etoposide, caspase-10 upregulation was not 
increased. Subsequently, stimulation with CHIR-124 plus etoposide did not influence the 
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caspase-10 upregulation levels. Our results indicated that upregulation of caspase-10 
was Chk1/Chk2-dependent and that this molecular event is important for the cell death 
triggered by 5-FU, but not etoposide. Thus, other molecular factors, namely Chk1/Ch2, 
which like ATR, which are involved in signalling from the DNA damage site towards the 
5-FU-induced caspase-10 upregulation, were identified (Figure 68).  
 
 
Figure 68. ATR, Chk1 and Chk2 are involved in signalling from the DNA damage site 
towards the 5-FU-induced caspase-10 upregulation and FADDosome formation.  
Following treatment with 5-FU leading to the DNA damage, caspase-10 undergoes upregulation, 
which is mediated either directly by activated ATR or indirectly by ATR-regulated downstream 
Chk1 and Chk2. Activation of the latter is also positively regulated by ATM, nevertheless ATM 
was found dispensable for 5-FU-induced caspase-10 upregulation. Increased caspase-10 levels 
lead to formation of the FADDosome complex, which in turn initiates apoptosis.18 
 
Additionally, it was observed that in HCT.shctrl cells exposed to the CHIR-124 plus 5-
FU or etoposide, the p53 and p21 levels were strongly increased, which was comparable 
with the results obtained for the HCT.shctrl cells stimulated with 5-FU or etoposide alone. 
Thus, in contrast to the ATR findings, blocking of Chk1 and Chk2 did not lead to the 
decrease of p53 in response to 5-FU. This indicated that induction of p53 does not 
require the involvement of activated Chk1 and Chk2 in 5-FU-induced apoptosis.  
 
 
18 Image created with BioRender.com 
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To date, the role of caspase-10 and its activity in the initiation of the programmed cell 
death in response to anti-tumour treatments has been examined and reported only by a 
few studies in vitro. It was demonstrated, that application of adriamycin and etoposide 
could promote transcription of the Casp10 gene through activation of p53, leading to the 
increase of the caspase-10 amount at the mRNA and protein levels in tumour cells 
(Rikhof et al., 2003). Such results were in contrast to the observations present in this 
study, as it was found that etoposide did not contribute to the elevation of caspase-10 
levels in HCT.shctrl cells. Moreover, contrary to Rikhof et al. (2003), it was demonstrated, 
that upregulation of caspase-10 was p53-independent in cancer cells exposed to 
chemotherapeutic drugs, such as 5-FU. However, it is noteworthy, that Rikhof et al. 
(2003) examined the types of cells, that were different from HCT.shctrl cells, namely 
H460 (lung cancer), PA-1 (ovarian cancer) and U2OS (osteosarcoma). Taken together, 
the results suggest that the increase of the caspase-10 levels and its regulation 
mechanisms is very like to be treatment type- and/or cell-type specific.  
 
Interestingly, it was suggested by some studies that caspase-10 can trigger apoptosis in 
a FADD-dependent manner, without involvement of the death receptor pathways after 
exposure to cytotoxic chemotherapeutic drugs (Park et al., 2004; Filomenko et al., 2006; 
Lee et al., 2007), which is in line with our findings (Mohr et al., 2018). Such cell death-
inducing mechanisms were found in human U937, 293T and HeLa cell lines stimulated 
with etoposide (Filomenko et al., 2006) and in human lymphoblastic leukaemia cells 
exposed to paclitaxel (taxol) (Park et al., 2004). Taken together, it is becoming more 
evident that apoptosis induction, which requires involvement of caspase-10 (and 
caspase-8) can occur without engagement of the death receptors and that this process 
is not limited to HCT116 cells and 5-FU treatment only.  
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5.10 Inhibition	of	Chk1/Chk2	Activation	Leads	to	a	Switch	
to	the	FLIPosome	Mode	of	Apoptosis	
 
Next, it was asked, whether Chk1 and Chk2 were involved in regulation of the 5-FU-
induced apoptosis and whether they could be responsible for determining the mode of 
cell death (FADDosome vs. FLIPosome) in cancer cells treated with the anti-tumour 
drug.  In this context, it was hypothesised that blocking of Chk1/Chk2 could lead to the 
significant elevation of the cell death levels in response to 5-FU.  
 
When the levels of apoptosis in HCT.shctrl cells, which were treated with a CHIR-124/5-
FU combination, were examined, it was observed that blocking of Chk1 and Chk2 
significantly increased the cell death triggered by 5-FU after 24 h. Following the 48 h 
stimulation with CHIR-124 plus 5-FU, the levels of apoptosis in HCT.shctrl cells were 
also strongly elevated and slightly higher, when compared with the result obtained for 
HCT.shctrl cells treated with 5-FU alone. Similar results were obtained for HCT116 cells, 
which were lacking ATR, caspase-10, RIP1 or TRAF2, as we observed that these cells 
could still undergo apoptosis in response to 5-FU. Thus, similar to the findings reported 
by our group previously (Mohr et al., 2018), the data obtained in this study for HCT.shctrl 
cells stimulated with CHIR-124 plus 5-FU suggest, that the cells might be able to switch 
to an alternative mode of apoptosis.  
 
Furthermore, our group showed that in the absence of ATR, caspase-10, RIP1 or 
TRAF2, cIAP1 was degraded in response to 5-FU, which is one of the main 
characteristics of the FLIPosome-mediated apoptosis. (Mohr et al., 2018). Having found 
that HCT.shctrl cells with blocked Chk1/Chk2 could still undergo apoptosis in response 
to 5-FU, it was asked, whether inhibition of these kinases could lead to the switch to the 
FLIPosome mode of apoptosis in cancer cells. Therefore, it was assumed, that in 
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HCT.shctrl cells treated with CHIR-124 plus 5-FU, cIAP1 could also undergo proteolytic 
degradation after the treatment. As expected, application of the CHIR-124/5-FU 
combination led to cIAP1 degradation. Thus, similar to the results obtained for the 
caspase-10-, ATR-, RIP1- and TRAF2-deficient cells (Mohr et al., 2018), when Chk1 and 
Chk2 are not present, it appears that HCT.shctrl cells can switch to the alternative 
mechanism of the FLIPosome.  
 
The findings presented in this study indicate that application of Chk1/Chk2 inhibitor 
sensitises cancer cells to treatment with anti-tumour drugs, leading to induction of more 
effective apoptotic response, which is in line with the observations described by others 
(Tse et al., 2007; Akasaka et al., 2014; Qiu et al., 2018). Similar to the results obtained 
in the present research, Akasaka et al. (2014) found that the synergistic effect of the 
Chk1 inhibitor and 5-FU enhances apoptosis in the treatment of colorectal cancer. The 
authors also demonstrated that blocking Chk1 can increase cell death in the treatment 
of gastric tumours in response to 5-FU (Akasaka et al., 2014). Moreover, Tse et al. (2007) 
and Qiu et al. (2018) reported that application of the Chk1/Chk2 inhibitor, CHIR-124, 
combined with topoisomerase poisons promotes apoptosis in breast cancer and p53-
mutated solid tumour cell lines. Thus, taken these and our findings together, application 
of Chk1/Chk2 inhibitors combined with anti-tumour drugs holds a significant promise and 
might provide therapeutic advantages in the treatment of various cancers, including p53-
null or p53-mutated tumours.  
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5.11 Conclusions		
 
In the present study, it was observed that DDEDs caspase-10 (wild-type), DDEDs 
caspase-8 (wild type), DDEDs cFLIP-L (wild-type) and FADD-FL were successfully 
expressed using induction with 0.1 mM (final concentration) IPTG and incubation at 18°C 
overnight, leading to production of good levels of proteins. The same expression 
conditions were optimal for production of DDEDs caspase-8 (C360A and D374A/D384A 
mutants), whereas expression of DDEDs caspase-10 (C410A and D415A mutants) 
required supplementation of the bacterial medium with 1% (final concentration) glucose 
and induction with 0.02 mM (IPTG) followed by incubation at 18°C overnight. 
 
Moreover, the results showed that the control DDEDs caspase-8 (C360A) and C-(His)6 
GST (a product of an empty modified pGEX-4-T3 vector) were successfully expressed 
after induction with 0.1 mM (final concentration) IPTG followed by incubation at 30°C for 
3 h. This led to production of very high levels of proteins. For expression of DDEDs 
caspase-10 (C401A and D415A mutants) and DDEDs cFLIP-L (wild type and D376A 
linker mutant), same expression conditions were found optimal. 
 
It was found that DDEDs caspase-8 (C360A) and C-(His)6 FADD-FL were successfully 
purified using column chromatography, leading to obtaining very good and satisfactory 
yields of highly pure proteins, which can be used in small-scale experiments, such as 
activity or pull-down assays, co-immunoprecipitation or ELISA. 
 
Furthermore, the novel function of the core driver of the FADDosome formation, 
caspase-10 as a potential caspase-8 activator was studied. It was discovered that 
caspase-10 is able to process caspase-8 in vitro. Moreover, the interaction between 
other key FADDosome components, namely FADD and caspase-8 was also 
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investigated. It was found that FADD and caspase-8 possibly interact via a novel 
mechanism in vitro that is independent of DED.  
 
In summary, the work presented in this study provides methods for protein expression 
and purification, which can be utilised in the next stages of this research as well as serve 
as a starting point in these studies, which aim to express and purify proteins for 
crystallography and protein structure studies. Moreover, the activity and pull-down 
assays results provide a better understanding of the functional relationships and 
interactions between the FADDosome components and serve as a foundation for further 
work to be carried out in the context of the complex reconstitution and switch to the 
FLIPosome. 
 
 
In this study, it was discovered that ATR, Chk1 and Chk2 kinases, which are 
conventionally involved in the regulation of the DNA damage response and the DNA 
repair, were phosphorylated after stimulation with 5-FU and required for the caspase-10 
upregulation followed by FADDosome formation. Moreover, it was discovered that Chk1 
and Chk2 kinases were activated in an ATR-dependent manner in response to 5-FU. 
(Figure 69). Thus, it was concluded that ATR acts as the key sensor of the 5-FU-induced 
DNA damage in colorectal cancer cells. Moreover, it was concluded that in the further 
signalling pathway downstream of ATR, Chk1 and Chk2 function as the DNA damage 
signal transducers towards caspase-10 and the FADDosome (Figure 69).  
 
Additionally, it was found that activated ATR plays a role in regulation of p53 
accumulation in response to 5-FU, suggesting that ATR is not only involved in the DNA 
damage response signalling towards the FADDosome, but also very likely regulates 
other 5-FU induced pathways, which depend on p53 (Figure 69). Thus, it was concluded 
that like Chk1 and Chk2, p53 acts as a DNA damage signal transducer downstream of 
ATR, however it regulates an apoptotic pathway that is distinct from the caspase-10-
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driven FADDosome (Figure 69). 
 
Moreover, it was discovered that, similar to inhibition of ATR, blocking of Chk1 and Chk2 
in 5-FU-treated HCT.shctrl cells appeared to promote a switch to an alternative cell death 
mechanism, which requires assembly of the FLIPosome platform (Figure 69).  
 
In summary, in the present study, ATR, Chk1 and Chk2 were identified as the novel 
factors involved in 5-FU-induced DNA damage signalling, caspase-10 upregulation and 
FADDosome formation in response to 5-FU. This led to discovery of the novel 
ATR/Chk1/Chk2/caspase-10 apoptotic network triggered in colorectal cancer cells 
exposed to 5-FU (Figure 69). Moreover, p53 was also identified as the molecular factor, 
which acts downstream of ATR and plays a role in the DNA damage signalling in 5-FU-
induced apoptosis, suggesting an involvement of another novel ATR/p53 cell death 
pathway in colorectal cancer cells (Figure 69).  
 
Moreover, the findings presented in this research indicate a novel mode of action of the 
ATR inhibitor AZD6738 and the Chk1/Chk2 inhibitor CHIR-124, when combined with 
other anti-tumour drugs, such as 5-FU, in the treatment of colorectal cancer. Since our 
group demonstrated previously that the FLIPosome executes apoptosis more effectively 
than the FADDosome and it does not require involvement of p53, promoting a switch to 
the FLIPosome mode of apoptosis holds a significant promise and provides therapeutic 
advantages in the treatment of p53-null or p53-mutated tumours. 
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Figure 69. Novel signalling pathways and the mechanisms of the FADDosome and 
FLIPosome formation in HCT.shctrl cells treated with 5-FU.  
The 5-FU-induced DNA damage is sensed by ATR and the signals from the DNA lesion site are 
transduced in the ATR-dependent manner towards the caspase-10 upregulation followed by 
FADDosome formation and subsequent apoptosis (left panel). In this signalling pathway, ATR 
also mediates phosphorylation of Chk1 and Chk2, which like ATR, are required for the 5-FU-
stimulated caspase-10 upregulation. Moreover, ATR also plays a role in induction of p53 in 
response to 5-FU. Therefore, we assume that ATR very likely mediates another, p53-regulated 
pathway and the molecular factors involved in this pathway need to be identified. Furthermore, 
similar to the loss of caspase-10, RIP1 and TRAF2, inhibition of ATR with AZD6738 (ATR 
inhibitor) as well as blocking of Chk1 and Chk2 with CHIR-124 (Chk1/Chk2 inhibitor) causes a 
shift to the FLIPosome mode of apoptosis in HCT.shctrl cells treated with 5-FU (right panel). 
However, the molecular factors involved in the DNA damage sensing and signal transduction 
toward the FLIPosome in response to 5-FU are yet to be identified.19 
 
 
 
 
 
 
 
 
19 Image created with BioRender.com  
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5.12 Future	Work		
 
In the present study, it was discovered that caspase-10 has the ability to cleave caspase-
8 in vitro. However, the question arises, whether caspase-10-mediated activation of 
caspase-8 could be possibly affected, either positively or negatively, after addition of 
FADD and/or cFLIP-L to the setting. This could provide more insights into the roles of 
FADD and cFLIP-L in terms of the FADDosome formation as well as into the 
mechanisms responsible for activation of caspase-8 at the complex.  
 
The mechanism of caspase-10-mediated caspase-8 activation in the presence of FADD 
and/or cFLIP-L could be tested by performing the activity assay. In one setting, caspase-
10, caspase-8 and FADD would be mixed and the cleavage of caspase-8 would be 
analysed after indicated timepoints, as described in this study. In another setting, 
caspase-10, caspase-8 and cFLIP-L would be mixed and the processing of caspase-8 
would be examined in the same manner. The cleavage efficiency could be then 
compared between all settings at selected timepoints, to detect any possible delays or 
acceleration of the caspase-8 activation.  
 
Moreover, it was found that FADD and caspase-8 can possibly interact via a novel DED-
independent mechanism. However, the exact details regarding the mechanism 
responsible for this interaction as well as the stoichiometry of the bound FADD and 
caspase-8 remain unknown. Thus, further research and application of different 
techniques are required in order to confirm this interaction and resolve the stoichiometry 
of the bound FADD and caspase-8 molecules. The binding between the proteins can be 
confirmed by performing immunoprecipitation, whereas the stoichiometry of associated 
FADD and caspase-8 can be assessed by using gel filtration chromatography analysis. 
Moreover, the structure modelling of the protein-protein interaction between FADD and 
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caspase-8 could provide more insights into what residues are responsible for the 
potential DED-independent binding between these proteins.  
 
Furthermore, it is hypothesised that upon 5-FU treatment, upregulated capsase-10 can 
outcompete cFLIP-L for binding to caspase-8, which results in formation of the 
FADDosome. Thus, it was asked, what are the actual binding preferences between 
caspase-10 and caspase-8/cFLIP-L. Investigation of this matter could provide more 
details regarding the potential switch mechanism from the FADDosome to the 
FLIPosome complex and vice versa. Also, it was asked, what effect would 
different/increasing concentrations of caspase-10 have on its binding preference and 
whether an increased concentration of caspase-10 would indeed outcompete cFLIP-L 
for binding to caspase-8, as hypothesised.  
 
The binding preferences between caspase-10 and caspase-8/cFLIP-L can be tested by 
mixing caspase-10 at different/increasing concentrations and caspase-8/cFLIP-L at 
constant concentrations. The effect of the increased amount of caspase-10 could be 
assessed by performing the binding assay and analysis of elution fractions for the 
presence of the proteins of interest, as described in this study. Alternatively, the binding 
preference of caspase-10 could also be tested by carrying out the activity assay and 
examination of the caspase-10-mediated cleavage of caspase-8 and cFLIP-L after 
selected timepoints.  
 
 
In the present study, it was shown that 5-FU-induced DNA damage signalling is mediated 
by ATR, Chk1 and Chk2 and that these kinases are involved in positive regulation of 
caspase-10 upregulation in response to the anti-tumour drug, leading to the formation of 
the FADDosome and apoptosis. Initially, the role of ATM in this process was ruled out, 
however further experiments revealed, that the activity of Chk2 was dependent on ATM, 
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leading to a conundrum that requires more detailed investigation and answers with 
respect to ATM phosphorylation status in 5-FU-treated cells.  
 
In the present study, an antibody that detects the Ser1981 phosphorylation site in ATM 
was used. It has been described that, upon occurrence of the DNA damage, ATM 
undergoes autophosphorylation at Ser1981, which is considered a hallmark of its 
activation and stabilisation (So et al., 2009). However, some studies reported that this 
kinase requires phosphorylation at Ser367, Ser1893, and Ser1981, in order to reach its 
full activity potential (Kozlov et al., 2011). Thus, examination of the ATM phosphorylation 
at Ser367 and Ser1893 is necessary to further assess the activity status and the role of 
this kinase in the DNA damage-induced signal transduction and apoptosis in response 
to 5-FU.  
 
In the light of the results obtained so far, the detailed information on how ATR, Chk1 and 
Chk2 mediate the 5-FU-induced caspase-10 upregulation remains unclear and requires 
further investigation. In this context, it is essential to identify the molecular factors that 
might be involved in regulation of caspase-10 expression. The Chk1 and Chk2 kinases 
phosphorylate and control a wide range of substrates, of which many play an important 
role in the DNA damage-induced gene transcription and apoptosis (Bartek and Lukas, 
2003; Christmann and Kaina, 2013). The most common substrates are the transcription 
factors BRCA1 and BRCA2, which normally are phosphorylated in the Chk2- and Chk1-
dependent manner, respectively. Moreover, it was reported that BRCA1 and BRCA2 can 
be also activated by ATR and ATM. Additionally, BRCA1 is known to interact with p53 
and transcriptionally regulate the activation of some genes involved in the DNA repair 
and apoptosis (Christmann and Kaina, 2013). Thus, examination of BRCA1 and BRCA2 
as potential members of the ATR/Chk1/Chk2 signalling pathway could provide more 
insights into the regulation of the 5-FU-induced caspase-10 expression in cancer cells.  
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In the present study, it was discovered that the loss of ATR led to a considerable 
decrease of p53 levels in the cells exposed to 5-FU. Moreover, in our previous report we 
found that HCT.p53-/- cells were protected from 5-FU-induced apoptosis and that 
caspase-9 was dispensable for this process (Mohr et al., 2018). Moreover, it was 
discovered by our group that 5-FU-induced apoptosis was regulated by the p53-
meduated TRAIL-R2/JNK network (Mehrabadi, 2018). Thus, a question arised, whether 
ATR could regulate the TRAIL-R2/JNK pathway through p53 after stimulation with 5-FU. 
Moreover, it was reported that BRCA1 transcriptionally activates GADD45a, which is 
believed to mediate the DNA repair process and activation of MEKK4. Once activated, 
this kinase regulates MKK4 and MKK7, which are responsible for regulation of the 
cytotoxic stress-induced activation of JNK (c-Jun-N-terminal kinase) (Takekawa et al., 
1998; Mita et al., 2002; Christmann and Kaina, 2013). Therefore, investigation of the 
roles of ATR in the regulation of p53-driven TRAIL-R2/JNK axis and BRCA1 in JNK 
activation would provide more insights into the mechanisms involved in the novel 
signalling pathways of the 5-FU-induced apoptosis.   
 
Moreover, it is hypothesised that the p53-regulated TRAIL-R2/JNK signalling pathway 
might be involved in the 5-FU-induced phosphorylation of Bid, as it was previously shown 
that JNK can activate and regulate Bid (Dhanasekaran and Reddy, 2008). Thus, we 
believe that phosphorylated Bid might potentially function as the meeting point of the 
FADDosome complex and the p53-driven TRAIL-R2/JNK signalling axis. It has been 
reported that ATR and ATM are involved in phosphorylation of Bid at Ser61 and Ser78 
(Kamer et al., 2005; Zinkel et al., 2006; Liu et al., 2011; Wang et al., 2014). Moreover, 
Liu et al. (2011) described that Bid plays an important role in the DNA damage response 
by interacting with ATR and ATRIP (ATR-interacting protein), which in turn leads to 
formation of a complex that is involved in initiation of ssDNA repair. The authors also 
reported that Bid can interact with RPA (replication protein A), which is involved in 
recognition and coating ssDNA. Upon the Bid-mediated ssDNA coating with RPA, the 
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Bid-regulated ATR-ATRIP complex is recruited to the point of DNA damage and thereby, 
initiates its repair. Most importantly, Liu et al. (2011) emphasises the fact that the 
functions of ATR in the replicative stress response are highly dependent on Bid activity 
and its interaction with RPA. Such observations suggest that Bid can be involved in a 
wide range of processes associated with the DNA damage response, including both pro-
apoptotic and pro-survival events, as well as it can interact with numerous proteins. Thus, 
the question arises, whether Bid could perform similar functions in the 5-FU-induced 
apoptosis in cancer cells. Therefore, more detailed investigation of different Bid functions 
and its interactions with other proteins can contribute to better understanding of the roles 
of Bid in the DNA damage response and novel 5-FU-induced pathways of apoptosis in 
cancer cells. 
 
The work presented in this study provided answers for the factors and pathways involved 
in regulation of the caspase-10 upregulation and the FADDosome in 5-FU-induced 
apoptosis. However, it still leaves the question, what molecular factors are responsible 
for the DNA damage signal transduction towards the FLIPosome-mediated apoptosis in 
response to 5-FU. Having found that ATR acts as the key regulator of the DNA damage-
induced signalling towards the caspase-10-dependent FADDosome formation, it was 
asked, whether ATM could be phosphorylated and signal towards the caspase-10-
independent FLIPosome in response to 5-FU. Furthermore, it was asked, whether, as 
shown for the FADDosome, Chk1 and Chk2 could also play a role in FLIPosome-
dependent apoptosis signalling and the complex formation. Thus, more detailed 
examination is needed in order to assess the importance of ATM and Chk1/Chk2 and 
their activation in signalling towards the 5-FU-induced FLIPosome formation. This 
hypothesis can be tested by using HCT.shC10 and HCT.shATR knockdown cells treated 
with 5-FU plus ATM inhibitor, which could be analysed for apoptosis levels by flow 
cytometry as well as cIAP1 levels by Western blot and TNF-a production by ELISA.  
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